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Executive Summary 
 
 
The establishment of criteria for a European categorisation will have to serve most of the needs 
of all parties involved: health professionals, drug regulatory agencies, drug manufacturers and 
patients. Clear warnings and symbols are needed so patients use their medicines in the most 
optimal (and safest) way possible  
 
The DRUID WP4 expert group established and agreed that, according to its influence on the 
ability to drive, a medicine could, regarding to driving, be categorized as followed:  
 
• category 0 (no or negligible influence on fitness to drive),  
• category I (minor  influence on fitness to drive),  
• category II (moderate influence on fitness to drive),  
• and category III (severe influence on fitness to drive). 
 
The DRUID methodology on categorisation/labelling on medicines and driving.  
 
In summary, categorisation of a medicine on driving includes several steps of evaluation after 
taken into account the conditions of use of the medicine on the European Union market: 
 
1. Pharmacodynamic and pharmacokinetic data 
2. Pharmacovigilance data (including prevalence of unwanted effects reported in the SmPC) 
3. Experimental and epidemiological data 
4. Additional data derived from the Patient Information Leaflet (PIL) and existing categorisation 
systems 
5. Synthesis  
 
Básically conditions of use of the medicine, pharmacodynamics, pharmacokinetic data, and 
pharmacovigilance data (including prevalence of unwanted effects) were derived from the 
SmPC, while section 3 was based on a scientific literature serach. Additional data step 
consisted of reviewing section 4.7 of the SmPC “Effects on ability to drive and use machines” 
and the PIL section on “driving and using machines” as well as reviewing the previous 
categorisations (if available) of the medicine in Belgium, France, Spain as well as to the 
ICADTS list. 
 
After evaluating all the available data, a provisional category was assigned to each active 
substance. The provisional category was proposed and discussed during WP4 meetings where 
a final and definitive category was assigned and approved by all WP4 partners.  
 
 
A mechanism for modifying the classification, based on new evidence.  
 
The existing methodology on DRUID categorisation on medicines and driving, allows to, if new 
evidences emerges, re-categorise the medicine or confirm the previous categorisaton following 
again the same 5 step process. 
 
 
Classification/categorisation, labelling and patient oriented information for the relevant 
therapeutic groups of medicines available in the European Union market. 
 
The aim of WP4 was to provide a categorisation for the relevant therapeutic groups of 
medicines available on the European Union Market.  
 
In this way, DRUID task 4.3 was able to provide categorisation, labelling and patient-oriented 
information for the following ATC groups (The Anatomical Therapeutic Chemical –ATC- 
classification system; http://www.whocc.no/). 
 
Individual medicines were categorized according to the DRUID classification system.   
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A - ALIMENTARY TRACT AND METABOLISM 
B - BLOOD AND BLOOD FORMING ORGANS 
C - CARDIOVASCULAR SYSTEM 
D - DERMATOLOGICALS 
M - MUSCULO-SKELETAL SYSTEM 
N - NERVOUS SYSTEM 
N01 ANESTHETICS 
N02 ANALGESICS 
N03 ANTIEPILEPTICS 
N04 ANTIPARKINSON 
N05 PSYCHOLEPTICS 
N05A Antipsychotics 
N05B Anxiolytics 
N05C Hypnotics and sedatives 
N06 PSYCHOANALEPTICS 
N06A Antidepressant 
N06B Psychostimulants, agents used for ADHD (attention deficit/hyperactivity 
disorder)  and Nootropics 
N06C Psycholeptics and psychonaleptics in combination 
N06D Anti-dementia drugs 
N07 OTHER NERVOUS SYSTEM  DRUGS 
R - RESPIRATORY SYSTEM 
S - SENSORY ORGANS 
 
Furthermore, Fact Sheets were produced for the N01-N07 (nervous system) and R06 
(respiratory system - antihistamines) ATC groups of medicines. Each fact sheet contains 
information on: source of information, presentations, indications, posology and method of 
administration, pharmacodynamic and pharmacokinetic properties, possible side-effects related 
to driving, Summary of Product Characteristics (SmPC) section 4.7 effects on effects on ability 
to drive and use machines, leaflet section on driving and using machines, studies on 
psychomotor performance and risk studies, current categorisation in some EU countries, 
proposed  DRUID categorisation, information for the patient, and place and date of agreement 
by the DRUID WP4 members. 
 
For analysis and categorisation The DRUID project has proposed a total of 3,054 medicines 
from these ATC groups. Of these 3,054 medicines, 1,513 have not been categorized, because 
they are not available on the European Union market (not available on DRUID WP4 countries 
Belgium, France, Greece, Germany, Netherlands, and Spain, as well as in the UK and Ireland), 
as there is no sense in categorizing/labelling medicines which are not available. 
 
The distribution of the 1,541 categorized medicines was as follows: Category 0 – 50,3%, 
Category I – 26%, Category II – 11,2%, Category III – 5,8%, Multiple category – 4,4% and the 
Depending on the medicine in combination 2,3%. 
 
 
Multiple categories: This appeared when a medicine can be included in more than one 
category. There can be several reasons for this: In most cases, the different categorisation 
depended on the route of administration (topical, oral, parenteral, etc). In the case of some 
medicines, in special ophthalmological preparations (SO1), the different categorisation 
depended on the presentation form of the medication (aqueous-vehicle, cream, drops or 
ointment, etc.), which is related with the duration of its action. In one case, codeine, 
categorisation was based on the dose of codeine base administered. For two hypnotics, 
zolpidem and zaleplon, categorisation was based on the time after the medication was taken. 
  
  
Depending on medicines in combination: This was stated when the categorisation depended 
on another medicine combined with the one under evaluation.  
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1. Introduction 
 
 
Within DRUID Work package 4 - Classification, Task 4.3 aims to categorize medicines available 
on the European Union market in relation to driving.  
 
In fact, the main goal of task 4.3 was to achieve objective 4, “Proposition of a 
classification/categorisation system for the relevant therapeutic groups of medicines available in 
the market”. Furthermore, Task 4.3 was also responsible for achieving objective 3, 
“Development of a methodology to continuously update the i) classification/categorisation 
system and ii) labelling system on medicines and driving (core contract page 96 out of 184, 
version 2006). 
 
Please see below for a full description of Task 7.3. in the core contract. 
 
 
Task 4.3 as described in the Annex I to the Core Contract of DRUID project 
 
 
Task 4.3 Establishment of framework for classification/categorisation and labelling of 
medicinal drugs and driving 
 
Task leader: Uva (University of Valladolid) 
 
Topics: 
 
- Classification/categorisation following criteria of Task 4.2 of some groups of medicinal drugs 
not done in Task 4.1 (for example, anticholinergic drugs, anti-Parkinson drugs, some 
antihypertensive drugs). This Task will cover some groups of drugs, not all the drugs not-
categorised in Task 4.1. The end of this Task is to propose a classification/categorisation 
system for the relevant therapeutic groups of medicines available in the market. 
 
- Classification/categorisation of drugs approved by EMA during the 2nd year of the DRUID 
project. That is, if the project starts in 2006, the approved medicinal drugs by EMA along 2007 
will be classified/categorised using the Task 4.2 criteria. This will allow seeing if the proposed 
criteria on Task 4.2 could be applied in practice. 
 
- If able to agree with EMA the Task 4.3 will be able to provide a classification/categorisation for 
the “new” medicinal drugs under EMA evaluation on 2007/2008 and not yet approved. That is 
prior to the approval by EMA of a new drugs, DRUID Task 4.3 will provide the suggested 
classification prior the registration of a new medicinal drug. 
 
- A mechanism for modifying the classification, based on new evidence, will also be proposed. 
 
Tasks 1.1 “Methodology and metaanalyses”, Task 1.3 ”Recommendation of thresholds” and 
Task 2.3 “Relative risk estimation”, Task 4.1 “Review” and Task 4.2 “Consensus” will serve as 
input for Task 4.3. 
 
First 18 months: From month 11 to 18 Task 4.3 will start with categorisation of some of the 
therapeutics groups not covered by Task 4.1 
 
Involved Partners: UGent, UVa, RUGPha, BASt, UGren, CERTH-HIT 
Duration of the Task: Month 11 – month 45 
 
DRUID 6th Framework Programme  Deliverable D.4.3.1  
Establishment of framework for classification/categorization 
and labelling of medicinal drugs and driving 
   Page 11 of 135 
 
 
1. 1. Input from other DRUID tasks 
 
There was a deep interrelation between Task 4.2 and Task 4.3. The development of Task 4.3 
was correlated with task 4.2 “The establishment of criteria for a European categorisation, based 
on expert consensus”, with the aim of achieving objective 2 “Proposition and agreement on the 
criteria and the methodology on the establishment of a European i) classification/categorisation 
system and ii) labelling system of medicines and driving”. Finally, Task 4.3 benefits from the 
knowledge acquired from Task 4.1, in which the existing i) classification/categorisation systems 
and ii) labelling systems regarding medicines and driving were reviewed.  
 
While Task 4.2 developed the basis for consensus on the criteria for establishing a European 
categorisation for medicines and driving, Task 4.3 was more practical and produced a 
categorisation/labelling for existing medicines, as well as producing specific information for 
health professionals (physicians and pharmacists) to be delivered to the driver patient. 
 
However, for Task 4.3, due to delays in the development of the respective tasks, not much 
desirable input has been obtained from Tasks 1.1 “Methodology and metaanalyses”, Task 1.3 
”Recommendation of thresholds” and Task 2.3 “Relative risk estimation”, as was initially 
expected during the development of the DRUID proposal. 
 
1.2. Input from previous experience of partners and national activities in the field 
 
The work in WP4-tasks has benefitted from previous experience of some of the partners in the 
field on medicines and driving [1-3], for instance, their contribution to former ICADTS 
categorisation on medicines and driving [4]. 
 
Furthermore, in the last few years, when the DRUID project was being carried out, there have 
been some national experiences that, without any doubt, have provided input for the WP4 
activities. For instance, the introduction of the pictogram in France [5] and later in Spain [6], as 
well as the development of a national programme regarding medicines and driving in The 
Netherlands [7].  
 
Several meetings have taken place in collaboration with national agencies. For instance, in 
AFSSAPS (Agence Francaise de Sécurité Sanitaire des Produits de Santé) on February 28th 
2008, where DRUID partners attended a “regular” meeting of the French Medicinal Agency 
regarding medicines and driving. The criteria used and the experience on labelling medicines 
regarding to driving in France was shown.  
 
The attendance at the Pharmacovigilance Working Party (PhVWP) at EMA (European Medicinal 
Agency) has also been of great value for the development of WP4 tasks. 
 
However, the DRUID categorisation system is, although it may have benefitted from many other 
early experiences, a new categorisation. 
 
1.3. Classification/categorisation system for the relevant therapeutic groups of medicines 
available in the market 
 
The aim of task 4.3 was to provide a categorisation for the relevant therapeutic groups of 
medicines available on the European Union Market.  
 
In this way, DRUID task 4.3 was able to provide categorisation, labelling and patient-oriented 
information for the following ATC groups (The Anatomical Therapeutic Chemical –ATC- 
classification system; http://www.whocc.no/) 
 
A - ALIMENTARY TRACT AND METABOLISM 
B - BLOOD AND BLOOD FORMING ORGANS 
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C - CARDIOVASCULAR SYSTEM 
D - DERMATOLOGICALS 
M - MUSCULO-SKELETAL SYSTEM 
N - NERVOUS SYSTEM 
N01 ANESTHETICS 
N02 ANALGESICS 
N03 ANTIEPILEPTICS 
N04 ANTIPARKINSON 
N05 PSYCHOLEPTICS 
N05A Antipsychotics 
N05B Anxiolytics 
N05C Hypnotics and sedatives 
N06 PSYCHOANALEPTICS 
N06A Antidepressant 
N06B Psychostimulants, agents used for ADHD (attention deficit/hyperactivity 
disorder) and Nootropics 
N06C Psycholeptics and psychonaleptics in combination 
N06D Anti-dementia drugs 
N07 OTHER NERVOUS SYSTEM  DRUGS 
R - RESPIRATORY SYSTEM 
S - SENSORY ORGANS 
 
In total, these represent 3,054 different medicines. A key aspect was to identify which medicines 
are available on the European Union market, as there is no sense in categorizing/labelling 
medicines which are not available. Of these 3,054 medicines, according to our criteria, 1,513 
were not available in most European Union member states and, therefore, categorisation was 
not provided.  
 
Furthermore, Fact Sheets were produced for the N01-N07 (nervous system) and R06 
(respiratory system - antihistamines) ATC groups of medicines. Each fact sheet contains 
information on: source of information, presentations, indications, posology and method of 
administration, pharmacodynamic and pharmacokinetic properties, possible side-effects related 
to driving, Summary of Product Characteristics (SmPC) section 4.7 effects on ability to drive and 
use machines, leaflet section on driving and using machines, studies on psychomotor 
performance and risk studies, current categorisation in some EU countries, proposed  DRUID 
categorisation, information for the patient, and place and date of agreement by the DRUID WP4 
members. 
 
The following ATC groups were not categorized: G (Genito urinary system and sex hormones), 
H (Systemic hormonal preparations, excluding sex hormones and insulins), J (Antiinfectives for 
systemic use), L (Antineoplastic and immunomodulating agents), P (Antiparasitic products, 
insecticides and repellents) and V (various). 
 
1.4. Structure of Deliverable 4.3 
 
Deliverable 4.3 is divided into three parts.  
 
Chapter 2 includes a description of the methodology used for the categorisation and labelling of 
medicines and driving used within DRUID Task 4.3. It should be noticed that the Training 
Manual used by DRUID partners for the categorisation/labelling of medicines regarding driving 
is provided in Annex 1. 
 
Chapter 3 includes an earlier (2008) document for internal use produced by the French partners 
to present guidelines regarding DRUID criteria for categorisation and labelling.  
 
Chapter 4 shows some general figures regarding the number of medicines categorized in each 
category within the DRUID project. 
 
Chapter 5 is an alphabetical list of the medicines categorized in the DRUID WP4.  
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Chapter 6 shows some examples of information oriented to patients with regard to medicines 
and driving. 
 
Chapter 7 shows the medicines approved by the EMA since January 2008, as well as the 
DRUID categorisation for these medicines. 
 
 
1.5. List of Annexes  
 
This deliverable includes 17 annexes. While Annex 1 is the Training Manual used by DRUID 
partners for the categorisation/labelling of medicines regarding driving, Annexes 2-17 included 
categorisation/labelling and patient-oriented information for each ATC medicines group 
categorized. 
 
Within each annex the following information is included:  
 
• A chapter analysing the relation between the diseases for which the medicines are 
used, the medicines and fitness to drive. 
• Categorisation and labelling on medicines and driving 
• Patient-oriented information on medicines and driving 
• Fact Sheet for each medicine categorized (available for ATC N-Nervous system and 
R06-Respiratory System - Antihistamines). 
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2.1. Introduction 
 
Driving a motor vehicle is a multifaceted task and it requires appropriate cognitive and 
psychomotor skills (e.g. alertness, concentration, reaction time, visual acuity) [1]. Psychoactive 
medications can adversely affect these driving-related skills, and, consequently, be a hazard to 
traffic safety [2, 3]. 
 
The European Council Directive 83/570/EEC of October 1983 established that the summary of 
product characteristics (SmPC) has to contain, in Article 4, information on clinical particulars, 
among which the “effects on the ability to drive and to use machines” [4]. In October 1991 the 
European Committee for Medicinal Products for Human Use (CHMP) provided a Note for 
Guidance for the SmPC in which it was stated that section 4.7 of medications registered from 
1st January 1992 had to indicate, on the basis on the pharmacodynamic profile, reported 
adverse drug reactions (ADRs) and/or impairment of driving performance or performance 
related to driving, 3 different levels of impairment with respect to the ability to drive and/or 
operate machines [1,5]. In September 2009 (which applies as from 1st of May 2010) a new 
SmPC guideline was issued, partly based on the proposal sent to EMA  during the consultation 
phase of the revision of the SmPC guidelines in March 2008 which established that “” [6].  
 
 
Table 1: Text of SmPC section 4.7 on Effects on ability to drive and use machines. Version 
september 2009, in force 1st May 2010. 
 
4.7 Effects on ability to drive and use machines 
 
 
On the basis of the pharmacodynamic and pharmacokinetic profile, reported adverse reactions 
and/or specific studies in a relevant target population addressing the performance related to 
driving and road safety or using machines, specify whether the medicinal product has a) no or 
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negligible influence b) minor influence, c) moderate influence or d) major influence on these 
abilities. Other important factors that affect the ability to drive and use machines should be 
considered if known, e.g. duration of the impairing effect and the development of tolerance or 
adverse reactions with continued use. For situations c and d, special warnings/precautions for 
use should be mentioned here (and also in section 4.4 for situation d) 
 
 
Despite the above mentioned regulations, at this moment, a European categorisation system 
has not been established yet, and warning systems for potentially driving impairing medicines 
have mainly been developed and/or implemented at national levels [1,7]. 
 
In 2008 Pil et al. performed a review of the existing systems for the classification of medicines 
and driving [8]. This review was carried out within the Driving Under the Influence of Drugs, 
Alcohol and Medicines (DRUID) project [9], and identified 15 systems. According to this 
document, the Netherlands were the first country to introduce a list of medications that can 
impair driving abilities, in 1973. This list was prepared by the Royal Dutch Society for the 
Advancement of Pharmacy (KNMP) and the use of a yellow warning label on medication boxes 
was established. This list was updated in 2008 in conjunction with a campaign of the Dutch 
Ministry of Transport, Public Works and Water Management and the Ministry of Health, Welfare 
and Sports, and the Contra-indication “Participation in traffic” was developed where the use of 
three different categories was set up [10]. In particular, it was established that this three-
category-system had to be implemented in the electronic systems of general practitioners and 
pharmacists, and could also be used as a background document by Dutch Driving Licensing 
Authority (CBR) while processing the applications for a new driving licence or the renewal of 
driving licences of professional drivers and drivers older than 70 [10]. 
 
In 1981 a warning label was launched and adopted in the Nordic countries (Denmark, Finland, 
Iceland, Norway, and Sweden). The label consisted of a red triangle printed on packages of 
“especially dangerous” medications, and, at the moment, it is still in use in Denmark, Finland, 
and Norway.  
 
Greece was the next European country to introduce a sort of indication concerning the influence 
of medications on the ability to drive. The Greek system was adopted in 1987, and, despite it is 
not a real categorisation system, it provides a warning about the risks associated with possible 
driving impairing medicines. 
 
Another categorisation system was proposed in 1991 by Wolschrijn and colleagues. This 
system was based on expert ratings, consisted of 7 categories, and covered more than 500 
medications [11].  
 
The Wolschrijn categorisation was used in 1997 by the Federal Union of German Associations 
of Pharmacists (ABDA) who developed a brochure for health care professionals (HCPs) based 
on the mean values of the above mentioned classification. Later on, in 1999, Belgium 
elaborated its own categorisation list and used the same system proposed by Wolschrijn et al., 
as well [12]. Similar categories as the Wolschrijn ones were also used in Portugal, in 2004, but, 
in this case, a five-level system was developed and adopted as a basic instrument for a proper 
medication use.  
  
In 1999, France introduced a warning label to indicate potential effects on driving performance. 
This system did not last long, because it was believed that because it was believed that it 
several significant downsides [8]. Later on, in 2004, a new warning sign on boxes of 
medications which could constitute a hazard to traffic safety. This sign was removed after a few 
years, but, in 2005, the “Journal Officiel de la République Française” published a classification 
system for medications according to their influence on driving performance which is legally 
binding and classifies the medications according to three levels of driving impairment [13]. 
 
A three-level system was also issued in Spain, in 2001; this system was updated in 2002 and 
2005, and this latter update introduced a forth category to rate all those medications which are 
supposed to impair driving-related skills. 
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Finally, in 2006, the International Council on Alcohol, Drugs and Traffic Safety (ICADTS) 
published a list of 389 driving impairing medications; this list is based on the Belgian, French 
and Spanish classification systems and it contains 3 categories which refer to 3 different levels 
of impairment [14]. The ICADTS list was recently used as a background document by Slovenia 
which developed and adopted its own categorisation system in 2008. The Slovenian 
categorisation system is also based on three categories which indicate the influence of each 
active substance on fitness to drive and are reflected in the warnings and labels that are printed 
in the documentation accompanying the medication [15].  
 
Although different categorisation systems are currently available across Europe, it is important 
to point out that none of these classifications have clearly described or published the criteria for 
the establishment of a categorisation system for potentially impairing medications nor were 
officially adopted at European level [8]. 
 
The main aim of DRUID Work Package (WP) 4 is to provide the bases and the methodology for 
the development of a European classification system for medications with respect to their 
impact on the ability to drive. Furthermore, DRUID WP4 also aims to provide a classification of 
relevant therapeutic groups of medicines that are currently on the market, in Europe, as well as 
new medications approved by the European Medicines Agency (EMA) in the years 2007 - 2009 
[9].  
 
 
2.2. The DRUID categorisation/labelling on medicines and driving.  
 
The DRUID WP4 expert group established and agreed that, according to its influence on the 
ability to drive, a medicine could be categorized as follows regarding driving (Figure 1):  
 
• category 0 (no or negligible influence on fitness to drive),  
• category I (minor  influence on fitness to drive),  
• category II (moderate influence on fitness to drive),  
• category III (severe influence on fitness to drive). 
 
This was in line with the recent approved SmPC guidelines adopted in September 2009 by EMA 
(please see Table 1), proposing that in section 4.7 ”Effects on ability to drive and use machines” 
it should be specified whether the medicinal product has a) no or negligible influence b) minor; 
c) moderate influence or d) major influence on these abilities. 
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Figure 1: DRUID Categorisation and labelling system for medicines and driving. 
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2.3. The DRUID methodology on categorisation on medicines and driving. 
 
The development of the DRUID categorisation system was based on the criteria that were 
established by a group of experts in the field of drugs and driving, involved in DRUID WP4, and 
based on their consensus [9].  
 
The selection of the active substances was done by means of an inventory of all available 
medicines in some European countries such as Belgium, France, Germany, Greece, the 
Netherlands, Spain, United Kingdom and Ireland. Old medications or medications available in 
only one of the previously mentioned countries were not included in the categorisation process. 
Figure 2 shows the process of identification if a medicine is available at the European Union 
market. 
 
After the joint meetings with the French Health Products Safety Agency (AFSSAPS) experts in 
categorizing medications affecting driving performance, the DRUID group decided to adopt a 
procedure similar to the one that was used in France, and, specifically, to evaluate the following 
information and data:  
 
0. Conditions of use of the medicine at the European Union market.  
1. Pharmacodynamic and pharmacokinetic data 
2. Pharmacovigilance data (including prevalence of unwanted effects reported in the SmPC) 
3. Experimental and epidemiological data  
4. Additional data derived derived from the Patient Information Leaflet (PIL) and existing 
categorisation systems [16], and information from other sources. 
5. Synthesis  
 
Basically, conditions of use of the medicine, pharmacodynamic and pharmacokinetic data, 
pharmacovigilance data (including prevalence of unwanted effects) were derived from the 
SmPC, while section 3 was based on a scientific literature serach.  
 
Figure 3 and Figure 4 summarize the methodology and process followed in assigning a 
category on driving to a medicine available at the European Union Market.  
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Figure 2: Process of identification if a medicine is available in the European Union market. 
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Figure 3: Methodology for the DRUID Categorisation and labelling system for medicines and driving. 
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Figure 4: Flowchart representing the methodology that was followed during the DRUID 
categorisation process. 
 
 
 
Legend:  SmPC: Summary of Product Characteristics 
  PIL: Patient Information Leaflet 
  EMA: European Medicines Agency  
  MHRA: Medicines and Healthcare products Regulatory Agency 
eMC: Electronic Medicines Compendium 
  IMB: Irish Medicines Board 
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The SmPC and PIL of the selected medications were found online, in one of the following 
websites: Medicines and Healthcare products Regulatory Agency (MHRA) [17], Electronic 
Medicines Compendium (eMC) [18], and Irish Medicines Board (IMB) [19], or, if needed, 
retrieved from national regulatory agencies. In case of recently approved active substances, the 
SmPC and PIL were found on the EMA website [20]. The selection of the above mentioned 
regulatory affairs agencies was simply based on the fact that the required information had to be 
available either in English or in a language that could be fully understood by DRUID WP4 
partners.  
 
Specific sections of the SmPC and PIL were used to retrieve details on the active substance 
presentations and strength, indications, posology, route of administration (step 0), 
pharmacodynamic and pharmacokinetic profile (step 1), effects on the ability to drive and use 
machines (step 4), and undesirable effects related to driving and operating machines (step 2).  
 
During the activities in Task 4.3 on categorisation of the existing medicines, the occurrence of 
undesirable effects was considered as key information for categorising some medicines, in 
circumstances that information on experimental studies for assessing a medicine’s effect on 
driving or skills related to driving or epidemiological data was lacking or limited. For that reason, 
section 4.8 of the SmPC was used (as well as specific literature search, if necessary). Recently, 
EMA has started to use the following categorisation on frequency of undesirable effects, side 
effects or adverse reactions: 
 
  very common (>1/10) 
  common (>1/100, <1/10)  
  uncommon (>1/1,000, <1/100)  
  rare (>1/10,000, <1/1,000)  
  very rare (<1/10,000) 
  not known (cannot be estimated from the available data, since no valid estimate can be 
derived from clinical trials or epidemiological studies). 
 
DRUID Partners have taken into account this categorisation of undesirable effects, side effects 
or adverse reactions in their categorisation framework for medicines and driving. Firstly by 
considering those effects categorised as very common (>1/10) and common (>1/100, <1/10), 
and secondly, those undesirable effects that can potentially impair the fitness to drive safely. In 
case rare or very rare unwanted effects or certain severely impairing effects occur, for example 
sudden sleep attacks, DRUID Partners recommend that this should be mentioned in the patient 
information leaflet. 
 
The following criteria were used for assigning a medicine to a specific category, in case 
experimental or epidemiological data are lacking (Table 2). 
 
 
 
Table 2: Relationship of the undesirable effects category in the SmPC to the DRUID 
categorisation system. 
 
Declaration of undesirable effects that can 
potentially impair the fitness to drive safely 
DRUID Category 
Very common (> 1/10) Category  II or higher 
Common (>1/100, <1/10) Category I (or II) 
Rare (>1/10,000, <1/1,000)  
or very rare (<1/10,000) 
Category 0 
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In Table 3 all relevant potentially undesirable effects to be considered when categorising the 
effects of medicines on driving are listed. 
 
 
Table 3: Undesirable effects that can impair the fitness to drive grouped by system organ class. 
  
System organ 
class 
Selection of undesirable effects that can impair the fitness to drive 
safely  
 
Nervous system 
disorders 
  Somnolence, dizziness, drowsiness 
  Confusion - cognitive disorder- disorientation – co-ordination 
disturbances 
  Involuntary movement disorders: ataxia, tremor, Parkinsonism, acute 
dystonic (dyskinesia) and dyskinetic reactions (dystonia) 
  Convulsions – seizures 
  Muscle weakness 
Psychiatric 
disorders 
  Perception disturbances (hallucination, visual hallucination, auditory 
hallucination, illusion) 
  Psychotic reactions and psychotic disorder (including paranoia 
psychosis) 
  [Other: Emotional lability, mood swings, aggression, nervousness, 
irritability, personality disorders, thinking abnormal, abnormal 
behaviour, euphoric mood, restlessness (emotional state of 
excitement), depersonalisation]  
Eye disorders   Diplopia or double vision  
  Blurred vision  
  Accommodation disorders 
  Visual acuity reduced 
  Photophobia 
  [Other: visual field defect, peripheral vision loss, altered visual depth 
perception, oculogyric crisis]. 
Ear and Labyrinth 
disorders 
  Vertigo 
  Hearing loss 
  [Other: buzzing, tinnitus] 
Metabolism and 
nutrition 
disorders 
  Hypoglycaemia 
 
Vascular 
disorders 
  Hypotension 
 
 
Data sources for the scientific literature evaluation were the electronic databases Medline, 
Science Direct, and PsycINFO. The search was performed by using (at least) these 
combinations of keywords: “active substance name and psychomotor performance”, “active 
substance name and automobile driving”, and “active substance name and traffic accidents”. 
The final data selection was limited to full text articles, not only published in English, and 
referred to side-effects, experimental and pharmacoepidemiological studies, case reports on 
each active substance to be categorized and its possible driving impairment. No restrictions 
concerning the publication year were applied. 
 
In case of severely impairing, recently approved medications, and medicines for ATC groups N 
and R06, all the collected data were compiled in fact sheets, with a standardized lay-out, which 
were used during the active substance evaluation procedure and the approval of its final 
category. 
 
Additional steps consisted of reviewing section 4.7 of the SmPC “Effects on ability to drive and 
use machines” and the PIL section on “Driving and using machines” as well as reviewing the 
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previous categorisation (if available) of the medicine in Belgium, France, Spain and the ICADTS 
list. 
After evaluating all the available data, a provisional category was assigned to each active 
substance. The provisional category was proposed and discussed during WP4 meetings where 
a final and definitive category was assigned and approved by all WP4 partners.  
 
 
2.4. A mechanism for modifying the classification, based on new evidence.  
 
The existing methodology on DRUID categorisation on medicines and driving allows categorise 
the medicine or to confirm the previous categorisation following again the same 5 step process, 
if new evidences emerge (Figure 4).   
 
 
2.5. Discussion 
 
The current DRUID categorisation system established and defined standard and harmonized 
criteria to categorize new and old active substances, based on their influence on the ability to 
drive. Up to date, this system nearly embraces the full ATC index and it intends to provide a 
complete coverage of the most commonly prescribed medications in Europe. The categorisation 
procedure was developed by a European group of experts and was meant to go beyond a 
national context in order to reach a broader European scenario and involve different facets of 
the health care practice. 
 
The categorisation system could be seen as a tool to improve prescribing and dispensing 
procedures both at a national and European level, and, therefore, as a instrument to better 
inform and involve HCPs (Health Care Professionals) [21]. With this respect, it is important that 
HCPs know the fundamentals of the categorisation system, and, consequently, use it properly in 
order to fully inform their patients about the risks of driving under the influence of impairing 
medicines. Furthermore, HCPs should be able to distinguish between the four levels of 
impairment, and, therefore, if possible, choose the least impairing medication within the same 
therapeutic group. Moreover, this system should encourage HCPs to update their knowledge on 
medicines and driving in order to be prepared to answer questions that patients might have on 
this topic [1, 22].  
 
The DRUID categorisation system should also be used as a tool to motivate health care 
professionals to provide patients with clear information, communicate to patients the risk 
associated with driving under the influence of medicines, and start HCP-patient discussion 
leading to both safer prescriptions and the patient’s conscious decision whether to drive or not 
[1, 21].  
 
From the patient point of view, this classification could play an active role in helping them to be 
involved along the decision-making process, to understand the hazards of some medications to 
traffic safety, and to remind them to use caution while driving until their individual responses to 
the therapy have been well established. 
 
To our knowledge, this is the first time that the European Commission (EC) assigned an expert 
group in the field of drugs and driving the task of establishing the criteria for a European 
classification system and developing a categorisation system for relevant therapeutic groups of 
medications with respect to their impact on driving skills. The categorisation efforts were carried 
out by an international group of DRUID partners, coming from 6 different institutions in Europe, 
and gathered all their scientific competence, knowledge, expertise, and experience in the field 
of road safety research and practice. All the available data, coming from different sources, were 
collected according to a standardized step-by-step procedure which, on the one hand, allows 
the future maintenance of the current DRUID categorisation system, and, on the other hand, 
constitutes a consistent evidence-based classification methodology to categorize new 
medications, prior to their market authorization. Last but not least, as reported above, the 
DRUID categorisation system almost encompasses the entire ATC list, and, therefore, provides 
a nearly complete overview of the influence of frequently prescribed medications on the ability 
to drive; additionally, in case of severely impairing and new medications, it is integrated with fact 
DRUID 6th Framework Programme  Deliverable D.4.3.1  
Establishment of framework for classification/categorization 
and labelling of medicinal drugs and driving 
   Page 25 of 135 
 
sheets which concisely emphasize the categorisation key-points and can be used as a support 
in HCP daily practice [9].  
 
Lastly, some limitations of the DRUID categorisation system should be considered. In particular, 
special attention should be paid to the fact that a category is attributed to the single active 
substance, given to an adult, for its main indication, in an normal dosage, and at the start of the 
treatment [1, 5, 8]. Therefore, if a medication is not prescribed according to these conditions, it 
is crucial to bear in mind that the categorisation system can only be used as background 
information, and it is necessary to carefully assess all the individual risk factors and avoid strict 
adherence to the medication classification. Furthermore, the system is focused on the effects of 
medications on the ability to drive and, consequently, the role of the disease, which could also 
influence the driving ability, is not considered and certainly needs further attention while 
counselling the patient [1, 5].  
 
 
2.6. Next steps and recommendations 
 
The categorisation system presented in this manuscript was developed within the DRUID 
project, and, therefore, in a European context. As a consequence, it is suggested that European 
regulatory authorities will be informed about this categorisation process, discuss and reach 
consensus on the criteria hereby proposed, and carry out special efforts to implement the 
current system at both international and national level, considering country specificities, as well. 
Since the categorisation needs a constant revision, it is also advised that an expert working 
group on drugs and driving could be established in order to keep the system functional, up-to-
date, and reliable.  
 
Furthermore, it is recommended that special attention will be paid in educating those subjects 
who might play an active role in traffic safety. With this respect, medical and pharmacy schools 
could develop targeted educational programs covering the issue of medication use and driving 
whereas police officers and driving instructors could be adequately trained on this topic in order 
to be able to transfer the message to potential patients who also participate in traffic.  
 
Finally, a guideline should be developed to explain the use of the categorisation system to 
HCPs and to serve as a support in the decision making process. On the other hand, since the 
patient package leaflet is the most accessible source of information for patients, it would also be 
advisable to develop an effective strategy to communicate the risk related to the use of 
medicines and driving. For instances, a straightforward grading system could be included in the 
patient package leaflet and the use of pictograms (warning labels) could be printed on the 
medication box to provide clear directions for patients. 
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3.1. Introduction 
 
In this position paper it is suggested to build on the experiences from the French experts in 
categorizing medicines affecting driving performance. It was agreed by WP 4 partners to follow 
up on their discussions in Task 4.3 (Establishment of a framework for 
classification/categorisation and labeling of medicinal drugs and driving). Therefore this position 
paper will focus on the procedures that are recommended within such a framework. 
 
Harmonization at the level of categorizing medicinal substances could be achieved by adopting 
the French approach for the classification of active substances. In this approach it is stated that 
the risk of impairment after taking a medicinal product on the ability to drive depends on several 
factors: 
 
• The pharmacodynamic effect of the medicinal product, knowing that the more serious this 
effect is (for example from mild sleepiness to sudden sleep), the more dangerous it will 
be for driving; 
 
• Individual sensitivity, the same dose of the same active substance can have variable 
effects according to subjects’ sensitivity to the substance (example: systemic 
antihistamines) or to subjects pathology. 
 
This individual sensitivity may concern a great number of treated patients while a substance 
induces very common or common unwanted effects: in these circumstances with no known 
pharmacodynamic mechanisms, clinical trials have a great interest in order to specify the 
prevalence of unwanted effects as well as the relations to changes in behaviour, convulsions, 
involuntary movements, psychotic reaction, etc. 
 
Pharmacovigilance data are mainly useful for severe or un-expected unwanted effects. 
 
• Conditions of use: doses administered interactions with other medicinal products, 
interaction with alcohol, etc. 
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As a consequence, each of these factors cannot be considered separately and the level of risk 
attributed to a medicinal product shall be the result of all these factors. The categorisation will 
have to reflect the overall impairment of these factors on the ability to drive, and translate these 
into three correctly defined levels.  
 
For the medicinal products which have the least impairing effect on driving, it is obvious that the 
risk depends primarily on the patient’s individual sensitivity. Then, as the pharmacodynamic 
effect on the ability to drive increases, individual sensitivity decreases to become second if the 
whole population of treated drivers is considered. Finally, for the most dangerous medicinal 
products, deleterious effects appear in a constant manner in all exposed patients. In order to 
define the warning level, the contribution of the pharmacodynamic effect on driving is therefore 
predominant. But potentially dangerous secondary effects, which can notably be identified using 
the pharmacovigilance data, are also taken into account.  
 
The warning level corresponds to the presumed impact of the medicinal product on the ability to 
drive. The grading scale may be similar to the scale which the World Health Organisation 
(WHO) uses in pharmacovigilance to evaluate the seriousness of the impact of the undesirable 
effects on everyday life.  
 
As the effects likely to have an impact on driving can be varied and multiple, it is necessary to 
draw up a list of these various effects but to establish one grading only for the overall impact of 
the medicinal product on the ability to drive. 
 
The problem of some unexpected and severe effects (for example, sudden sleep induced by 
dopaminergic agonists), which cannot always be predicted in view of the pharmacodynamic 
properties of the medicinal product, may sometimes arise. This is the reason why 
pharmacovigilance data should systematically be searched for. 
 
Next to the pharmacovigilance data, the experimental data and the epidemiological data (when 
they exist) need to be reviewed as well as various additional data [influence of the dose, the 
pharmaceutical form, the route of administration, the interactions with other medicinal products, 
the interaction with alcohol, the pharmacokinetic data, the concerned pathology(ies), the misuse 
data].  
 
To simplify procedures, the evaluation of categorisation is first performed according to the active 
substance (according to the ATC classification). However, it is also necessary to take in account 
factors related to the various available medicines which can possibly modify the warning level 
attributed to the active substance, e.g. the excipients (excipient with a notorious effect), the 
route of administration, the conditions of use and the general classification for supply 
(prescription only, OTC or self-medication). 
 
3.2. Evaluation by following different steps  
 
The categorisation by experts includes several steps of evaluation: 
 
1. Pharmacodynamic and pharmacokinetic data 
2. Experimental and epidemiological data  
3. Pharmacovigilance data 
4. Additional data 
5. Synthesis  
 
 
3.2.1. Pharmacodynamic and pharmacokinetic data 
 
Identification of a side effect able to interfere with driving performance is first carried out by 
reviewing the expected effect regarding to the pharmacological profile. In particular by 
identification of the pharmacodynamic properties likely to have an effect on driving is carried out 
on the basis of the SmPCs of the corresponding medicines, the marketing authorization 
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application dossiers and references (i.e. Goodman & Gilman's, Martindale…). Related 
medicines can also be examined (same chemical family or same pharmacological class) likely 
to modify the ability to drive. The pharmacodynamic effects are known thanks to the in vitro 
studies (for example, GABA receptor affinity studies), the other pre-clinical and clinical studies. 
These expected effects are frequent but may be more severe if there are other interfering 
factors (pathology, old age, renal or hepatic insufficiency, etc.). Some pharmacodynamic effects 
(for example, disinhibition associated with anxiolytics) may be less frequent, while these effects 
occur only in specific conditions; however, these effects may modify the driving behaviour. 
Pharmacodynamic effects studies need to include not only sedative (hypnosis; sleep attacks, 
etc.) effects but also other effects (cognitive, behavioural, visual, cardio-vascular effects). 
Pharmacodynamic tolerance may explain the sedative effects only during the first days of 
psychotropic drug treatment and some written cautions in the Summary Product Characteristics 
(SmPC) for this period. Clinical pharmacokinetic studies may give sufficient information about 
drug effects due to various drug liposolubility, bioavailability, distribution volume, Blood-Brain-
Barrier permeability, different half-lives, drug metabolites activity and the consequences of age, 
renal or hepatic insufficiency.  
 
Pharmacokinetic studies show also the possible drug-drug interactions and their expected 
clinical effects.In order to inform the health professional and the patient, it is important to define 
the time after which the ability to drive is back to normal, in particular for the medicinal products 
with the highest level of risk. 
 
For a same active substance but different medicinal specialties, the categorisation may also 
differ with different routes (oral or parenteral use) of drug administration. 
 
  
3.2.2 Experimental and epidemiological data 
  
Demonstration of the impairing effect can be obtained through study of frequency and intensity 
of this effect. This can be achieved by  
 
• Preclinical, clinical or epidemiological studies may predict or summarize the frequency 
and intensity of unwanted effects 
 
An effect linked with dose - blood concentration? 
 
The pharmacodynamic studies may give (or not) good correlations between drug administrated 
dose, blood concentrations and clinical effects. This may induce, after evaluation, proposals of a 
different drug categorisation in case of different uses, indications, doses, and pharmaceutical 
specialties. 
 
Clinical trials have a great interest in order to specify the prevalence of unwanted effects as well 
as the relations to changes in behaviour, convulsions, involuntary movements, psychotic 
reactions, etc. These data give new informations about common effects and are arguments to 
scale up the score of categorisation. 
 
Epidemiological studies give informations about the relative risk of accidents when drivers use 
some drugs when driving (for an example, benzodiazepine anxiolytics increase approximately 
two times the accident relative risk in European countries).  
 
For another example, data about a possible increase of accident reports and varenicline which 
is indicated for nicotine dependence treatment need to be detailed and evaluated by experts. 
The mechanisms of this possible relationship between varenicline and accidents need also to 
be specified (unwanted psychiatric, vigilance, cognitive effects due to the drug or to the drug 
withdrawal syndrome) 
 
• Concerning specific studies 
  
Have they been conducted? 
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A reference research is necessary in order to look for specific studies. Evaluation of the quality 
of the studies has to be done by experts. The published data only are examined (evaluation 
tests, especially with psychomotor and cognitive effects studies, epidemiological studies, 
reported cases), taking into account their level of evidence. Potential data on related medicines 
can be taken into consideration as in the first step. When they exist, experimental and 
epidemiological data will lead to: 
  
 -  either confirm the warning level, or 
  
 -  re-examine the level (scaling up or down) depending on these data’s relevance. 
 
In case of lacking specific studies, evaluation of drug effects may be possible or not. In the last 
case, new specific studies may be proposed in order to categorise drugs. The type of studies 
needed for this purpose can be derived from a document developed by the ICADTS Working 
Group on Guidelines on experimental studies undertaken to determine a medicinal drug’s effect 
on driving or skills related to driving (see www.ICADTS.org)  
 
Risk Management Plan may include the need of other specific studies. New pharmacovigilance 
data may induce the need of new specific studies to define the conditions of occurrence of the 
unwanted effects and the proposals to prevent them. 
 
 
3.2.3. Pharmacovigilance data 
 
Identification of unexpected effects is carried out by reviewing pharmacovigilance data. Data are 
collected at the European Pharmacovigilance Evaluation Network. They clearly influence the 
evaluation of a drug during the post marketing period. The pharmacovigilance data allow 
identifying undesirable effects (unexpected, new or unpredictable effects) which could seriously 
alter the ability to drive. The evaluation of pharmacovigilance data (data derived from literature, 
spontaneous notifications to the national pharmacovigilance system) leads to one of the three 
following outcomes: 
 
- The pharmacovigilance data don’t give any additional information; 
 
- The pharmacovigilance data confirm the pharmacodynamic data; 
 
- The pharmacovigilance data give new information which has to be taken into account; in this 
case, it seems to be necessary to scale up the score obtained in the categorisation. In some 
cases, pharmacovigilance data may give new informations indicating that some drugs have less 
unwanted effects (less sedative effects in a new therapeutic class, etc.): these data may induce 
a scaling down of the score of categorisation. 
 
For example, in case of unexpected sleep attacks, the pharmacovigilance network may induce 
a proposal of a modified SmPC in order to prevent consequences of sleep attacks on driving. 
These unexpected data may also induce a Risk Management Plan (RMP) including a Risk 
Minimisation Plan about drug effects on driving behaviour. 
 
Level of demonstration of the effect  
 
Expected and unexpected effects may give a level of demonstration which is influenced by the 
quality of the studies and case reports, the number of treated patients, the duration of studies 
and follow-up. 
  
a. Confirmation by specific studies 
 
Some specific studies may have been carried out and may define more precisely the drug 
influence on (experimental or actual traffic) driving. These studies may inform about the lack of 
significant drug effect or an increasing relative risk of a drug effect on driving. 
 
b. No demonstration of any drug effect (in case of performed studies) 
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Some studies provide proof of absence of a drug’s impairing side effect. 
 
c. Lack or insufficiency of experimental data 
 
Some studies may lack or may be insufficient to conclude about a drug effect on driving for 
many reasons which must be detailed and discussed in evaluation process. 
 
 
3.2.4. Additional data 
 
Additional data are needed to answer several questions, such as: is the frequency of the effect 
quantifiable? 
 
a) With available data 
 
Unwanted effects may be dose dependent effects. Available data may give an evaluation of the 
effect frequency which can be different in case of increasing doses of the same active 
substance in different pharmaceutical specialties: therefore, the categorisation may be different 
for these various pharmaceutical specialties. The categorisation may also differ with different 
routes of drug administration. Even if specific (preclinical and clinical) data for each drug may be 
asked, data may be available only for substances of the same pharmacological class of the 
evaluated drug: in this case, even if some pharmacological and pharmacokinetic differences 
may exist and modify the drug scaling, comparison with drugs of the same class may help the 
harmonization of the drug categorisation. 
 
b) With specific data 
 
Experimental data, case reports or epidemiological studies may be specific with a drug effect on 
drug driving abilities and accidents. Drug categorisation evaluation takes in account all these 
data. 
  
The effect is influenced by several factors which have to be taken into account before the final 
evaluation can start. The following factors need to be addressed: 
 
• Patient's age  
 
Age dependent physiological neurological and cognitive evolution may be increased by various 
drugs i.e. sedative, myorelaxant and anticholinergics. With increasing patient’s age, renal and 
hepatic functions decrease: for these reasons and for age-dependent increasing fat body 
weight, drug elimination half life may increase. 
 
• Alcohol use 
 
Many psychoactive drugs effects are potentiated by ethyl alcohol. In some drug evaluation, 
contra-indication of alcohol drinking during the treatment may be written in the SMPC, while 
data have described the noxious effects of an interaction between a drug an ethyl alcohol.. 
 
Some medicinal products (phlebotonics, etc.) may contain ethyl alcohol ; in these cases, if the 
maximum daily dosage contains a sufficient quantity of alcohol (for example, more than 3g of 
alcohol) which may disturb driving abilities, there will be a need of information and a 
pharmaceutical specialty categorisation due to the alcohol effects.If the medicinal product 
contains an important quantity of alcohol and another substance likely to have effects on driving 
ability, the expected interaction must influence the specialty’s categorisation. 
  
• Combination with other medicinal drugs 
 
Drug interactions are frequent and induce many unwanted effects. There may be an addition, a 
synergy or potentiation of effects. Interactions may worsen effects when two drugs have the 
same type of pharmacodynamic effects. Pharmacokinetic interactions (for example, hepatic 
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microsomial cytochrome P 450 inhibitors) may also induce serious side effects with the 
increasing inhibited drug blood concentration. These interactions are written in the SMPC. The 
categorisation does not usually take in account the risks of interaction, unless the two drugs are 
combined in the same pharmaceutical specialty. 
 
• Pathology 
 
It is necessary to take in account the identification of an indication which makes driving 
inconsistent. For example, ambulatory surgery needs the use of anaesthesic drugs : the 
anaesthesist has to specify the necessary interval of time after what  the patient is allowed to 
drive. Benzodiazepine hypnotics are prescribed against insomnia: driving is not allowed during 
the drug sedative effects. Patient’s pathology may be the necessary condition of the occurrence 
of an unwanted effect: antiparkinsonian drug sleep attacks are only described in Parkinson’s 
disease. Some anticonvulsant drugs may paradoxically induce myoclonic effects in epileptic 
patients. Pathology itself may (chronically or occasionally) decrease the driving abilities. 
 
 
3.2.5. Synthesis (Result of the evaluation)  
 
Based on the different steps (or items), a classification notice takes up again the principal items 
justifying the active substance evaluation procedure. After the evaluation of drug 
pharmacodynamic, pharmacokinetic, preclinical and clinical pharmacological (clinical trials, 
pharmacovigilance) studies, epidemiological and additional data, the conclusion of the effect of 
a drug's effect is the result of the integration of three parameters: likelihood, frequency and 
intensity. 
 
a. Likelihood 
 
Several levels of likelihood are considered with definitions that are given as follows: 
 
• Certain 
 
A certain or very suggestive degree of likelihood in the drug-effect relationship is not usual 
unless the drug effects are known pharmacodynamic effects like mydriasis with mydriatics, or 
sedation with anaesthesics. 
 
• Plausible  
 
The likelihood in the drug effect may be plausible (for example, myorelaxant effects associated 
with drugs which interfere with GABA or glycine receptors, orthostatic hypotension effect 
associated with calcium antagonists). 
 
• Doubtful, unlikely 
 
The relationship between a drug and an unwanted effect may be doubtful, unlikely while 
pharmacological data and clinical data are not sufficient. 
 
• Excluded 
 
There may be no likelihood between a drug and an unwanted effect. The imputability of the drug 
may be incompatible, especially for chronological or for semiological criteria.  
 
b. Frequency  
 
It is difficult to take into consideration the sole frequency of occurrence of the effects, as those 
can turn out to be dangerous in any case. However, the frequency may help to influence the 
categorisation of the warning level: 
 
- Very frequent (very common) : > 1/10 
- Frequent (common) : > 1/ 100 
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- Not frequent (infrequent) : between 1/ 100 and 1/ 1000 
- Rare or uncommon : between 1/ 10 000 and 1/ 1000 
- Very uncommon : < 1/ 10 000 
- Unknown (frequency cannot be estimated from the available data, since no valid estimate 
can be derived from clinical trials or epidemiological studies). For old medicinal drugs, there 
is often no available information. Other sources are needed like pharmacological or 
therapeutic reviews. 
- No effect: when no demonstrated effect occurs on driving ability, the drug may be 
categorised as a drug with no effect on driving ability 
 
c. Intensity 
 
The evaluation of intensity of the effect(s) on the ability to drive is carried out according to the 
following scale.  
 
- A mild effect may be defined as " not generally questioning the ability to drive", 
- A moderate effect may be defined as "possibly questioning, in some cases, the ability to 
drive", 
- A severe effect may be defined as "recommending not to drive". 
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Work sheet and evaluation 
 
 
1. IDENTIFICATION OF POTENTIALLY PHARMACODYNAMIC EFFECTS 
AMENDING THE ABILITY TO DRIVE A VEHICLE 
 
• Sedation 
• Vision 
• Behaviour 
• Other  
 
By type of effect:  
 
2. ASSESSING THE LEVEL OF PROBABILITY AND THE EFFECT OF INTENSITY 
CHANGE THE ABILITY TO DRIVE A VEHICLE  
(justification SmPC + any data from literature) 
for each type of effect, the outcomes 5.1, 4.7, 4.4, of SmPC of the items are listed 
  
3. POSITION IN THE CLASSIFICATION 
Intensity of the pharmacodynamic effect on the performance 
Likelihood of the effect 
on the conduct 
Minor Moderate Severe 
Certain I II III 
Possible I II III 
 
The classification needs to take in account the case of no effect on the conduct 
 
Repeat steps 2 and 3 for each type of effect identified 
 
 
4. REPETITION OF STEPS 1, 2 AND 3 FOR EVERY TYPE OF EFFECTS 
IDENTIFIED 
for each type of effect, the outcome of sections 4.8 or 4.4, of SmPC are listed 
 
5. ADDITIONAL DATA 
5.1 about drug interactions  
5.2 about the association with alcohol 
5.3 about the deadline beyond the capacity of conduct are recovered (when possible) 
5.4 about the therapeutic indications possibly falling of pathologies modifying the 
capacity of conduct 
 
6. SYNTHESIS 
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Examples of unwanted effects that can impair driving ability  
 
System organ 
class 
Selection of undesirable effects that can impair the ability to drive safely  
 
Nervous system 
disorders 
  Somnolence, dizziness, drowsiness 
  Confusion - cognitive disorder- disorientation 
  Involuntary movement disorders: ataxia, tremor, Parkinsonism, 
acute dystonic (dyskinesia) and dyskinetic reactions (dystonia) 
  Convulsions -seizures 
 
Psychiatric 
disorders 
  Perception disturbances (hallucination, visual hallucination, auditory 
hallucination, illusion) 
  Psychotic reactions and  psychotic disorder (including paranoia 
psychosis) 
  [Other: Emotional lability, mood swings, aggression, nervousness, 
irritability, personality disorders, thinking abnormal, abnormal 
behaviour,  euphoric mood, restlessness (emotional state of 
excitement), depersonalisation]  
Eye disorders   Diplopia or double vision,  
  Vision blurred 
  Accommodation disorders 
  Visual acuity reduced 
  Photophobia 
  [Other: visual field defect, peripheral vision loss, altered visual depth 
perception, oculogyric crisis]. 
Ear and 
Labyrinth 
disorders 
  Vertigo 
  Hearing loss 
  [Other: buzzing, tinnitus] 
 
Metabolism and 
nutrition 
disorders 
  Hypoglycaemia 
 
Vascular 
disorders 
  Hypotension 
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4. Distribution of categorized medicines 
within DRUID categories 
 
4.1 Number of medicines categorized by ATC groups 
 
Table 4, below, shows the DRUID categorisation of the medicines in the groups ATC, A, B, C, 
D, M, N, R and S evaluated in DRUID WP4. Tables 5 to 12 show the number of medicines 
assigned to each category, as well as the number of medicines not evaluated in the various 
therapeutic groups analyzed. 
 
The DRUID project has proposed for analysis and categorisation a total of 3,054 medicines 
from the groups ATC, A, B, C, D, M, N, R, and S. Of these 3,054 medicines, 1,513 have not 
been categorized (49,5%), because they are not available in most of the DRUID WP4 countries 
(Belgium, France, Greece, Germany, Netherlands, and Spain) as well as in the UK and Ireland.  
 
 
Table 4: Number of medicines categorized by ATC groups 
 
DRUID Categorisation ATC GROUP 
 
Not 
evaluated. 
Not 
available 
at  
EU 
market 
0 I II III Multiple  
categories
Depending 
on the 
medicine in 
combination 
TOTAL
         
A - ALIMENTARY 
TRACT AND 
METABOLISM 
243 234 69 8 1 4 4 563 
B - BLOOD AND 
BLOOD FORMING 
ORGANS 
86 135 1 1   
2 
225 
C - 
CARDIOVASCULAR 
SYSTEM 
246 90 200 11  1  548 
D - 
DERMATOLOGICALS 
156 192 1   4  353 
M - MUSCULO-
SKELETAL SYSTEM 
88 22 44 28 15   197 
N - NERVOUS 
SYSTEM 
346 9 30 86 53 36  560 
R - RESPIRATORY 
SYSTEM 
195 62 24 32 10 5 14 342 
S - SENSORY 
ORGANS 
153 31 31 6 11 18 16 266 
 
TOTAL 1513 775 400 172 90 68 36 3054 
 
 
Not evaluated. No proposed categorisation and labelling because this medicine is not available 
in most of the DRUID WP4 countries (Belgium, France, Greece, Germany, The Netherlands, 
and Spain) as well as in the UK and Ireland. 
 
DRUID Categorisation: Four categories were proposed regarding the possible effect of the 
medicine on fitness to drive. 
 
- Category 0:  Presumed to be safe on fitness to drive. 
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- Category I:  Likely to produce minor adverse effects on fitness to drive. 
- Category II:  Likely to produce moderate adverse effect on fitness to drive. 
- Category III:  Likely to produce severe effects on fitness to drive or presumed to be 
potentially dangerous. 
 
Multiple categories: This is when a medicine can be included in more than one category, 
generally according to route of administration (topical, oral, parenteral, etc) or according to the 
presentation form of the medication (aqueous-vehicle, cream, drops or ointiment, etc.). Table 13 
shows the cases of multiple classifications. 
 
Depending on medicines in combination: When the categorisation depended on the 
medicine in combination to with those under evaluation. Table 13 shows the cases of medicines 
categorized depending on medicines in combination. 
 
4.2 Category percentage 
 
1,541 medicines from the DRUID WP4 categorisation were evaluated. The percentage of 
medicines assigned to each category is shown in Figure 5. The distribution of the 1,541 
categorized medicines was as follows: Category 0 – 50,3%, Category I – 26%, Category II – 
11,2%, Category III – 5,8%, Multiple category – 4,4% and the Depending on the medicine in 
combination 2,3%. 
 
 
Figure 5: Percentage of medicines categorized within each DRUID category 
 
 
50,3%
26,0%
11,2%
5,8% 4,4%
2,3%
0%
10%
20%
30%
40%
50%
60%
Category 0 Category I Category II Category III Multiple
Category
Dependin
the medic
 
4.3 Number of medicines assigned to each category 
 
Tables 5 to 12 show the number of medicines assigned to each category, as well as the number 
of medicines not evaluated in the various therapeutic groups analyzed. 
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Table 5: Number of medicines from the ATC-Group, A-ALIMENTARY TRACT AND METABOLISM, categorized in each DRUID category 
 
DRUID Categorisation ATC GROUP 
 
A-ALIMENTARY TRACT AND METABOLISM 
Not 
evaluated. 
Not 
available in 
EU market 
0 I II III Multiple 
categories
Depending on the medicine 
in combination 
TOTAL 
         
A01       STOMATOLOGICAL PREPARATIONS 15 23      38 
A02       DRUGS FOR ACID RELATED DISORDERS 25 30 13     68 
A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL 
DISORDERS 
73 14 1 2 1 3  94 
A04 ANTIEMETICS AND ANTINAUSEANTS 7 7  2  1  17 
A05 BILE AND LIVER THERAPY 12 5      17 
A06 LAXATIVES 25 35      60 
A07 ANTIDIARRHEALS, INTESTINAL 
ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS 
25 30  3   1 59 
A08 ANTIOBESITY PREPARATIONS, EXCL. DIET 
PRODUCTS 
12 1      13 
A09 DIGESTIVES, INCL. ENZYMES 7 3      10 
A10 DRUGS USED IN DIABETES 18 8 44     70 
A10A Insulins and analogues   25     25 
A10B Blood glucose lowering drugs, excl. insulins 17 8 19     44 
A10X Other drugs used in diabetes 1       1 
A11 VITAMINS 2 35     1 38 
A12 MINERAL SUPPLEMENTS 8 32     2 42 
A13 TONICS  1      1 
A14 ANABOLIC AGENTS FOR SYSTEMIC USE 9 3      12 
A15 APPETITE STIMULANTS    1    1 
A16 OTHER ALIMENTARY TRACT AND METABOLISM 
PRODUCTS 
5 7 11     23 
TOTAL  243 234 69 8 1 4 4 563 
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Table 6: Number of medicines from the ATC-Group, B-BLOOD AND BLOOD FORMING ORGANS MEDICINES, categorized in each DRUID category 
 
DRUID Categorisation ATC GROUP 
 
B-BLOOD AND BLOOD FORMING ORGANS MEDICINES 
Not evaluated. 
Not available in 
EU market 
0 I II III Multiple 
categories 
Depending 
on the 
medicine in 
combination
TOTAL 
         
B01      ANTITHROMBOTIC AGENTS 27 37  1   1 66 
B02 ANTIHEMORRHAGICS 10 25 1     36 
B03 ANTIANEMIC PREPARATIONS 16 30      46 
B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS 27 41     1 69 
B06 OTHER HEMATOLOGICAL AGENTS 6 2      8 
TOTAL 86 135 1 1   2 225 
 
 
Table 7: Number of medicines from the ATC-Group, C-CARDIOVASCULAR SYSTEM MEDICINES, categorized in each DRUID category 
 
DRUID Categorisation ATC GROUP 
 
C - CARDIOVASCULAR SYSTEM 
Not evaluated. 
Not available in 
EU market 
0 I II III Multiple 
categories 
Depending 
on the 
medicine in 
combination
TOTAL 
         
C01 CARDIAC THERAPY 94  39     133 
C02 ANTIHYPERTENSIVES 43  15 10    68 
C03 DIURETICS 38 23 12     73 
C04 PERIPHERAL VASODILATORS 16 3 17 1    37 
C05 VASOPROTECTIVES 3 40 2   1  46 
C07 BETA BLOCKING AGENTS 17  48     65 
C08 CALCIUM CHANNEL BLOCKERS 8  16     24 
C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 4 2 51     57 
C10 LIPID MODIFYING AGENTS 23 22      45 
TOTAL 246 90 200 11  1  548 
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Table 8: Number of medicines from the ATC-Group, D-DERMATOLOGICALS MEDICINES, categorized in each DRUID category 
 
DRUID Categorisation ATC GROUP 
 
D-DERMATOLOGICALS 
Not evaluated. 
Not available in 
EU market 
0 I II III Multiple 
categories 
Depending 
on the 
medicine in 
combination
TOTAL 
         
D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 33 20      53 
D02 EMOLLIENTS AND PROTECTIVES  12      12 
D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS 9 3      12 
D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 11 10    1  22 
D05 ANTIPSORIATICS 8 8 1     17 
D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR 
DERMATOLOGICAL USE 
10 25      35 
D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 29 47      76 
D08 ANTISEPTICS AND DISINFECTANTS 28 24      52 
D09 MEDICATED DRESSINGS 5 10      15 
D10 ANTI-ACNE PREPARATIONS 10 19    2  31 
D11 OTHER DERMATOLOGICAL PREPARATIONS 13 14    1  28 
TOTAL 156 192 1   4  353 
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Table 9: Number of medicines from the ATC-Group, M-MUSCULO-SKELETAL SYSTEM MEDICINES, categorized in each DRUID category 
 
DRUID Categorisation ATC GROUP 
 
M-MUSCULO-SKELETAL SYSTEM MEDICINES 
Not evaluated. 
Not available in 
EU market 
0 I II III Multiple 
categories 
Depending 
on the 
medicine in 
combination
TOTAL 
M01 ANTI-INFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 53 2 32     87 
M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 17 12      29 
M03 MUSCLE RELAXANTS 4   27 15   46 
M04  ANTIGOUT PREPARATIONS 7 1 4     12 
M05 DRUGS FOR TREATMENT OF BONE DISEASES 5 7 5 1    18 
M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL 
SYSTEM 
2  3     5 
TOTAL 88 22 44 28 15   197 
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Table 10: Number of medicines from the ATC-Group, N-NERVOUS SYSTEM MEDICINES, categorized in each DRUID category 
 
DRUID Categorisation ATC GROUP 
 
N-NERVOUS SYSTEM 
 
Not evaluated. 
Not available at 
EU market 
0 I II III Multiple 
categories 
Depending on the 
medicine in 
combination 
TOTAL 
         
N01 ANESTHETICS 31 3 3 1 12 10  60 
N01A  Anesthetics, general 20    11 1  32 
N01B Anesthetics, local 11 3 3 1 1 9  28 
N02 ANALGESICS 93 2 7 10 3 7  122 
N02A Opioids 31    2 7  40 
N02B Other analgesics and antipyretics 52 2 6 1 1   62 
N02C Antimigraine preparations 10  1 9    20 
N03 ANTIEPILEPTICS 23   14 4 2  43 
N03A Antiepileptics 23   14 4 2  43 
N04 ANTIPARKINSON 16  3 16  1  36 
N04A  Anticholinergic agents 10   4  1  15 
N04B Dopaminergic agents 6  3 12    21 
N05 PSYCHOLEPTICS 107  4 16 26 12  165 
N05A Antipsychotics 31   13 8 9  65 
N05B Anxiolytics 23  1 3 7 1  35 
N05C Hypnotics and sedatives 53  3  11 2  69 
N06 PSYCHOANALEPTICS 62 2 10 20 7 1  102 
N06A Antidepressant 37 1 7 12 7 1  65 
N06B Psychostimulants, agents used for ADHD 
(attention deficit/hyperactivity disorder)  and 
Nootropics 
22  3 4    29 
N06C Psycholeptics and psychonaleptics in 
combination 
2       2 
N06D Anti-dementia drugs 1 1  4    6 
N07  OTHER NERVOUS SYSTEM  DRUGS 14 2 3 9 1 3  32 
N07A Parasympathomimetics 6   2  1  9 
N07B Drugs used in addictive disorders 2 2 1 4 1 2  12 
N07C Antivertigo preparations  2  1 2    5 
N07X Other nervous system drugs 4  1 1    6 
TOTAL 346 9 30 86 53 36  560 
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Table 11: Number of medicines from the ATC-Group, R-RESPIRATORY SYSTEM MEDICINES, categorized in each DRUID category 
 
DRUID Categorisation ATC GROUP 
 
R-RESPIRATORY SYSTEM 
Not evaluated.  
Not available at  
EU market 
0 I II III Multiple  
categories 
Depending 
on the 
medicine in 
combination
TOTAL 
         
R01 NASAL PREPARATIONS 32 22 2   1 3 60 
R02 THROAT PREPARATIONS 15 11    1  27 
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 65 19 4   2 5 95 
R05 COUGH AND COLD PREPARATIONS 44 9 5 4 1 1 4 68 
R06 ANTIHISTAMINES FOR SYSTEMIC USE 27  11 28 9  2 77 
R07 RESPIRATORY SYSTEM 12 1 2     15 
TOTAL 195 62 24 32  5 14 342 
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Table 12: Number of medicines from the ATC-Group, S-SENSORY ORGANS MEDICINES, categorized in each DRUID category 
 
 
DRUID Categorisation ATC GROUP 
 
S-SENSORY ORGANS 
Not evaluated.  
Not available at  
EU market 
0 I II III Multiple  
categories 
Depending 
on the 
medicine in 
combination
TOTAL 
         
S01 OPHTHALMOLOGICALS         
S01A Antiinfectives 40 6 2   9 2 59 
S01B Antiinflammatory agents 17 4 1   3 4 29 
S01C Antiinflammatory agents and antiinfectives in combination 5 1    6 5 17 
S01E Antiglaucoma preparations and miotics 21  13 6    40 
S01F Mydriatics and cycloplegics 4    8   12 
S01G Decongestants and antiallergics 7  13    2 22 
S01H Local Anesthetics 6  2     8 
S01J  Diagnostic agents 1 1     1 3 
S01K Surgical aids 3 1      4 
S01L Ocular vascular disorder agents 1    3   4 
S01XA Other ophthalmologicals 13 4      17 
S02 OTOLOGICALS 24 8     2 34 
S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS 11 6      17 
TOTAL 153 31 31 6 11 18 16 266 
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4.4 Multiple categories and categorisation depending on the medicine in combination 
 
A medicine has been placed in multiple categories when it can be in more than one category. 
There can be several reasons for this:  
− In most cases, the different categorisation depended on the route of administration (topical, 
oral, parenteral, etc). 
− In the case of some medicines, in special ophthalmological preparations (SO1), the different 
categorisation depended on the presentation form of the medication (aqueous-vehicle, 
cream, drops or ointment, etc.), which is related with the duration of its action.  
− In one case, codeine, categorisation was based on the dose of codeine base administered.  
− For two hypnotics, zolpidem and zaleplon, categorisation was based on the time after the 
medication was taken. 
− In some cases, the categorisation depended on the medicines in combination.   
 
Table 13 shows the cases of multiple classifications and categorisations depending on the 
medicine in combination. 
 
 
Table 13: Medicines with multiple categorisations and depending on the medicine in 
combination, according to the ATC code.  
 
A - ALIMENTARY TRACT AND METABOLISM CATEGORISATION 
 
A03BB01 Butylscopolamine  
- Oral administration 
- Parenteral administration (i.v) 
 
I 
II 
A03DB04 Butylscopolamine and analgesics. 
- Oral administration 
- Parenteral administration  
 
I 
II 
A03FA01 Metoclopramide  
- Oral administration 
- Parenteral administration  
 
I 
II 
A04AD01 Scopolamine  
- Oral and rectal administration 
- Parenteral administration 
 
I 
II 
A07DA53 Loperamide, combinations  Depending on the 
medicine in 
combination 
A11CC20 Combinations  
(Vitamin D and analogues) 
Depending on the 
medicine in 
combination 
A12BA30 Combinations  
(Potassium) 
Depending on the 
medicine in 
combination 
A12BA51 
Potassium chloride, Combinations Depending on the 
medicine in 
combination 
B BLOOD AND BLOOD FORMING ORGANS  
B01AC30 Combinations  
(Platelet aggregation inhibitors excl. 
heparin) 
Depending on the 
medicine in 
combination 
B05XA31 Electrolytes in combination with other drugs Depending on the 
medicine in 
combination 
D - DERMATOLOGICALS  
D10BA01 Isotretinoin  
- Oral administration 
 
II 
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- Topical use 0 
D11AH01 
(L04AD02 in intravenous 
and oral administration) 
Tacrolimus 
- Intravenous administration 
- Oral administration 
- Topical use 
 
III 
II 
0 
D11AX19 Alitretinoin  
- Oral administration 
- Topical use 
 
I 
0 
N - NERVOUS SYSTEM  
N01B Anesthetics, local The categorisation was depending on the 
route of administration and place of 
administration. Not all local anesthetics are 
available for all routes of administration. 
For example use in topical anaesthesia 
was considered as category 0. 
 
− Surface o topical anaesthesia:  
− Infiltration anaesthesia: 
− Intravenous regional anaesthesia  
− Regional nerve block 
− Spinal  
 
N01BA02 Procaine 0 to III 
N01BA03 Tetracaine 0 to III 
N01BB01 Bupivacaine I to III 
N01BB02 Lidocaine 0 to III 
N01BB03 Mepivacaine (carbocaine) I to III 
N01BB04 Prilocaine 0 to III 
N01BB10 Levobupivacaine I to III 
N01BB51 Bupivacaine combinations I to III 
N01BB52 Lidocaine combinations 0 to III 
N02 ANALGESICS  
N02AA01 Morphine 
- Oral administration 
- Parenteral admin. 
III/II* 
III 
N02AA03 Hydromorphone III/II* 
N02AA05 Oxycodone III/II* 
N02AA08 Dihydrocodeine III/II* 
N02AA59 Codeine, combinations excl. psycholeptics 
> 20 mg of codeine base 
≤ 20 mg of codeine base 
 
II 
I 
N02AB03 Fentanyl 
- Oral administration 
- Parenteral admin. 
- Transdermal administration 
 
III 
III 
III/II* 
N02AE01 Buprenorphine 
- Oral administration 
- Parenteral admin. 
- Transdermal administration 
 
III 
III 
III/II* 
N03 ANTIEPILEPTICS  
N03AE01 Clonazepam 
‐ Oral administration 
‐ Parenteral administration 
 
II 
III 
N03AG01 Valproic acid 
- Oral administration 
- Parenteral administration 
 
II 
III 
N04 ANTIPARKINSON  
N04AA02 Biperiden  
- Oral administration 
 
II 
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- Parenteral administration III 
N05 PSYCHOLEPTICS  
N05AD01 Haloperidol 
- Oral administration 
- Parenteral administration:i.v./i.m. 
 
II 
III 
N05AD06 Bromperidol 
- Oral administration 
- Parenteral administration: depot i.m. 
 
II 
III 
N05AE04 Ziprasidone 
- Oral administration 
- Parenteral administration: i.m. 
 
II 
III 
N05AF01 Flupentixol 
- Oral administration 
- Parenteral administration: depot i.m. 
 
II 
III 
N05AF05 Zuclopenthixol 
- Oral administration 
- Parenteral administration: depot i.m. 
 
II 
III 
N05AH03 Olanzapine 
- Oral administration 
- Parenteral administration: i.m. 
 
II 
III 
N05AX08 Risperidone 
- Oral administration 
- Parenteral administration: depot i.m. 
 
II 
III 
N05AX09 Clotiapine 
- Oral administration 
- Parenteral administration: i.m./i.v. 
 
II 
III 
N05AX12 Aripiprazole 
- Oral administration 
- Parenteral administration: i.m. 
 
II 
III 
N05BA05 Potassium clorazepate 
- Oral administration 
- Parenteral administration im/iv 
 
II 
III 
N05CF02 Zolpidem 
- after 8h of administration 
III 
II 
N05CF03 Zaleplon 
- after 12 h of administration 
III 
I 
N06 PSYCHOANALEPTICS  
N06A Antidepressant    
N06AA21 Maprotiline 
- Oral administration 
- Parenteral administration 
 
II 
III 
N07  OTHER NERVOUS SYSTEM  DRUGS  
N07AA01 Neostigmine 
- Oral administration 
- Parenteral administration   
 
II 
III 
N07BC01 Buprenorphine 
- Oral administration 
- Parenteral admin. 
- Transdermal administration 
 
III 
III 
III/II* 
N07BC02 Methadone 
- Oral administration 
- Parenteral administration 
 
II 
III 
R-RESPIRATORY SYSTEM  
R01AB01 Phenylephrine  
(Sympathomimetics, combinations excl. 
corticosteroids) 
Depending on the 
medicine in 
combination 
R01AB05 Ephedrine  
(Sympathomimetics, combinations excl. 
Depending on the 
medicine in 
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corticosteroids) combination 
R01BA52 Pseudoephedrine, combinations 
+ loratadine 
+ triprolidine 
 
I 
III 
R01BA53 Phenylephrine, combinations Depending on the 
medicine in 
combination 
R03AK03 Fenoterol and other drugs for obstructive 
airway diseases  
Depending on the 
medicine in 
combination 
R03AK04 Salbutamol and other drugs for obstructive 
airway diseases  
Depending on the 
medicine in 
combination 
R03AK06 Salmeterol and other drugs for obstructive 
airway diseases  
Depending on the 
medicine in 
combination 
R03AK07 Formoterol and other drugs for obstructive 
airway diseases  
Depending on the 
medicine in 
combination 
R03DA04 Theophylline 
- Oral administration 
- Parenteral administration 
 
0 
I 
R03DA05 Aminophylline 
- Oral administration 
- Parenteral administration 
 
0 
I 
R03DB04   Theophylline and adrenergics Depending on the 
medicine in 
combination 
R05DA04   Codeine  
> 20 mg of codeine base 
≤ 20 mg of codeine base 
 
II 
I 
R05DA20   Combinations 
(Opium alkaloids and derivatives) 
Depending on the 
medicine in 
combination 
R05FA02 Opium derivatives and expectorants II or higher depending 
on the medicine in 
combination 
R05FB01 Cough suppressants and mucolytics Depending on the 
medicine in 
combination 
R05FB02 Cough suppressants and expectorants Depending on the 
medicine in 
combination 
R06AE51 Buclizine, combinations Depending on the 
medicine in 
combination 
R06AE53 Cyclizine, combinations Depending on the 
medicine in 
combination 
S01 OPHTHALMOLOGICALS  
S01AA01 Chloramphenicol 
S01AA02 Chlortetracycline 
S01AA03 Neomycin 
S01AA04 Oxytetracycline 
S01AA11 Gentamicin 
S01AA12 Tobramycin 
S01AA13 Fusidic acid 
Drops: 0 
Oinment: I 
S01AA20 Antibiotics in combination  Depending on the 
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with other drugs medicine in 
combination 
S01AA30 Combinations of different antibiotics Depending on the 
medicine in 
combination 
S01AX13 Ciprofloxacin 
S01AX17 Lomefloxacin 
S01BA01 Dexamethasone 
S01BA07 Fluorometholone 
S01BA13 Rimexolone 
Drops: 0 
Oinment: I 
S01BB01 Hydrocortisone and mydriatics 
S01BB02 Prednisolone and mydriatics 
S01BB03 Fluorometholone and mydriatics 
S01BB04 Betamethasone and mydriatics 
Depending on the 
mydriatic in 
combination 
S01CA01 Dexamethasone and antiinfectives 
S01CA02 Prednisolone and antiinfectives 
S01CA03 Hydrocortisone and antiinfectives 
S01CA05 Betamethasone and antiinfectives 
S01CA06 Fludrocortisone and antiinfectives 
S01CA07 Flourometholone and antiinfectives 
Drops: 0 
Oinment: I 
S01CB01 Dexamethasone 
(Corticosteroids/antiinfectives/mydriatics in 
combination)  
S01CB02 Prednisolone 
(Corticosteroids/antiinfectives/mydriatics in 
combination) 
S01CB03 Hydrocortisone 
(Corticosteroids/antiinfectives/mydriatics in 
combination) 
S01CB04 Betamethasone 
(Corticosteroids/antiinfectives/mydriatics in 
combination)  
S01CB05 Fluorometholone 
(Corticosteroids/antiinfectives/mydriatics in 
combination) 
Depending on the 
mydriatic in 
combination 
S01GA51 Naphazoline, combinations 
S01GA55 Phenylephrine, combinations 
S01JA51 Fluorescein, combinations 
S02DA30 Combinations (Analgesics and anesthetics) 
S02DC Combinations (Indifferent preparations) 
Depending on the 
medicine in 
combination 
 
*) prolonged release formulation; when a steady state of dosage has been reached 
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5. Alphabetical list of the medicines 
categorized with the DRUID WP4 
 
 
A list of all the medicines categorized within the DRUID project in alphabetical order is now 
presented (Table 14). 
 
Some active substances have more than one ATC code, as they can be used for different 
indications. The categorisation has been carried out by analyzing each medicine within its 
therapeutic group. Sometimes, the categorisation of the same active substance has been the 
same in all the therapeutic groups, while in other cases the same active substance has been 
categorized differently in each ATC code. For example: Beclometasone has 4 ATC codes 
(A07EA07, D07AC15, R01AD01, R03BA01) and in all cases has been categorized as category 
0. However, Cromoglicic acid has 5 ATC codes and different categorisations according to the 
pharmaceutical group (ATC code) it belongs to, (A07EB01, R01AC01, R03BC01 Category 0), 
(S01GX01 Category I) and (D11AH03 Not evaluated). 
 
Table 14: Alphabetical list of the medicines categorized with the DRUID WP4 
 
A ATC CODE CATEGORISATION 
labelling 
(2-benzhydryloxyethyl)diethyl-methylammonium 
iodide 
A03AB16 NE 
2-(4-chlorphenoxy)-ethanol D01AE06 NE 
Abciximab B01AC13 0 
Absorbable gelatin sponge  B02BC01 0 
Acadesine C01EB13 NE 
Acamprosate N07BB03 0 
Acarbose A10BF01 0 
Acebutolol C07AB04 I 
Acebutolol and thiazides C07BB04 I 
Aceclidine S01EB08 NE 
Aceclidine, combinations S01EB58 NE 
Aceclofenac M01AB16 I 
Aceclofenac M02AA25 0 
Acefylline piperazine R03DA09 NE 
Acemetacin M01AB11 I 
Acenocoumarol B01AA07 0 
Acepromazine N05AA04 NE 
Acetarsol A07AX02 NE 
Acetazolamide  S01EC01 II 
Acetic acid S02AA10 NE 
Acetohexamide A10BB31 NE 
Acetophenazine N05AB07 NE 
Acetoxolone A02BX09 NE 
Acetylcarnitine N06BX12 NE 
Acetylcholine  S01EB09 II 
Acetylcysteine R05CB01 
S01XA08 
0 
Acetyldigitoxin C01AA01 NE 
Acetyldigoxin C01AA02 NE 
Acetyldigoxin, combinations C01AA52 NE 
Acetyldihydrocodeine R05DA12 II 
Acetylglycinamide chloralhydrate N05CC03 NE 
Acetylic acid and corticosteroids M01BA03 NE 
Acetylleucine N07CA04 NE 
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Acetylsalicylic acid A01AD05 
B01AC06 
N02BA01 
0 
Acetylsalicylic acid, combinations excl 
psycholeptics 
N02BA51 NE 
Acetylsalicylic acid, combinations with 
psycholeptics 
N02BA71 NE 
Acexamato de zinc A02BX 0 
Aciclovir D06BB03 0 
Aciclovir S01AD03 I  
Aciclovir, combinations D06BB53 NE 
Acipimox C10AD06 0 
Acitretin  D05BB02 I 
Acriflavinium chloride R02AA13 NE 
Acrivastine R06AX18 I 
Adapalene D10AD03 0 
Adapalene, combinations D10AD53 0 
Ademetionine A16AA02 NE 
Adenosine C01EB10 I 
Adinazolam N05BA07 NE 
Adrafinil N06BX17 NE 
Adrenalone A01AD06 NE 
Adrenalone B02BC05 NE 
Agalsidase alfa  A16AB03 I 
Agalsidase beta  A16AB04 I 
Agomelatine N06AX22 II 
Ajmaline C01BA05 NE 
Alanyl glutamine B05XB02 NE 
Alaproclate N06AB07 NE 
Albumin  B05AA01 0 
Albumin tannate A07XA01 NE 
Albumin tannate, combinations A07XA51 NE 
Alclofenac M01AB06 NE 
Alclometasone D07AB10 0 
Alclometasone S01BA10 NE 
Alcuronium M03AA01 III 
Alendronic acid M05BA04 0 
Alendronic acid and colecalciferol M05BB03 I 
Alfa1 antitrypsin B02AB02 0 
Alfacalcidol A11CC03 0 
 Alfaxalone N01AX05 NE 
 Alfentanil N01AH02 III 
Algeldrate A02AB02 0 
Alginic acid A02BX13 NE 
Alglucerase A16AB01 NE 
Alglucosidase alfa  A16AB07 I 
Alimemazine R06AD01 III 
Alipogene tiparvovec C10AX10 NE 
Aliskiren C09XA02 0 
Aliskiren and hydrochlorothiazide C09XA52 0 
Alitretinoin  
- Oral administration 
- Topical use 
D11AX19  
I 
0 
Alizapride A03FA05 NE 
Allobarbital N05CA21 NE 
Allopurinol M04AA01 I 
Allopurinol, combinations M04AA51 I 
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Almagate A02AD03 0 
Almasilate A02AD05 0 
Alminoprofen M01AE16 NE 
Almitrine R07AB07 I 
Almotriptan N02CC05 II 
Alogliptin A10BH04 NE 
Aloglutamol   A02AB06 0 
Alosetron A03AE01 NE 
Aloxiprin B01AC15 
N02BA02 
NE 
Alprazolam N05BA12 III 
Alprenolol C07AA01 I 
Alprostadil C01EA01 I 
Alteplase B01AD02 0 
Alteplase S01XA13 NE 
Althea root R05CA05 NE 
Altizide and potassium-sparing agents 
(spironolactone) 
C03EA04 I 
Alum S01XA07 NE 
Aluminium acetoacetate A02AB05 0 
Aluminium acetotartrate S02AA04 NE 
Aluminium chloride D10AX01 0 
Aluminium chlorohydrate D09AA08 
M05BX02 
NE 
Aluminium clofibrate C10AB03 NE 
Aluminium glycinate  A02AB07 0 
Aluminium hydroxide A02AB01 0 
Aluminium nicotinate C10AD04 NE 
Aluminium oxide D10AX04 NE 
Aluminium phosphate A02AB03 0 
Aluminium preparations C05AX01 0 
Alverine A03AX08 0 
Alverine, combinations A03AX58 NE 
Alvimopan A06AH02 NE 
 Amantadine N04BB01 I 
Ambazone R02AA01 NE 
Ambenonium N07AA30 NE 
Ambrisentan C02KX02 I 
Ambroxol R05CB06 0 
Ambutonium and psycholeptics A03CA07 NE 
Amcinonide   D07AC11 NE 
Amfepramone A08AA03 NE 
Amfetamine N06BA01 NE 
Amifampridine N07XX05 II 
Amikacin D06AX12 0 
Amikacin S01AA21 NE 
Amiloride C03DB01 0 
Amineptine N06AA19 NE 
 Amino (diphenylhydantoin) valeric acid N03AB03 NE 
Amino acids B05BA01 0 
Aminoacridine D08AA02 0 
Aminobenzoic acid D02BA01 0 
 Aminobutyric acid (GABA) N03AG03 NE 
Aminomethylbenzoic Acid B02AA03 NE 
Aminophenazone N02BB03 NE 
Aminophenazone, combinations excl. 
Psycholeptics 
N02BB53 NE 
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Aminophenazone, combinations with. 
Psycholeptics 
N02BB73 NE 
Aminophylline 
- Oral administration 
- Parenteral administration 
R03DA05  
0 
I 
Aminophylline and adrenergics R03DB05 NE 
Aminophylline, combinations R03DA55 NE 
Amiocaproic acid  B02AA01 0 
Amiodarone C01BD01 I 
Amisulpride N05AL05 II 
Amitriptyline N06AA09 III 
Amitryptiline and psycholeptics N06CA01 NE 
Amlexanox A01AD07 
R03DX01 
NE 
Amlodipine C08CA01 I 
Ammonium chloride B05XA04 0 
Amobarbital N05CA02 NE 
Amorolfine  D01AE16 0 
Amoxapine N06AA17 NE 
Amphotericin B  A01AB04 
A07AA07 
0 
Ampicilin S01AA19 NE 
Amrinone C01CE01 NE 
Ancrod B01AD09 NE 
Androstanolone A14AA01 NE 
Anecortave S01LA02 NE 
Anethole trithione A16AX02 NE 
Angiotensinamide C01CX06 NE 
 Anileridine N01AH05 NE 
Aniracetam N06BX11 NE 
Anistreplase B01AD03 NE 
Antacids with antispasmodics A02AG NE 
Antacids, other combinations A02AH 0 
Antacids with sodium bicarbonate A02AG 0 
Antazoline R01AC04 
R06AX05 
NE 
Antibiotics in combination  with other drugs S01AA20 Depending on the medicine in 
combination 
Antiinfectives, combinations 
 
S02AA30 0 
Antimony pentasulfide R05CA07 NE 
Antispasmodics in combination with other drugs A03ED 
 
II 
Antithrombin III B01AB02 0 
 Apomorphine N04BC07 II 
Apraclonidine S01EA03 II 
Aprepitant A04AD12 0 
Aprindine C01BB04 I 
Aprobarbital N05CA05 NE 
Apronal N05CM12 NE 
Aprotinin B02AB01 0 
Arbutamine C01CA22 NE 
Argatroban B01AE03 NE 
Arginine glutamate  A05BA01 NE 
Arginine hydrochloride B05XB01 NE 
Aripiprazole 
- Oral administration 
N05AX12  
II 
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- Parenteral administration: i.m. III 
 Articaine N01BB08 NE 
 Articaine combinations N01BB58 I 
Artificial tears and other indifferent preparations S01XA20 0 
Ascorbic acid S01XA15 NE 
Ascorbic acid (vit C) A11GA01 0 
Ascorbic acid (vit C) and calcium A11GA02 0 
Astemizole  R06AX11 I 
Atenolol C07AB03 I 
Atenolol - chlortalidone C07FB03 NE 
Atenolol - nifedipine C07FB03 NE 
Atenolol and other antihypertensives C07FB03 I 
Atenolol and other diuretics C07CB03 I 
Atenolol and other diuretics, combinations C07CB53 I 
Atenolol and thiazide C07BB03 I 
Atenolol, thiazides and other diuretics C07DB01 I 
Atomoxetine N06BA09 I 
Atorvastatin C10AA05 0 
Atorvastatin and amlodipine C10BX03 NE 
Atracurium M03AC04 III 
Atropine  A03BA01 
S01FA01 
III 
Atropine and psycholeptics A03CB03 NE 
Atropine+escopolamine+phenylephrine S01FAP1 III 
Attapulgite A07BC04 NE 
Attapulgite, combinations (combination with 
morphine) 
A07BC54 II 
Auranofin M01CB03 NE 
Aurothioglucose M01CB04 NE 
Aurotioprol M01CB05 NE 
Azapetine C04AX30 NE 
Azapropazone M01AX04 NE 
Azatadine R06AX09 II 
Azelaic acid D10AX03 0 
Azelastine R06AX19 
S01GX07 
I 
Azelastine antazoline R01AC03 0 
Azidamfenicol S01AA25 NE 
Azithromycin S01AA26 0 
   
B ATC CODE CATEGORISATION 
labelling 
Bacitracin D06AX05 0 
Bacitracin R02AB04 NE 
Baclofen M03BX01 II 
Balsalazide A07EC04 0 
Bambuterol R03CC12 NE 
Bamethan C04AA31 I 
Bamifylline R03DA08 NE 
Bamipine D04AA15 
R06AX01 
NE 
 Barbexaclone N03AA04 NE 
Barbital N05CA04 NE 
Barbiturates in combinations with other drugs N05CB02 NE 
Barnidipine C08CA12 NE 
Batroxobin  B02BX03 NE 
Becaplermin A01AD08 0 
 
DRUID 6th Framework Programme  Deliverable D.4.3.1  
Establishment of framework for classification/categorization 
and labelling of medicinal drugs and driving 
   Page 56 of 135 
 
D03AX06 
 Beclamide N03AX30 NE 
Beclometasone A07EA07 
D07AC15 
R01AD01 
R03BA01 
0 
Beclometasone and antibiotics D07CC04 0 
Befunolol S01ED06 I 
Belladonna total alkaloids A03BA04 NE 
Belladonna total alkaloids and psycholeptics A03CB02 NE 
Bemegride R07AB05 NE 
Bemiparin B01AB12 0 
Benazepril C09AA07 I 
Benazepril and diuretics C09BA07 I 
Bencyclane C04AX11 NE 
Bendazac M02AA11 
S01BC07 
NE 
Bendroflumethiazide C03AA01 0 
Bendroflumethiazide and potassium C03AB01 0 
Bendroflumethiazide and potassium-sparing 
agents (spirolactone) 
C03EA13 I 
Benflumethiazide - reserpine C02LA01 NE 
Benfluorex A10BX06 
C10AX04 
NE 
Benfotiamine  A11DA03 0 
Benidipine C08CA15 NE 
Benorilate N02BA10 NE 
Benoxaprofen M01AE06 NE 
Benperidol N05AD07 II 
Benproperine R05DB02 NE 
Benzalkonium  D08AJ01 
D09AA11 
R02AA16 
0 
Benzatropine N04AC01 NE 
Benzbromarone M04AB03 NE 
Benzethonium R02AA09 NE 
Benzethonium chloride D08AJ08 0 
Benzethonium chloride, combinations D08AJ58 0 
Benzilone A03AB01 NE 
Benziodarone C01DX04 NE 
Benziodarone, combinations C01DX54 NE 
Benzocaine C05AD03 
D04AB04 
N01BA05 
R02AD01 
0 
Benzoctamide N05BD01 NE 
Benzododecinium D09AA05 NE 
Benzonatate R05DB01 NE 
Benzoxonium chloride A01AB14 
D08AJ05 
NE 
Benzoyl peroxide D10AE01 0 
Benzoyl peroxide, combinations D10AE51 0 
Benzydamine A01AD02 
M02AA05 
0 
Benzydamine M01AX07 I 
Benzylpenicilin S01AA14 NE 
Bepridil C08EA02 NE 
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Beraprost B01AC19 NE 
Bergapten D05BA03 NE 
Betacarotene A11CA02 
D02BB01 
0 
Betahistine N07CA01 I 
Betaine A16AA06 0 
Betaine hydrochloride A09AB02 NE 
Betamethasone A07EA04 
C05AA05 
D07AC01 
D07XC01 
R01AD06 
0 
Betamethasone R03BA04 
S01BA06 
S02BA07 
S03BA03 
NE 
Betamethasone 
(Corticosteroids/antiinfectives/mydriatics in 
combination) 
S01CB04 Depending on the mydriatic in 
combination 
Betamethasone and antibiotics D07CC01 0 
Betamethasone and antiinfectives 
- Drops 
- Oinment 
S01CA05  
0 
I 
Betamethasone and antiinfectives S03CA06 0 
Betamethasone and antiseptics D07BC01 0 
Betamethasone and mydriatics S01BB04 Depending on the mydriatic in 
combination 
Betanidine C02CC01 NE 
Betaxolol C07AB05 
S01ED02 
I 
Betaxolol, combinations S01ED52 NE 
Bethanechol N07AB02 NE 
Bevantolol C07AB06 NE 
Bevantolol and thiazides C07BB06 NE 
Bevonium A03AB13 NE 
Bevonium and Analgesics A03DA03 NE 
Bevonium and psycholeptics A03CA06 NE 
Bezafibrate C10AB02 0 
Bezitramide N02AC05 NE 
Bibenzonium bromide R05DB12 NE 
Bibrocathol S01AX05 NE 
Bietaserpine C02AA07 NE 
Bietaserpine and diuretics C02LA07 NE 
Bietaserpine, combinations C02AA57 NE 
Bifemelane N06AX08 NE 
Bifonazole D01AC10 NE 
Bifonazole, combinations D01AC60 NE 
Bimatoprost  S01EE03 I 
Biotin A11HA05 0 
Biperiden  
- Oral administration 
- Parenteral administration 
N04AA02  
II 
III 
Biphenylol D08AE06 NE 
Bisacodyl A06AB02 
A06AG02 
0 
Bisacodyl, combinations A06AB52 0 
Bismuth preparations, combinations C05AX02 0 
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Bismuth subcitrate A02BX05 0 
Bismuth subnitrate A02BX12 NE 
Bisoprolol C07AB07 I 
Bisoprolol - hydrochlorothiazide C07BB 
Not yet determined 
NE 
Bisoprolol and thiazide C07BB07 I 
Bisoprolol, combinations C07AB57 I 
Bisoxatin A06AB09 NE 
Bithionol D10AB01 NE 
Bitolterol R03AC17 NE 
Bivalirudin B01AE06 0 
Blood plasma B05AX03 NE 
Bopindolol C07AA17 NE 
Bopindolol and other diuretics C07CA17 NE 
Boric acid  S02AA03 NE 
 Bornaprine N04AA11 NE 
Bosentan C02KX01 I 
Botulinum toxin A 
Botulinum toxin B 
M03AX01 II 
II 
Bretylium tosilate C01BD02 NE 
Brimonidine S01EA05 II 
Brinase B01AD06 NE 
Brinzolamide S01EC04 I 
Bromazepam N05BA08 III 
Bromazine R06AA01 NE 
Bromelains B06AA11 NE 
Bromhexine R05CB02 0 
Bromides N05CM11 NE 
Bromisoval N05CM03 NE 
Bromochlorosalicylanilide D01AE01 NE 
 Bromocriptine N04BC01 II 
Bromopride A03FA04 NE 
Bromperidol 
- Oral administration 
- Parenteral administration: depot i.m. 
N05AD06  
II 
III 
Brompheniramine R06AB01 II 
Brompheniramine, combinations R06AB51 II 
Brotizolam N05CD09 III 
Broxyquinoline A07AX01 NE 
Bucetin N02BE04 NE 
Bucetin, combinations excl. Psycholeptics N02BE54 NE 
Bucetin, combinations with Psycholeptics N02BE74 NE 
Bucillamine M01CC02 NE 
Bucladesine C01CE04 NE 
Buclizine R06AE01 II 
Buclizine, combinations R06AE51 Depending on the medicine in 
combination 
Budesonide  A07EA06 
D07AC09 
R01AD05 
R03BA02 
0 
 Budipine N04BX03 NE 
Bufexamac M01AB17 
M02AA09 
NE 
Buflomedil C04AX20 I 
Buformin A10BA03 NE 
Bufylline  R03DA10 NE 
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Bumadizone M01AB07 NE 
Bumetanide C03CA02 0 
Bumetanide and potassium C03CB02 0 
Bumetanide and potassium-sparing agents C03EB02 0 
Bunaftine C01BD03 NE 
Buphenine C04AA02 I 
 Bupivacaine N01BB01 I to III 
Depending on the route of 
administration 
 Bupivacaine combinations N01BB51 I to III 
Depending on the route of 
administration 
Bupranolol C07AA19 I 
Buprenorphine 
- Oral administration 
- Parenteral admin. 
- Transdermal admin  
N02AE01 
N07BC01 
 
III 
III 
III/II* 
*) prolonged release 
formulation; when a steady 
state of dosage has been 
reached 
Buprenorphine, combinations N07BC51 III 
Bupropion (amfebutamone) N07BA02 II 
Buspirone N05BE01 I 
Butalamine C04AX23 I 
Butamirate R05DB13 NE 
 Butanilicaine N01BB05 NE 
Butaperazine N05AB09 NE 
Butenafine  D01AE23 NE 
Butizide and potassium-sparing 
agents(spironolactone) 
C03EA14 NE 
Butobarbital N05CA03 NE 
Butorphanol N02AF01 NE 
Butriptyline N06AA15 NE 
Butylscopolamine  
- Oral administration 
- Parenteral administration (i.v) 
A03BB01  
I 
II 
Butylscopolamine and analgesics. 
- Oral administration 
- Parenteral administration  
A03DB04  
I 
II 
   
C ATC CODE CATEGORISATION 
labelling 
C1-inhibitor B02AB03 0 
 Cabergoline N04BC06 II 
Cadexomer iodine D03AX01 NE 
Cadmium compounds D11AC02 0 
Cadralazine C02DB04 NE 
Cafedrine C01CA21 NE 
Caffeine N06BC01 NE 
Calcifediol A11CC06 0 
Calcipotriol D05AX02 0 
Calcipotriol, combinations D05AX52 0 
Calcitriol A11CC04 
D05AX03 
0 
Calcium (different salts in combination) A12AA20 0 
Calcium acetate anhydrous A12AA12 0 
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Calcium alginate  B02BC08 NE 
Calcium carbasalate - metoclopramide N02BA15 NE 
Calcium carbimide N07BB02 II 
Calcium carbonate  A02AC01 
A12AA04 
0 
Calcium chloride A12AA07 
B05XA07 
0 
Calcium citrate lysine complex A12AA09 0 
Calcium compounds A07XA03 NE 
Calcium dobesilate C05BX01 0 
Calcium dobesilate, combinations C05BX51 0 
Calcium glubionate A12AA02 0 
Calcium glucoheptonate A12AA10 0 
Calcium gluconate A12AA03 0 
Calcium gluconate D11AX03 NE 
Calcium glycerylphosphate A12AA08 0 
Calcium hexamine thiocyanate R01AX01 NE 
Calcium lactate A12AA05 0 
Calcium lactate gluconate A12AA06 0 
Calcium laevulate A12AA30 0 
Calcium pangamate A12AA11 0 
Calcium pantothenate A11HA31 
D03AX04 
NE 
Calcium phosphate A12AA01 0 
Calcium silicate  A02AC02 0 
Camazepam N05BA15 NE 
Camolenic acid D11AX02 NE 
Camostat B02AB04 NE 
Camphora C01EB02 NE 
Camylofin A03AA03 NE 
Camylofin and analgesics A03DA05 NE 
Candesartan C09CA06 I 
Candesartan and diuretics C09DA06 I 
Canrenone C03DA03 NE 
Capsaicin M02AB01 
N01BX04 
0 
Captodiame N05BB02 NE 
Captopril C09AA01 I 
Captopril and diuretics C09BA01 I 
Carbachol N07AB01 
S01EB02 
NE 
 Carbamazepine N03AF01 II 
Carbamide B05BC02 NE 
Carbamide D02AE01 0 
Carbamide, combinations D02AE51 0 
Carbamide products D02AE 0 
Carbasalate calcium B01AC08 0 
Carbasalate calcium combinations excl. 
Psycholeptics 
N02BA65 NE 
Carbazochrome  B02BX02 NE 
Carbenoxolone  A02BX01 0 
Carbenoxolone, combinations excl. 
psycholeptics 
A02BX51 NE 
Carbenoxolone, combinations with 
psycholeptics 
A02BX77 NE 
Carbinoxamine R06AA08 II 
Carbocisteine R05CB03 0 
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Carbocromen C01DX05 NE 
Carbohydrates B05BA03 0 
Carbon dioxide producing drugs A06AX02 NE 
Carbromal N05CM04 NE 
Carbutamide A10BB06 NE 
Carbuterol R03AC10 
R03CC10 
NE 
Cardioplegia solutions B05XA16 0 
Carglumic acid A16AA05 0 
Carisoprodol M03BA02 II 
Carisoprodol, combinations excl. psycholeptics M03BA52 II 
Carisoprodol, combinations with psycholeptics M03BA72 II 
Caroverine A03AX11 NE 
Carteolol C07AA15 
S01ED05 
I 
Carteolol, combinations S01ED55 NE 
Carvedilol C07AG02 I 
Cascara A06AB07 0 
Cascara, combinations A06AB57 0 
Casopitant A04AD13 NE 
Castor oil  A06AB05 0 
Cathine A08AA07 NE 
Celecoxib M01AH01 I 
Celiprolol C07AB08 I 
Ceratonia A07XA02 NE 
Cerium oxalate A04AD02 NE 
Cerivastatin C10AA06 NE 
Cetiedil C04AX26 I 
Cetirizine R06AE07 II 
Cetrimide D08AJ04 
D11AC01 
0 
Cetrimonium  D08AJ02 0 
Cetrimonium R02AA17 NE 
Cetylpyridinium B05CA01 NE 
Cetylpyridinium D08AJ03 
D09AA07 
R02AA06 
0 
Chenodeoxycholic acid A05AA01 NE 
Chloral hydrate N05CC01 NE 
Chloralodol N05CC02 NE 
Chloramphenicol D06AX02 
D10AF03 
0 
Chloramphenicol 
- Drops 
- Oinment 
S01AA01  
0 
I 
Chloramphenicol S02AA01 
S03AA08 
NE 
Chlorbenzoxamine A03AX03 NE 
Chlorcyclizine R06AE04 NE 
Chlordiazepoxide N05BA02 II 
Chlorhexidine A01AB03 
D08AC02 
D09AA12 
R02AA05 
0 
Chlorhexidine B05CA02 
S02AA09 
S03AA04 
NE 
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Chlorhexidine, combinations D08AC52 0 
Chlormezanone M03BB02 II 
Chlormezanone, combinations excl. 
psycholeptics 
M03BB52 II 
Chlormezanone, combinations with 
psycholeptics 
M03BB72 II 
Chlormidazole D01AC04 NE 
Chlorobutanol  A04AD04 NE 
Chlorobutanol, combinations A04AD54 0 
Chloroform N01AB02 NE 
Chloroprednisolone and antiinfectives S01CA09 NE 
 Chloroprocaine N01BA04 NE 
Chloropyramine D04AA09 
R06AC03 
NE 
Chloropyramine, combinations R06AC53 NE 
Chlorothiazide C03AA04 NE 
Chlorothiazide and potassium C03AB04 NE 
Chlorothiazide, combinations C03AH01 NE 
Chloroxylenol D08AE05 0 
Chlorphenamine R06AB04 II 
Chlorphenamine, combinations R06AB54 II 
Chlorphenesin D01AE07 NE 
Chlorphenoxamine D04AA34 NE 
Chlorphenoxamine R06AA06 II 
Chlorphenoxamine, Combinations R06AA56 NE 
Chlorproethazine N05AA07 NE 
Chlorpromazine N05AA01 III 
Chlorpropamide A10BB02 I 
Chlorprothixene N05AF03 NE 
Chlorquinaldol  D08AH02 0 
Chlorquinaldol R02AA11 NE 
Chlortalidone C03BA04 I 
Chlortalidone and potassium C03BB04 I 
Chlortalidone and potassium-sparing agents 
(spirolactone) 
C03EA06 I 
Chlortetracycline A01AB21 
D06AA02 
 
0 
Chlortetracycline 
- Drops 
- Oinment 
S01AA02  
0 
I 
Chlorzoxazone M03BB03 II 
Chlorzoxazone, combinations excl. 
psycholeptics 
M03BB53 II 
Chlorzoxazone, combinations with 
psycholeptics 
M03BB73 II 
Cholic acid A05AA03 NE 
Choline alfoscerate N07AX02 NE 
Choline salicylate N02BA03 NE 
Choline theophyllinate R03DA02 NE 
Choline theophyllinate and adrenergics R03DB02 NE 
Chondroitin sulfate M01AX25 NE 
Chondroitin sulfate-iron complex B03AB07 NE 
Chymopapain  M09AB01 NE 
Chymotrypsin B06AA04 
S01KX01 
NE 
Cibenzoline C01BG07 I 
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Ciclesonide R03BA08 0 
Cicletanine C03BX03 0 
Ciclonicate C04AC07 NE 
Ciclonium and analgesics A03DA04 NE 
Ciclopirox  D01AE14 0 
Ciclosporin S01XA18 NE 
Cilansetron A03AE03 NE 
Cilazapril C09AA08 I 
Cilazapril and diuretics C09BA08 I 
Cilnidipine C08CA14 NE 
Cilostazol  B01AC 0 
Cimetidine  A02BA01 I 
Cimetidine, combinations  A02BA51 I 
Cimetropium bromide A03BB05 NE 
Cinchocaine C05AD04 
D04AB02 
0 
 Cinchocaine N01BB06 
S01HA06 
NE 
Cinchophen M04AC02 NE 
Cinepazet C01DX14 NE 
Cinepazide C04AX27 NE 
Cinitapride  A03FA 
(not ATC code) 
0 
Cinnarizine N07CA02 II 
Cinnarizine, combinations N07CA52 NE 
Cinolazepam N05CD13 NE 
Ciprofibrate C10AB08 0 
Ciprofloxacin 
- Drops 
- Oinment  
S01AX13  
0 
I 
Ciprofloxacin S02AA15 0 
Ciprofloxacin S03AA07 NE 
Cisapride A03FA02 0 
Cisatracurium M03AC11 III 
Citalopram N06AB04 I 
Citicoline N06BX06 NE 
Citiolone A05BA04 NE 
Citric acid  A09AB04 0 
Clebopride  A03FA06 0 
Clemastine D04AA14 NE 
Clemastine R06AA04 III 
Clemastine, combinations  R06AA54 III 
Clenbuterol R03AC14 
R03CC13 
NE 
Clidinium and psycholeptics A03CA02 NE 
Clindamycin D10AF01 0 
Clindamycin, combinations D10AF51 0 
Clioquinol  D08AH30 0 
Clioquinol D09AA10 
S02AA05 
0 
Clobazam N05BA09 II 
Clobenzorex A08AA08 NE 
Clobetasol D07AD01 0 
Clobetasol and antibiotics D07CD01 NE 
Clobetasone D07AB01 0 
Clobetasone S01BA09 NE 
Clobetasone and antiinfectives S01CA11 NE 
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Clobutinol R05DB03 NE 
Clocortolone D07AB21 NE 
Clodronic acid  M05BA02 0 
Clofedanol R05DB10 NE 
Clofenamide C03BA07 NE 
Clofenamide and potassium C03BB07 NE 
Clofezone M01AA05 
M02AA03 
NE 
Clofibrate C10AB01 NE 
Clofibride C10AB10 NE 
Clomethiazol N05CM02 I 
Clomipramine N06AA04 II 
 Clonazepam 
-  Oral administration 
-  Parenteral administration 
N03AE01  
II 
III 
Clonidine C02AC01 
N02CX02 
S01EA04 
II 
Clonidine and diuretics C02LC01 II 
Clonidine and diuretics, combinations with other 
drugs 
C02LC51 II 
Clonixin N02BG 
Not yet determined 
NE 
Clopamide C03BA03 I 
Clopamide and potassium C03BB03 I 
Clopenthixol N05AF02 NE 
Cloperastine R05DB21 I 
Clopidogrel B01AC04 0 
Clopidogrel + Acetilsalicilic acid B01AC30 Depending on the medicine in 
combination 
Cloranolol C07AA27 NE 
Clorazepate combinations N05CX04 NE 
Clorexolone C03BA12 NE 
Clorexolone, comb. with psycholeptics C03BA82 NE 
Clorhexidine S01AX09 NE 
Cloricromen B01AC02 NE 
Cloridarol C01DX15 I 
Clorindione B01AA09 NE 
Clotiapine 
- Oral administration 
- Parenteral administration: i.m./i.v. 
N05AX09  
II 
III 
Clotiazepam N05BA21 III 
Clotrimazole A01AB18 NE 
Clotrimazole D01AC01 0 
Clovoxamine N06AA 
Not yet determined 
NE 
Cloxazolam N05BA22 NE 
Clozapine N05AH02 III 
Coagulation factor IX  B02BD04 0 
Coagulation factor IX, II, VII and X in 
combination  
B02BD01 0 
Coagulation factor VII (in combination with 
other factors) 
B02BD05 0 
Coagulation factor VIII  B02BD02 0 
Coagulation factor XIII  B02BD07 NE 
Cobamamide B03BA04 0 
Cocaine N01BC01 NE 
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R02AD03 
S01HA01 
S02DA02 
Cod-liver oil ointments D03AA 0 
Codeine  
> 20 mg 
≤ 20 mg 
R05DA04  
II 
I 
Codeine, combinations excl .psycholeptics 
> 20 mg 
≤ 20 mg 
N02AA59  
II 
I 
Codeine, combinations with psycholeptics N02AA79 NE 
Colchicine M04AC01 0 
Colecalciferol A11CC05 0 
Colesevelam C10AC04 0 
Colestipol C10AC02 0 
Colestyramine C10AC01 0 
Colextran C10AC03 0 
Colfosceril palmitate  R07AA01 NE 
Colistin A07AA10 0 
Collagen  B02BC07 NE 
Collagen, combinations D11AX57 NE 
Collagenase D03BA02 NE 
Collagenase, combinations D03BA05 NE 
Comb. of rauwolfia alkaloids and diuretics incl. 
other combinations 
C02LA50 NE 
Combinations (Adrenergic and dopaminergic agents) C01CA30 I 
Combinations (Aluminium compounds) A02AB10 0 
Combinations (Analgesics and anesthetics) S02DA30 Depending on the medicine in 
combination 
 Combinations (Anesthetics, local, amides) N01BB20 NE 
Combinations (Antifungals for topical use, Antibiotics) D01AA20 NE 
Combinations (Butylpyrazolidines) M01AA99 NE 
Combinations (Calcium compounds) A02AC10 0 
Combinations (Caries prophylactic agents) A01AA30 NE 
Combinations (Enemas) A06AG20 0 
Combinations (Expectorants) R05CA10 NE 
Combinations (Imidazole and triazole derivatives) D01AC20 NE 
Combinations (Insulins and analogues for injection, fast-
acting) 
A10AB30 I 
Combinations (Insulins and analogues for injection, 
intermediate-acting) 
A10AC30 I 
Combinations (Insulins and analogues for injection, 
intermediate-acting combined with fast-acting) 
A10AD30 I 
Combinations (Insulins and analogues for injection, 
long-acting) 
A10AE30 I 
Combinations (Irrigating solutions, Antiinfectives) B05CA10 NE 
Combinations (Irrigating solutions, Salt solutions) B05CB10 0 
Combinations (Local anesthetics) S01HA30 I 
Combinations (Local hemostatics) B02BC30 0 
Combinations (Lung surfactants) R07AA30 NE 
Combinations (Magnesium compounds) A02AA10 0 
Combinations (Mucolytics) R05CB10 NE 
Combinations (Opium alkaloids and derivatives) R05DA20 Depending on the medicine in 
combination 
Combinations (Other cough suppressants) R05DB20 NE 
Combinations (Other intestinal adsorbents) A07BC30 NE 
Combinations (Other irrigating solutions) B05CX10 0 
Combinations (Other nasal preparations) R01AX30 NE 
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Combinations (Platelet aggregation inhibitors excl. 
heparin) 
B01AC30 Depending on the medicine in 
combination 
Combinations (Solutions for parenteral nutrition) B05BA10 0 
Combinations (Vitamin A and D, incl. combinations of 
the two) 
A11CC20 Depending on the medicine in 
combination 
Combinations of barbiturates N05CB01 NE 
Combinations of corticosteroids D07AB30 
D07XB30 
0 
Combinations of different antibiotics S01AA30 Depending on the medicine in 
combination 
Combinations of electrolytes B05XA30 0 
Combinations of rauwolfia alkaloids C02AA03 NE 
Combinations of rauwolfia alkoloids, 
combinations 
C02AA53 NE 
Combinations of vitamins A11JA 0 
Combinations of xanthines R03DA20 NE 
Combinations (Other antifungals for topical use) D01AE20 NE 
Combinations, (potassium) A12BA30 Depending on the medicine in 
combination 
Conivaptan C03XA02 NE 
Contact laxatives in combination A06AB20 0 
Contact laxatives in combination with 
belladonna alkaloids 
A06AB30 NE 
Cortisone S01BA03 NE 
Cosfocreatine C01EB06 NE 
Cough suppressants and expectorants R05FB02 Depending on the medicine in 
combination 
Cough suppressants and mucolytics R05FB01 Depending on the medicine in 
combination 
Crataegus glycosides C01EB04 NE 
Creatinolfosfate C01EB05 NE 
Creosote R05CA08 NE 
Cromoglicic acid A07EB01 
R01AC01 
R03BC01 
0 
Cromoglicic acid D11AH03 NE 
Cromoglicic acid S01GX01 I 
Cromoglicic acid, combinations R01AC51 
S01GX51 
NE 
Crospovidone A07BC03 NE 
Curcuma A05AX 
Not yet determined 
0 
Cxyphenonium, combinations A03AB53 NE 
Cyacobalamin B03BA01 0 
Cyamemazine N05AA06 NE 
Cyanocobalamin tannin complex B03BA02 NE 
Cyanocobalamin, combinations B03BA51 0 
Cyclandelate C04AX01 I 
Cyclizine  R06AE03 II 
Cyclizine, combinations R06AE53 Depending on the medicine in 
combination 
Cyclobarbital N05CA10 NE 
Cyclobenzaprine M03BX08 II 
Cyclobutyrol A05AX03 0 
Cyclopentamine R01AA02 NE 
Cyclopenthiazide C03AA07 0 
Cyclopenthiazide and potassium. C03AB07 NE 
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Cyclopenthiazide and potassium-sparing 
agents (spironolactone) 
C03EA07 NE 
Cyclopentolate S01FA04 III 
Cyclothiazide C03AA09 NE 
Cyclothiazide and potassium C03AB09 NE 
Cymarin C01AC03 NE 
Cyproheptadine R06AX02 II 
   
D ATC CODE CATEGORISATION 
labelling 
Dabigatran etexilate B01AE07 0 
Dalteparin B01AB04 0 
Danaparoid B01AB09 0 
Dantrolene M03CA1 II 
Dantron A06AB03 0 
Dantron, combinations A06AB53 0 
Dantron, incl. Combinations A06AG03 0 
Dapiprazole S01EX02 NE 
Dapsone D10AX05 0 
Darbepoetin alfa B03XA02 0 
Deanol N06BX04 I 
Debrisoquine C02CC04 NE 
Defibrotide B01AX01 NE 
Delapril C09AA12 I 
Delapril and diuretics C09BA12 I 
Delapril and manidipine C09BB12 I 
Demecarium S01EB04 NE 
Demeclocycline D06AA01 NE 
Denosumab  M05BX04 I 
Deptropine R06AX16 NE 
Dequalinium D08AH01 
R02AA02 
0 
Dermatan sulfate B01AX04 NE 
Deserpidine C02AA05 NE 
Deserpidine and diuretics. C02LA03 NE 
 Desflurane N01AB07 III 
Desipramine N06AA01 NE 
Desirudin B01AE01 0 
Deslanoside C01AA07 NE 
Desloratadine R06AX27 I 
Desonide D07AB08 
S01BA11 
NE 
Desonide and antiseptics D07BB02 NE 
Desoximetasone D07AC03 0 
Desoximetasone D07XC02 NE 
Desoxyribonuclease B06AA10 NE 
Desvenlafaxine N06AX23 NE 
Dexamethasone A01AC02 
C05AA09 
D07AB19 
D07XB05 
D10AA03 
R01AD03 
0 
Dexamethasone 
- Drops 
- Oinment 
S01BA01  
0 
I 
Dexamethasone S01CB01 Depending on the mydriatic in 
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combination 
Dexamethasone S02BA06 
S03BA01 
NE 
Dexamethasone and antibiotics D07CB04 NE 
Dexamethasone and antiinfectives 
- Drops 
- Oinment 
S01CA01  
0 
I 
Dexamethasone and antiinfectives S02CA06 
S03CA01 
0 
Dexamethasone, combinations R01AD53 NE 
Dexamfetamine N06BA02 II 
Dexbrompheniramine R06AB06 II 
Dexbrompheniramine, combinations R06AB56 NE 
Dexchlorpheniramine R06AB02 II 
DexchlorpheniramineCombinations R06AB52 II 
 Dexetimide N04AA08 NE 
Dexfenfluramine A08AA04 NE 
Dexibuprofen M01AE14 I 
Dexketoprofen M01AE17 I 
Dexmedetomidine N05CM18 NE 
Dexpanthenol A11HA30 0 
Dexpanthenol D03AX03 
S01XA12 
NE 
Dextran   B05AA05 0 
Dextranomer D03AX02 NE 
Dextriferron B03AB05 NE 
Dextriferron B03AC01 0 
Dextriferron (carboximaltosa) B03AD04 0 
Dextromethorphan R05DA09 I 
Dextromoramide N02AC01 NE 
Dextropropoxyphene N02AC04 NE 
Dextropropoxyphene combinations excl. 
psycholeptics 
N02AC54 NE 
Dextropropoxyphene, comb. With 
psycholepctics 
N02AC74 NE 
Dextrothyroxine C10AX01 NE 
Dezocine N02AX03 NE 
Diacerein M01AX21 NE 
Diamorphine N02AA09 NE 
Diastase A09AA01 NE 
Diazepam N05BA01 III 
Diazoxide C02DA01 I 
Dibenzepin N06AA08 III 
Dibotermin alfa (Kit for implant) M05BC01 0 
Dibrompropamidine D08AC01 0 
Dibrompropanamidine S01AX14 NE 
Dibunate R05DB16 NE 
Dichloralphenazone N05CC04 NE 
Dichlorobenzyl alcohol R02AA03 0 
Diclofenac M01AB05 
N02BG 
I 
Diclofenac (ophtalmologic use) S01BC03 0 
Diclofenac (topic use) M02AA15 
D11AX18 
0 
Diclofenac and antiinfectives S01CC01 0 
Diclofenac, combinations M01AB55 I 
Diclofenamide S01EC02 I 
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Dicoumarol B01AA01 NE 
Dicycloverine A03AA07 0 
Didecyldimethylammonium chloride D08AJ06 NE 
 Diethyl ether N01AA01 NE 
Difemerine A03AA09 NE 
Difenoxin A07DA04 NE 
Difenpiramide M01AB12 NE 
Diflorasone D07AC10 0 
Diflucortolone D07AC06 0 
Diflucortolone D07XC04 NE 
Diflucortolone and antiseptics D07BC04 0 
Diflunisal N02BA11 NE 
Difluprednate D07AC19 NE 
Digitalis leaves C01AA03 NE 
Digitoxin C01AA04 I 
Digoxin C01AA05 I 
Dihexyverine A03AA08 NE 
Dihydralazine C02DB01 NE 
Dihydralazine and diuretics C02LG01 NE 
Dihydralazine and diuretics, combinations with 
other drugs 
C02LG51 NE 
Dihydrocodeine  N02AA08 III/II* 
*)prolonged release 
formulation; when a steady 
state of dosage has been 
reached 
Dihydrocodeine combinations N02AA58 NE 
Dihydroergocristine C04AE04 I 
Dihydroergocristine, combinations C04AE54 I 
Dihydroergocrypti mesylate N04BC03 NE 
Dihydroergocryptine mesylate N04BC03 NE 
Dihydroergotamine N02CA01 NE 
Dihydrostreptomycin S01AA15 NE 
Dihydrotachysterol A11CC02 0 
Dihydroxialumini sodium carbonate A02AB04 0 
Diiodohydroxypropane D08AG04 NE 
Diisopromine A03AX02 NE 
Dilazep C01DX10 NE 
Diltiazem C08DB01 I 
Dimazole D01AE17 NE 
Dimecrotico acido A05AA (Not yet 
determined) 
0 
Dimefline R07AB08 NE 
Dimemorfan R05DA11 NE 
Dimetacrine N06AA18 NE 
Dimethoxanate R05DB28 NE 
Dimethyl sulfoxide M02AX03 NE 
DimethylaminopropionyIphenothiazine A03AC2 NE 
Dimethyltubocurarine M03AA04 III 
Dimetindene D04AA13 0 
Dimetindene R06AB03 II 
Dimetofrine C01CA12 NE 
Dimetotiazine N02CX05 NE 
Diosmectite A07BC05 NE 
Diosmin C05CA03 0 
Diosmin, combinations C05CA53 0 
Diphemanil A03AB15 NE 
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Diphemanil and psycholeptics A03CA08 NE 
Diphenadione B01AA10 NE 
Diphenhydramine  D04AA32 0 
Diphenhydramine R06AA02 III 
Diphenhydramine methylbromide  D04AA33 0 
Diphenhydramine, combinations R06AA52 III 
Diphenoxylate A07DA01 NE 
Diphenylpyraline R06AA07 NE 
Diphenylpyraline, combinations R06AA57 NE 
Dipiperonylamino-ethanol, combinations N05CX06 NE 
Dipivefrine S01EA02 NE 
Diprophylline R03DA01 NE 
Diprophylline and adrenergics R03DB01 NE 
Diprophylline, combinations R03DA51 NE 
Dipyridamole B01AC07 0 
Dipyrocetil, combinations with psycholeptics N02BA79 NE 
Dipyrocetyl N02BA09 NE 
Dipyrocetyl and corticosteroids M01BA02 NE 
Dipyrocetyl, combinations excl. Psycholeptics N02BA59 NE 
Disopyramide C01BA03 I 
Distigmine N07AA03 NE 
Disulfiram N07BB01 II 
Ditazole B01AC01 NE 
Dithranol D05AC01 0 
Dithranol, combinations D05AC51 0 
Dixyrazine N05AB01 NE 
Dobutamine C01CA07 I 
Docosanol D06BB11 NE 
Docusate sodium A06AA02 0 
Docusate sodium, incl. combinations A06AG10 0 
Dodeclonium bromide, combinations D08AJ59 NE 
Dofetilide C01BD04 NE 
Dolasetron A04AA04 NE 
Domiodol R05CB08 NE 
Domiphen  A01AB06 NE 
Domperidone A03FA03 0 
Donepezil N06DA02 II 
Dopamine C01CA04 I 
Dopexamine C01CA14 NE 
Dornase alfa (desoxyribonuclease) R05CB13 0 
Dorzolamide S01EC03 I 
Dosmalfato A02BX 0 
Dosulepin N06AA16 III 
Doxacurium chloride M03AC07 III 
Doxapram R07AB01 I 
Doxazosin C02CA04 I 
Doxefazepam N05CD12 NE 
Doxepin N06AA12 III 
Doxofylline R03DA11 NE 
Doxycycline A01AB22 0 
Doxylamine R06AA09 III 
Dronabinol A04AD10 NE 
 Droperidol N01AX01 III 
Droperidol, injectable N05AD08 III 
Dropropizine R05DB19 NE 
Drotaverine A03AD02 NE 
Drotrecogin alfa (activated) B01AD10 0 
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Droxicam M01AC04 NE 
Droxypropine R05DB17 NE 
Duloxetine N06AX21 II 
 Dyclonine N01BX02 
R02AD04 
NE 
Dyhydroergotamine, combinations N02CA51 NE 
   
E ATC CODE CATEGORISATION 
labelling 
Ebastine R06AX22 I 
Econazole D01AC03 0 
Ecothiopate S01EB03 NE 
Edoxudine D06BB09 NE 
Eflornithine D11AX16 0 
Efloxate C01DX13 NE 
Electrolytes  B05BB01 0 
Electrolytes in combination with other drugs  B05XA31 Depending on the medicine in 
combination 
Electrolytes with Carbohydrates B05BB02 0 
Eletriptan N02CC06 II 
Eltrombopag  B02BX05 0 
Emedastine S01GX06 I 
Emepronium and psycholeptics A03CA30 NE 
Emepronium, combinations N05CX05 NE 
Emodina A05AX  
Not yet determined 
NE 
Emylcamate N05BC03 NE 
Enalapril C09AA02 I 
Enalapril and diuretics C09BA02 I 
Enalapril and lercanidipine C09BB02 I 
Encainide C01BC08 NE 
Endralazine C02DB03 NE 
 Enflurane N01AB04 NE 
Enoxaparin B01AB05 0 
Enoximone C01CE03 NE 
Enoxolone D03AX10 NE 
Enprostil  A02BB02 NE 
 Entacapone N04BX02 II 
Eosin D08AX02 NE 
Epanolol C07AB10 NE 
Eperisone M03BX09 NE 
Ephedrine R01AB05 Depending on the medicine in 
combination 
Ephedrine R03CA02 I 
Ephedrine S01FB02 NE 
Ephedrine, combinations A08AA56 NE 
Epinastine R06AX24 I 
Epinastine S01GX10 NE 
Epinephrine A01AD01 
B02BC09 
0 
Epinephrine C01CA24 I 
Epinephrine R01AA14 
R03AA01 
S01EA01 
NE 
Epinephrine and other drugs for obstructive 
airway diseases  
R03AK01 NE 
Epinephrine, combinations S01EA51 NE 
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Epitizide and potassium-sparing agents 
(spironolactone) 
C03EA03 NE 
Eplerenone C03DA04 0 
Epomediol A05BA05 NE 
Epoprostenol B01AC09 0 
Eprazinone R05CB04 NE 
Eprosartan C09CA02 I 
Eprosartan and diuretics C09DA02 I 
Eprozinol R03DX02 NE 
Eptacog alfa (activated)  B02BD08 0 
Eptifibatide  B01AC16 0 
Eptotermin alfa M05BC02 0 
Erdosteine R05CB15 0 
Ergocalciferol (in combinacion, Vitalipid) A11CC01 0 
Ergoloid mesylates C04AE01 NE 
Ergoloid mesylates, combination C04AE51 I 
Ergotamine N02CA02 NE 
Ergotamine, combinations N02CA72 NE 
Ergotamine, combinations excl. psycholeptics N02CA52 I 
Eritrityl tetranitrate C01DA13 NE 
Eritrityl tetranitrate, combinations C01DA63 NE 
Erythrocytes B05AX01 NE 
Erythromycin D10AF02 0 
Erythromycin, combinations D10AF52 0 
Erythropoietin (epoetin alfa, beta, theta) B03XA01 0 
Erytromycin S01AA17 I 
Escitalopram N06AB10 I 
 Esketamine N01AX14 NE 
 Eslicarbazepine N03AF04 II 
Esmolol C07AB09 I 
Esomeprazole A02BC05 I 
Esomeprazole, amoxicillin and clarithromycin  A02BD06 NE 
Estazolam N05CD04 NE 
Eszopiclone N05CF04 NE (SMPC not yet published) 
Etacrynic acid C03CC01 NE 
Etafenone C01DX07 NE 
Etallobarbital N05CA20 NE 
Etamiphylline R03DA06 NE 
Etamiphylline and adrenergics R03DB06 NE 
Etamivan R07AB04 NE 
Etamsylate  B02BX01 0 
 Etanautine N04AB01 NE 
Ethacridine lactate B05CA08 
D08AA01 
NE 
Ethadione N03AC03 NE 
Ethanol D08AX08 0 
Ethchlorvynol N05CM08 NE 
Ethenzamide N02BA07 NE 
Ethenzamide, combinations excl. Psycholeptics N02BA57 NE 
Ethenzamide, combinations with psycholeptics N02BA77 NE 
 Ethosuximide combinations N03AD51 NE 
 Ethotoin N03AB01 NE 
 Ethoxusimide N03AD01 II 
Ethulose A06AC02 NE 
Ethyl biscoumacetate B01AA08 NE 
 Ethyl chloride N01BX01 NE 
Ethyl hydroxybenzoate D01AE10 NE 
 
DRUID 6th Framework Programme  Deliverable D.4.3.1  
Establishment of framework for classification/categorization 
and labelling of medicinal drugs and driving 
   Page 73 of 135 
 
Ethyl loflazepate N05BA18 NE 
Ethylestrenol A14AB02 NE 
Ethylmorphine R05DA01 III 
Ethylmorphine S01XA06 NE 
 Etidocain combinations N01BB57 NE 
 Etidocaine N01BB07 NE 
Etidronic acid M05BA01 I 
Etidronic acid and calcium, sequential M05BB01 NE 
Etifoxine N05BX03 NE 
Etilamfetamine A08AA06 NE 
Etilefrine C01CA01 I 
Etilefrine, combinations C01CA51 I 
 Etilevodopa and  decarboxylase inhibitor N04BA06 NE 
Etizolam N05BA19 NE 
Etodolac M01AB08 I 
Etofenamate M02AA06 0 
Etofibrate C10AB09 NE 
Etofylline nicotinate C04AD04 NE 
 Etomidate N01AX07 III 
Etoperidone N06AB09 NE 
Etoricoxib M01AH05 I 
Etozolin C03CX01 I 
Etretinate D05BB01 NE 
 Etybenzatropine N04AC30 NE 
Euflavine D08AA03 NE 
Exenatide A10BX04 I 
Ezetimibe C10AX09 0 
   
F ATC CODE CATEGORISATION 
labelling 
Factor VIII inhibitor bypassing activity B02BD03 0 
Famciclovir S01AD07 NE 
Famotidine A02BA03 I 
Famotidine, combinations A02BA53 I 
Fasudil C04AX32 NE 
Fat emulsions B05BA02 NE 
Fazadinium bromide  M03AC08 III 
Febarbamate M03BA05 II 
Febuxostat M04AA03 I 
Fedrilate R05DB14 NE 
 Felbamate N03AX10 NE 
Felbinac M02AA08 0 
Felodipine C08CA02 I 
Femoxetine (N06AB)  
Not yet determined 
NE 
Fenazocine N02AD02 NE 
Fenbufen M01AE05 NE 
Fencamfamin N06BA06 NE 
Fendiline C08EA01 NE 
Fenetylline N06BA10 NE 
Fenfluramine A08AA02 NE 
Fenofibrate C10AB05 0 
Fenoldopam C01CA19 NE 
Fenoprofen M01AE04 
N02BG 
NE 
Fenoterol R03AC04 0 
Fenoterol R03CC04 NE 
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Fenoterol and other drugs for obstructive 
airway diseases  
R03AK03 Depending on the medicine in 
combination 
Fenoverine A03AX05 NE 
Fenoxazoline R01AA12 NE 
Fenozolone N06BA08 NE 
Fenpiprane A03AX01 NE 
Fenpiverinium A03AB21 NE 
Fenproporex N06BA NE 
Fenquizone C03BA13 NE 
Fenspiride R03BX01 
R03DX03 
NE 
 Fentanyl 
- Oral administration 
- Parenteral administration 
- Transdermal administration   
N01AH01 
N02AB03 
 
III 
III 
III/II* 
*) prolonged release 
formulation; when a steady 
state of dosage has been 
reached 
Fentanyl combinations N01AH51 NE 
Fentiazac M01AB10 
M02AA14 
NE 
Fenticonazole D01AC12 0 
Fentonium A03BB04 NE 
Fenyramidol M03BX30 NE 
Feprazone M01AX18 
M02AA16 
NE 
Feprazone, combinations M01AX68 NE 
Ferric acetyl transferrin B03AB08 NE 
Ferric citrate B03AB06 0 
Ferric hydroxide B03AB04 0 
Ferric oxide dextran complex B03AC06 0 
Ferric proteinsuccinylate B03AB09 0 
Ferric sodium citrate B03AB01 NE 
Ferric sodium gluconate complex B03AC07 NE 
Ferric sorbitol gluconic acid complex B03AC05 NE 
Ferrous amino acid complex B03AD01 0 
Ferrous ascorbate B03AA10 NE 
Ferrous aspartate B03AA09 NE 
Ferrous carbonate B03AA04 NE 
Ferrous chloride B03AA05 NE 
Ferrous fumarate B03AA02 
B03AD02 
0 
Ferrous gluconate B03AA03 0 
Ferrous glycine sulfate B03AA01 0 
Ferrous iodine B03AA11 NE 
Ferrous succinate B03AA06 NE 
Ferrous sulfate B03AA07 
B03AD03 
0 
Ferrous tartrate B03AA08 NE 
Fexofenadine R06AX26 I 
Fibrinogen, human  B02BC10 0 
Fibrinolysin B01AD05 NE 
Fibrinolysin and desoxyribonuclease B06AA02 NE 
Finasteride  D11AX10 0 
Fipexide N06BX05 NE 
Flecainide C01BC04 I 
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Floctafenine N02BG04 NE 
Flosequinan C01DB01 NE 
Flourometholone and antiinfectives 
- Drops 
- Oinment 
S01CA07  
0 
I 
Fluanisone N05AD09 NE 
Flubiprofen S01BC04 NE 
Fluclorolone D07AC02 0 
Fluconazole D01AC15 NE 
Flucytosine  D01AE21 NE 
Fludiazepam N05BA17 NE 
Fludrocortisone and antiinfectives 
- Drops 
- Oinment 
S01CA06  
0 
I 
Fludrocortisone and antiinfectives S02CA07 
S03CA05 
0 
Fludroxycortide D07AC07 NE 
Fludroxycortide and antibiotics D07CC03 NE 
Flufenamic acid M01AG03 NE 
Flumedroxone N02CB01 NE 
Flumetasone  D07AB03 
D07XB01 
0 
Flumetasone and antibiotics D07CB05 NE 
Flumetasone and antiinfectives S02CA02 NE 
Flumetasone and antiseptics D07BB01 0 
Flunarizine N07CA03 II 
Flunisolide R03BA03 NE 
Flunitrazepam N05CD03 III 
Flunoxaprofen M01AE15 NE 
Fluocinolone acetonide C05AA10 
D07AC04 
0 
Fluocinolone acetonide S01BA15 
S02BA08 
NE 
Fluocinolone acetonide and antibiotics D07CC02 0 
Fluocinolone acetonide and antiinfectives S01CA10 NE 
Fluocinolone acetonide and antiinfectives S02CA05 0 
Fluocinolone acetonide and antiseptics D07BC02 0 
Fluocinonide C05AA11 
D07AC08 
0 
Fluocinonide and antibiotics D07CC05 0 
Fluocortin D07AB04 0 
Fluocortolone C05AA08 NE 
Fluocortolone D07AC05 0 
Fluocortolone and antibiotics D07CC06 NE 
Fluocortolone and antiinfectives S01CA04 NE 
Fluocortolone and antiseptics D07BC03 0 
Fluorescein S01JA01 0 
Fluorescein, combinations S01JA51 Depending on the medicine in 
combination 
Fluoride, combinations A12CD51 0 
Fluorocarbon blood substitutes B05AA03 NE 
Fluorometholone C05AA06 
D07XB04 
0 
Fluorometholone  
- Drops 
- Oinment 
S01BA07  
0 
I 
Fluorometholone  D07AB06 NE 
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D10AA01 
Fluorometholone S01CB05 Depending on the mydriatic in 
combination 
Fluorometholone and antibiotics D07CB03 NE 
Fluorometholone and mydriatics S01BB03 Depending on the mydriatic in 
combination 
Fluostigmine S01EB07 NE 
Fluoxetine N06AB03 I 
Flupentixol 
- Oral administration 
- Parenteral administration: depot i.m. 
N05AF01  
II 
III 
Fluperolone D07AB05 NE 
Fluphenazine: injection depot i.m. N05AB02 II 
Flupirtine N02BG07 NE 
Fluprednidene D07AB07 
D07XB03 
NE 
Fluprednidene and antibiotics D07CB02 NE 
Flurazepam N05CD01 III 
Flurbiprofen M01AE09 I 
Flurbiprofen M02AA19 
R02AX01 
0 
Fluspirilene: injection i.m. N05AG01 II 
Fluticasone  D07AC17 
R01AD08 
R03BA05 
0 
Fluticasone furoate R01AD12 0 
Flutrimazole D01AC16 0 
Fluvastatin C10AA04 0 
Fluvoxamine N06AB08 I 
Folic acid B03BB01 0 
Folic acid, combinations B03BB51 0 
Fomivirsen S01AD08 NE 
Fondaparinux B01AX05 0 
Formocortal S01BA12 NE 
Formoterol R03AC13 0 
Formoterol and other drugs for obstructive 
airway diseases  
R03AK07 Depending on the medicine in 
combination 
Fosaprepitant A04AD 0 
Fosinopril C09AA09 I 
Fosinopril and diuretics C09BA09 I 
 Fosphenytoin N03AB05 NE 
Framycetin D09AA01 
R01AX08 
S01AA07 
NE 
Frovatriptan N02CC07 II 
Fructose 1,6-diphosphate C01EB07 NE 
Fumaric acid D05AX01 NE 
Fumaric acid derivatives, combinations D05BX51 NE 
Funisolide R01AD04 0 
Furosemide C03CA01 0 
Furosemide and potassium C03CB01 0 
Furosemide and potassium-sparing agents C03EB01 0 
Fusafungine R02AB03 NE 
Fusidic acid D06AX01 
D09AA02 
0 
Fusidic acid 
- Drops 
S01AA13  
0 
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- Oinment I 
   
G ATC CODE CATEGORISATION 
labelling 
Gabapentin N03AX12 II 
Galantamine N06DA04 II 
Gallamine  M03AC02 III 
Gallopamil C08DA02 NE 
Galsulfase  A16AB08 I 
Gamolenic acid, combinations D11AX52 NE 
Ganciclovir S01AD09 0 
Gatifloxacin S01AX21 NE 
Gedocarnil N05BX02 NE 
Gefarnate A02BX07 NE 
Gefarnate, combinations with psycholeptics A02BX77 NE 
Gelatin agents B05AA06 0 
Gemfibrozil C10AB04 0 
Gentamicin  D06AX07 0 
Gentamicin 
- Drops 
- Oinment 
S01AA11  
0 
I 
Gentamicin S02AA14 
S03AA06 
NE 
Gepefrine C01CA15 NE 
Gepirone N06AX19 NE 
Ginkgo Biloba N06DX02 0 
Gitoformate C01AA09 NE 
Glafenine N02BG03 NE 
Glibenclamide A10BB01 I 
Glibornuride A10BB04 NE 
Gliclazide A10BB09 I 
Glimepiride A10BB12 I 
Glimepiride and pioglitazone A10BD06 I 
Glimepiride and rosiglitazone A10BD04 I 
Glipizide A10BB07 I 
Gliquidone A10BB08 I 
Glisoxepide A10BB11 NE 
Glucosamine M01AX05 I 
Glucosaminoglykan polysulfate M01AX12 NE 
Glucose B05CX01 0 
Glucose, combinations C05BB56 0 
Glutamic acid hydrochloride A09AB01 NE 
Glutamine  A16AA03 0 
Glutethimide N05CE01 NE 
Glycerol A06AG04 
A06AX01 
0 
Glyceryl trinitrate C01DA02 
C05AE01 
I 
Glyceryl trinitrate, combinations C01DA52 NE 
Glycine B05CX03 0 
Glycopyrronium A03AB02 0 
Glycopyrronium and psycholeptics A03CA05 NE 
Glycyrrhizic acid A05BA08 NE 
Glymidine A10BC01 NE 
Gramicidin R02AB30 NE 
Granisetron  A04AA02 0 
Griseofulvin D01AA08 NE 
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Griseofulvin  D01BA01 0 
G-strophanthin C01AC01 NE 
Guacetisal N02BA14 NE 
Guaiacolsulfonate R05CA09 NE 
Guaiazulen S01XA01 NE 
Guaifenesin R05CA03 I 
Guanazodine C02CC06 NE 
Guanethidine C02CC02 I 
Guanethidine S01EX01 NE 
Guanethidine and diuretics C02LF01 I 
Guanfacine C02AC02 II 
Guanoclor C02CC05 NE 
Guanoxabenz C02CC07 NE 
Guanoxan C02CC03 NE 
Guar gum A10BX01 0 
   
H ATC CODE CATEGORISATION 
labelling 
Hachimycin D01AA03 NE 
Halazepam N05BA13 NE 
Halcinonide D07AD02 NE 
Halometasone D07AC12 0 
Haloperidol 
- Oral administration 
- Parenteral administration:i.v./i.m. 
N05AD01  
II 
III 
Haloprogin D01AE11 NE 
 Halothane N01AB01 NE 
Hematin B06AB01 0 
Hemoglobin crosfumaril B05AA08 NE 
Hemoglobin glutamer (bovine) B05AA10 NE 
Hemoglobin raffimer B05AA09 NE 
Heparin B01AB01 
C05BA03 
0 
Heparin S01XA14 NE 
Heparin, combinations B01AB51 NE 
Heparin, combinations C05BA53 0 
Heparinoid, combinations C05BA51 0 
Heptabarbital N05CA11 NE 
Heptaminol C01DX08 NE 
Hexachlorophene D08AE01 NE 
Hexafluronium M03AC05 III 
Hexamidine D08AC04 
R01AX07 
R02AA18 
S01AX08 
S03AA05 
NE 
Hexapropymate N05CM10 NE 
Hexetidine A01AB12 0 
 Hexobarbital N01AF02 
N05CA16 
NE 
Hexobendine C01DX06 I 
Hexocyclium A03AB10 NE 
Hexoprenaline R03AC06 
R03CC05 
NE 
Hexylresorcinol R02AA12 0 
Hidrosmin C05CA05 0 
Histapyrrodine R06AC02 II 
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Histapyrrodine, combinations R06AC52 NE 
Homatropine S01FA05 III 
Human fibrinogen B02BB01 0 
Human fibrinogen / Human thrombin (Evicel®) B02BC 0 
Hyaluronic acid M09AX01 I 
Hyaluronic acid R01AX09 
S01KA01 
D03AX05 
NE 
Hyaluronic acid, combinations S01KA51 NE 
Hyaluronidase B06AA03 0 
Hydralazine C02DB02 I 
Hydralazine and diuretics C02LG02 I 
 Hydrixybutiric acid N01AX11 NE 
Hydrochloric acid A09AB03 NE 
Hydrochloric acid B05XA13 0 
Hydrochlorothiazide C03AA03 0 
Hydrochlorothiazide and potassium C03AB03 0 
Hydrochlorothiazide and potassium-sparing 
agents (spironolactone) 
C03EA01 I 
Hydrochlorothiazide, combinations C03AX01 0 
Hydrocodone R05DA03 II 
Hydrocortisone A01AC03 
A07EA02 
C05AA01 
D07AA02 
D07XA01 
0 
Hydrocortisone S01BA02 I Oinment 
Hydrocortisone (with mydriatics) S01CB03 Depending on the mydriatic in 
combination 
Hydrocortisone S02BA01 NE 
Hydrocortisone aceponate D07AC16 NE 
Hydrocortisone and antibiotics D07CA01 0 
Hydrocortisone and antiinfectives 
- Drops 
- Oinment 
S01CA03  
0 
I 
Hydrocortisone and antiinfectives S02CA03 0 
Hydrocortisone and antiinfectives S03CA04 0 
Hydrocortisone and antiseptics D07BA04 0 
Hydrocortisone and mydriatics S01BB01 Depending on the mydriatic in 
combination 
Hydrocortisone buteprate D07AB11 NE 
Hydrocortisone butyrate D07AB02 0 
Hydrocortisone butyrate and antiseptics D07BB04 NE 
Hydrocortisone, combinations R01AD60 NE 
Hydroflumethiazide C03AA02 0 
Hydroflumethiazide and potassium C03AB02 0 
Hydroflumethiazide, combinations C03AH02 NE 
Hydrogen peroxide A01AB02 
D08AX01 
0 
Hydrogen peroxide S02AA06 NE 
Hydromorphone  N02AA03 III/II* 
*) prolonged release 
formulation; when a steady 
state of dosage has been 
reached 
Hydromorphone and antispasmodics N02AG04 NE 
Hydroquinidine C01BA NE 
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Hydroquinine M09AA01 I 
Hydroquinone D11AX11 0 
Hydrotalcite A02AD04 0 
Hydroxocobalamin B03BA03 0 
Hydroxocobalamin, combinations B03BA53 0 
Hydroxybutyryc acid N07XX04 NE 
Hydroxyethylpromethazine R06AD05 NE 
Hydroxyethylpromethazine, combinations R06AD55 NE 
Hydroxyethylstarch B05AA07 0 
Hydroxyzine N05BB01 II 
Hydroxyzine, combinations N05BB51 NE 
Hymecromone A05AX02 NE 
Hyoscyamine A03BA03 NE 
Hyoscyamine and Psycholeptics A03CB31 NE 
Hypericine N06AX20 0 
Hypertonic solutions  B05DB 0 
Hypromellose S01KA02 0 
   
I ATC CODE CATEGORISATION 
labelling 
Ibacitabine D06BB08 NE 
Ibandronic acid  M05BA06 I 
Ibopamine C01CA16 
S01FB03 
NE 
Ibudilast R03DC04 NE 
Ibuprofen C01EB16 NE 
Ibuprofen M02AA13 0 
Ibuprofen M01AE01 
N02BG 
I 
Ibuprofen, combinations M01AE51 I 
Ibuproxam M01AE13 NE 
Ibutilide C01BD05 I 
Icatibant C01EB19 I 
Ichtasol D10BX01 NE 
Idanpramine A03AX06 NE 
Idebenone N06BX13 NE 
Idoxuridine D06BB01 0 
Idoxuridine S01AD01 NE 
Idursulfase  A16AB09 I 
Ifenprodil C04AX28 NE 
Iloprost (for inhalation use) B01AC11 II 
Imidapril C09AA16 I 
Imidazole salicylate N02BA16 NE 
Imiglucerase A16AB02 0 
Imipramine N06AA02 II 
Imipramine oxide N06AA03 NE 
Imiquimod   D06BB10 0 
Imolamine C01DX09 NE 
Indacaterol R03AC18 0 
Indalpine N06AB 
Not yet determined 
NE 
Indapamide C03BA11 0 
Indifferent preparations                                         S02DC Depending on the medicine in 
combination 
Indobufen B01AC10 NE 
Indometacin C01EB03 
S01BC01 
NE 
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Indometacin M01AB01 I 
Indometacin M02AA23 0 
Indometacin, combinations M01AB51 I 
Indoprofen M01AE10 NE 
Indoramin C02CA02 I 
Inosine  D06BB05 0 
Inosine S01XA10 NE 
Inositol   A11HA07 0 
Inositol nicotinate C04AC03 0 
Insulin (beef) A10AB02 I 
Insulin (beef) A10AC02 I 
Insulin (beef) A10AD02 I 
Insulin (beef) A10AE02 I 
Insulin (human) A10AB01 I 
Insulin (human) A10AC01 I 
Insulin (human) A10AD01 I 
Insulin (human) A10AE01 I 
Insulin (human) A10AF01 I 
Insulin (pork) A10AB03 I 
Insulin (pork) A10AC03 I 
Insulin (pork) A10AD03 I 
Insulin (pork) A10AE03 I 
Insulin aspart A10AB05 I 
Insulin aspart A10AD05 I 
Insulin detemir A10AE05 I 
Insulin glargine A10AE04 I 
Insulin glulisine A10AB06 I 
Insulin lispro A10AB04 I 
Insulin lispro A10AC04 I 
Insulin lispro A10AD04 I 
Insulin (human) A10AF01 I 
Interferon S01AD05 NE 
Invert sugar C05BB03 0 
Iodine D08AG03 0 
Iodine/octylphenoxypolyglycolether  D08AG01 NE 
Iodoform D09AA13 NE 
Iodoheparinate S01XA09 NE 
Ipecacuanha R05CA04 0 
Ipratropium bromide R01AX03 0 
Ipratropium bromide R03BB01 I 
Iprazochrome N02CX03 NE 
Ipriflavone M05BX01 NE 
Iprindole N06AA13 NE 
Iproclozide N06AF06 NE 
Iproniazide N06AF05 NE 
Irbesartan C09CA04 I 
Irbesartan and diuretics C09DA04 I 
Iron and multivitamins B03AE03 0 
Iron, multivitamins and folic acid B03AE02 0 
Iron, multivitamins and minerals B03AE04 0 
Iron, vitamin B12 and folic acid B03AE01 0 
Iron-sorbitol-citric acid complex B03AC03 NE 
Isoaminile R05DB04 NE 
Isobromindione M04AB04 NE 
Isocarboxazide N06AF01 NE 
Isoconazole D01AC05 NE 
Isoetarine R03AC07 NE 
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R03CC06 
 Isoflurane N01AB06 III 
Isometheptene  A03AX10 0 
Isoprenaline C01CA02 I 
Isoprenaline R03AB02 
R03CB01 
NE 
Isoprenaline and other drugs for obstructive 
airway diseases  
R03AK02 NE 
Isoprenaline, combinations R03CB51 NE 
Isopropamide A03AB09 NE 
Isopropamide and psycholeptics A03CA01 NE 
Isopropanol D08AX05 NE 
Isosorbide dinitrate C01DA08 
C05AE02 
I 
Isosorbide dinitrate, combinations C01DA58 NE 
Isosorbide mononitrate C01DA14 I 
Isothipendyl  D04AA22 NE 
Isothipendyl R06AD09 II 
Isotonic solutions B05DA 0 
Isotretinoin  
- Oral administration 
- Topical use 
D10AD04 
D10BA01 
 
II 
0 
Isotretinoin, combinations (with erythromycin, 
topical use) 
D10AD54 0 
Isoxsuprine C04AA01 I 
Ispaghula (psylla seeds) A06AC01 0 
Ispaghula, combinations A06AC51 0 
Isradipine C08CA03 I 
Itramin tosilate C01DX01 NE 
Itramin tosilate, combinations C01DX51 NE 
Ivabradine C01EB17 I 
   
K ATC CODE CATEGORISATION 
labelling 
Kallidinogenase C04AF01 NE 
Kanamycin A07AA08 
S01AA24 
NE 
Kaolin A07BC02 NE 
Kebuzone M01AA06 NE 
 Ketamine N01AX03 III 
Ketanserin C02KD01 NE 
Ketazolam N05BA10 NE 
Ketobemidone N02AB01 NE 
Ketobemidone and antispasmodics N02AG02 NE 
Ketoconazole D01AC08 0 
Ketoprofen M02AA10 0 
Ketoprofen M01AE03 
N02BG 
I 
Ketoprofen, combinations M01AE53 I 
Ketorolac M01AB15 I 
Ketorolac S01BC05 0 
Ketotifen R06AX17 II 
Ketotifen S01GX08 I 
   
L ATC CODE CATEGORISATION 
labelling 
Labetalol C07AG01 I 
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Labetalol and other diuretics C07CG01 I 
Labetalol and thiazides C07BG01 I 
Lacidipine C08CA09 I 
 Lacosamide N03AX18 II 
Lactic acid producing organisms A07FA01 0 
Lactic acid producing organisms, combinations A07FA02 0 
Lactitol A06AD12 0 
Lactulose A06AD11 0 
Lactulose, combinations A06AD61 NE 
Lafutidine  A02BA08 NE 
 Lamotrigine N03AX09 II 
Lanatoside C C01AA06 NE 
Lansoprazole A02BC03 I 
Lansoprazole, amoxicillin and clarithromycin  A02BD07 NE 
Lansoprazole, amoxicillin and metronidazole  A02BD03 NE 
Lansoprazole, tetracycline and metronidazole  A02BD02 NE 
Laronidase  A16AB05 I 
Latanoprost S01EE01 I 
Laurilsulfate, incl. combinations A06AG11 0 
Lepirudin B01AE02 0 
Lercanidipine C08CA13 I 
Letosteine R05CB09 NE 
Levacetylmethadol N07BC03 NE 
 Levetiracetam N03AX14 II 
Levobunolol S01ED03 I 
 Levobupivacaine N01BB10 I to III 
Depending on the route of 
administration 
Levocabastine R01AC02 0 
Levocabastine S01GX02 I 
Levocarnitine A16AA01 0 
Levocetirizine R06AE09 I 
 Levodopa N04BA01  II 
Levodopa and  decarboxylase inhibitor 
Levodopa+carbidopa 
Levodopa+benserazide 
N04BA02 II 
Levodopa, decarboxylase inhibitor and COMT 
inhibitor 
Levodopa+carbidopa+entocapone 
N04BA03 II 
Levodropropizine R05DB27 I 
Levofloxacin S01AX19 NE 
Levomepromazine N05AA02 III 
Levopenbutolol C07AA I 
Levorphanol N02AF NE 
Levosimendan C01CX08 I 
Levosulpiride  N05AL07 
A04AD 
II 
Levoverbenone R05CA11 NE 
Lidocaine S01HA07 
S02DA01 
NE 
Lidocaine (Anesthetics, local)  N01BB02 
C05AD01 
D04AB01 
R02AD02 
0 to III 
Depending on the route of 
administration 
Lidocaine (Antiarrhytmics, parenteral use) C01BB01 I 
Lidocaine,  combinations (Anesthetics, local)  N01BB52 
 
0 to III 
Depending on the route of 
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administration 
Lidoflazine C08EX01 NE 
Linopirdine N06BX09 NE 
Linseed A06AC05 0 
Linseed, combinations A06AC55 NE 
Linsidomine C01DX18 NE 
Liquid paraffin A06AA01 0 
Liquid paraffin, combinations A06AA51 0 
Liquid plaster D02AD 0 
Liraglutide A10BX07 I 
Lisinopril C09AA03 I 
Lisinopril and amlodipine C09BB03 I 
Lisinopril and diuretics C09BA03 I 
 Lisuride N02CA07 
G02CB02 
NE 
Lithium N05AN01 II 
Lithium succinate D11AX04 NE 
Lodoxamide S01GX05 I 
Lofepramine N06AA07 II 
Lofexidine N07BC04 NE 
Lomefloxacin 
- Drops 
- Oinment 
S01AX17  
0 
I 
Lomoxicam M01AC05 NE 
Lonazolac M01AB09 NE 
Loperamide A07DA03 0 
Loperamide oxide A07DA05 NE 
Loperamide, combinations A07DA53 Depending on the medicine in 
combination 
Loprazolam N05CD11 III 
Lorajmine C01BA12 NE 
Loratadine R06AX13 I 
Lorazepam N05BA06 III 
Lorazepam, combinations N05BA56 NE 
Lorcainide C01BC07 NE 
Lormetazepam N05CD06 III 
Losartan C09CA01 I 
Losartan and diuretics C09DA01 I 
Loteprednol S01BA14 NE 
Lovastatin C10AA02 0 
Lovastatin and nicotinic acid C10BA01 0 
Loxapine N05AH01 NE 
Lubiprostone A06AX03 NE 
Lumiracoxib M01AH06 NE 
Lysine  B05XB03 NE 
Lysozyme  D06BB07 0 
   
M ATC CODE CATEGORISATION 
labelling 
Macrogol A06AD15 0 
Macrogol, combinations A06AD65 0 
Mafenide D06BA03 NE 
Magaldrate A02AD02 0 
Magaldrate and antiflatulents A02AF01 0 
Magnesium (different salts in combination) A12CC30 0 
Magnesium aspartate A12CC05 NE 
Magnesium carbonate  A02AA01 0 
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Magnesium carbonate  A06AD01 NE 
Magnesium chloride A12CC01 
B05XA11 
0 
Magnesium citrate A06AD19 
A12CC04 
B05CB03 
NE 
Magnesium gluconate A12CC03 NE 
Magnesium hydroxide A02AA04 0 
Magnesium lactate A12CC06 0 
Magnesium levulinate A12CC07 NE 
Magnesium orotate A12CC09 NE 
Magnesium oxide  A06AD02 NE 
Magnesium oxide A12CC10 0 
Magnesium peroxide  A02AA03 
A06AD03 
NE 
Magnesium phosphate B05XA10 0 
Magnesium pidolate A12CC08 0 
Magnesium pyridoxal 5-phosphate glutamate C10AX07 NE 
Magnesium silicate  A02AA05 0 
Magnesium sulfate A06AD04 
B05XA05 
NE 
Magnesium sulfate A12CC02 
D11AX05 
NE 
Mandelic acid B05CA06 NE 
Manidipine C08CA11 I 
Mannitol A06AD16 NE 
Mannitol B05BC01 
B05CX04 
0 
Maprotiline 
- Oral administration:  
- Parenteral administration 
N06AA21  
II 
III 
 Mazaticol N04AA10 NE 
Mazindol A08AA05 NE 
Mebeverine A03AA04 0 
Mebhydrolin R06AX15 II 
Mebutamate N05BC04 NE 
Mebutizide C03AA13 NE 
Mebutizide and potassium-sparing agents 
(spironolactone) 
C03EA05 NE 
Meclocycline D10AF04 0 
Meclofenamic acid M01AG04 
M02AA18 
NE 
Meclofenoxate N06BX01 NE 
Meclozine R06AE05 II 
Meclozine, combinations R06AE55 NE 
Mecobalamin B03BA05 NE 
Medazepam N05BA03 NE 
Medicinal charcoal A07BA01 0 
Medicinal charcoal, combinations A07BA51 0 
Medifoxamine N06AX13 NE 
Medrysone S01BA08 NE 
Mefenamic Acid M01AG01 
N02BG 
I 
Mefenorex A08AA09 NE 
Mefruside C03BA05 NE 
Mefruside and potassium C03BB05 NE 
Meglutol C10AX05 NE 
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Melagatran B01AE04 NE 
Melatonin N05CH01 I 
 Melevodopa N04BA04 NE 
 Melevodopa and decarboxylase inhibitor N04BA05 NE 
Melitracen N06AA14 NE 
Melitracen and psycholeptics N06AC02 NE 
Meloxicam M01AC06 I 
Melperone N05AD03 NE 
Memantine N06DX01 II 
Menadione B02BA02 0 
Mepartricin A01AB16 
D01AA06 
NE 
Mepenzolate A03AB12 NE 
Mephenesin M03BX06 II 
Mephenoxalone N05BX01 NE 
Mephentermine C01CA11 NE 
 Mephenytoin N03AB04 NE 
 Mephenytoin, combinations N03AB54 NE 
 Mepivacaine N01BB03 0 to III 
Depending on the route of 
administration 
 Mepivacaine combinations N01BB53 I 
Mepixanox R07AB09 NE 
Meprobamate N05BC01 NE 
Meprobamate in association N05CX01 NE 
Meprobamate, combinations N05BC51 NE 
Meprotixol R05DB22 NE 
Meptazinol N02AX05 NE 
Mepyramine   D04AA02 0 
Mepyramine R06AC01 II 
Mequinol D11AX06 0 
Mequitazine R06AD07 II 
Mercaptamine  A16AA04 I 
Mercuric amidochloride D08AK01 NE 
Mercuric chloride D08AK03 NE 
Mercuric iodide D08AK30 NE 
Mercurochrome D08AK04 0 
Mercury compounds S01AX01 NE 
Mercury, metallic D08AK05 NE 
Mersalyl C03BC01 NE 
Mesalazine A07EC02 0 
Mesna R05CB05 NE 
Mesoridiazine N05AC03 NE 
Mesulfen D10AB05 NE 
 Mesuximide N03AD03 NE 
 Metabutethamine N01BA01 NE 
Metahexamide A10BB10 NE 
Metamfetamine N06BA03 NE 
Metamizole sodium (noramydopyrine) N02BB02 NE 
Metamizole sodium, combinations excl. 
Psycholeptics 
N02BB52 NE 
Metamizole sodium, combinations with. 
Psycholeptics 
N02BB72 NE 
Metandienone A14AA03 
D11AE01 
NE 
Metaraminol C01CA09 NE 
Metenolone A14AA04 0 
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Metformin  A10BA02 0 
Metformin and pioglitazone A10BD05 0 
Metformin and rosiglitazone A10BD03 0 
Metformin and sitagliptin A10BD07 I 
Metformin and sulfonamides A10BD02 I 
Metformin and vildagliptin A10BD08 I 
 Methabarbital N03AA30 NE 
Methadone 
- Oral administration:  
- Parenteral administration 
N07BC02  
II 
III 
Methadone. Comb. Excl. Psycholectics N02AC52 NE 
Methantheline A03AB07 NE 
Methapyrilene R06AC05 NE 
Methaqualone N05CM01 NE 
Methaqualone, combinations N05CX02 NE 
Methazolamide S01EC05 NE 
Methdilazine R06AD04 NE 
Methiosulfonium chloride  A02BX04 NE 
Methocarbamol M03BA03 II 
Methocarbamol, combinations excl. 
psycholeptics 
M03BA53 II 
Methocarbamol, combinations with 
psycholeptics 
M03BA73 II 
 Methohexital N01AF01 NE 
Methoserpidine C02AA06 NE 
Methoserpidine and diuretics C02LA04 NE 
Methoxamine C01CA10 NE 
Methoxsalen D05AD02 NE 
Methoxsalen  D05BA02 0 
Methoxy polyethylene glycol-epoetin beta B03XA03 0 
 Methoxyflurane N01AB03 NE 
Methoxyphenamine R03CB02 NE 
Methyclothiazide C03AA08 NE 
Methyclothiazide and potassium. C03AB08 NE 
Methylatropine A03BB02 NE 
Methylcellulose A06AC06 0 
Methyldigoxin C01AA08 I 
Methyldopa (levorotatory) C02AB01 II 
Methyldopa (levorotatory) and diuretics C02LB01 II 
Methyldopa (racemic) C02AB02 II 
Methylhomatropine and psycholeptics A03CB04 NE 
Methylnaltrexone Bromide  A06AH01 0 
Methylpentynol N05CM15 NE 
Methylpentynol, combinations N05CX03 NE 
Methylphenidate N06BA04 II 
 Methylphenobarbital N03AA01 NE 
Methylprednisolone  D07AA01 NE 
Methylprednisolone D10AA02 0 
Methylprednisolone aceponate D07AC14 0 
Methylprednisolone and antibiotics D07CA02 NE 
Methylprednisolone and antiinfectives S01CA08 NE 
Methylpropylpropanediol dinitrate C01DA04 NE 
Methylpropylpropanediol dinitrate, combinations C01DA54 NE 
Methylprylon N05CE02 NE 
Methylrosaniline D01AE02 0 
Methylscopolamine A03BB03 
S01FA03 
NE 
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Methylscopolamine and psycholeptics (with 
Chlordiazepoxide) 
A03CB01 II 
Methysergide N02CA04 NE 
Meticrane C03BA09 NE 
Metipranolol S01ED04 NE 
Metipranolol and thiazides, combinations C07BA68 NE 
Metipranolol, combinations S01ED54 NE 
Metirosine C02KB01 NE 
 Metixene  N04AA03 NE 
Metizoline R01AA10 NE 
Metoclopramide  
- Oral administration 
- Parenteral administration  
A03FA01  
I 
II 
Metolazone C03BA08 I 
Metolazone and potassium-sparing agents 
(spironolactone) 
C03EA12 NE 
Metopimazine A04AD05 NE 
Metoprolol C07AB02 I 
Metoprolol - chlortalidone C07BB02 NE 
Metoprolol - felodipin C07FB02 NE 
Metoprolol and other antihypertensives C07FB02 I 
Metoprolol and other diuretics C07CB02 I 
Metoprolol and thiazides C07BB02 I 
Metoprolol and thiazides, combinations C07BB52 I 
Metoprolol, combinations C07AB52 I 
Metronidazole  A01AB17 
D06BX01 
0 
Mexiletine C01BB02 I 
Mianserin N06AX03 III 
Miconazole A01AB09 
A07AC01 
D01AC02 
0 
Miconazole S02AA13 NE 
Miconazole, combinations D01AC52 0 
Micronomicin S01AA22 NE 
Midazolam N05CD08 III 
Midodrine C01CA17 NE 
Miglitol A10BF02 0 
Miglustat  A16AX06 I 
Milnacipran N06AX17 NE 
Milrinone C01CE02 I 
Minaprine N06AX07 NE 
Mineral salts in combination A06AD10 NE 
Minocycline  A01AB23 0 
Minoxidil C02DC01 I 
Minoxidil D11AX01 0 
Mirtazapine N06AX11 III 
Misoprostol A02BB01 0 
Mitiglinide A10BX08 NE 
Mivacurium chloride M03AC10 III 
Mizolastine R06AX25 II 
Moclobemide N06AG02 II 
Modafinil NO6BA07 II 
Moexipril C09AA13 I 
Moexipril and diuretics C09BA13 I 
Mofebutazone M01AA02 
M02AA02 
NE 
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Molindone N05AE02 NE 
Molsidomine C01DX12 NE 
Mometasone D07AC13 
D07XC03 
R01AD09 
R03BA07 
0 
Monobenzone D11AX13 NE 
Monoethanolamine oleate C05BB01 0 
Monoxerutin C05CA02 0 
Montelukast R03DC03 0 
Moperone N05AD04 NE 
Moracizine C01BG01 NE 
Morclofone R05DB25 NE 
Morniflumate M01AX22 I 
Morphine 
- Oral administration  
- Parenteral administration 
N02AA01  
III/II* 
III 
*) prolonged release 
formulation; when a steady 
state of dosage has been 
reached 
Morphine and antispasmodics N02AG01 NE 
Morphine combinations N02AA51 NE 
Morphine, combinations. A07DA52 II 
Morpholine salicylate N02BA08 NE 
Mosapramine N05AX10 NE 
Motretinide D10AD05 NE 
Moxaverine A03AD30 NE 
Moxifloxacin S01AX22 0 
Moxisylyte C04AX10 I 
Moxonidine C02AC05 II 
Moxonidine and diuretics C02LC05 II 
Multienzymes (lipase, protease etc.) A09AA02 0 
Multienzymes and acid preparations A09AC02 NE 
Multivitamins and calcium A11AA02 0 
Multivitamins and iron A11AA01 0 
Multivitamins and other minerals, incl. 
combinations 
A11AA03 0 
Multivitamins and trace elements A11AA04 0 
Mupirocin D06AX09 
R01AX06 
0 
Muzolimine C03CD01 NE 
Myristyl-benzalkonium R02AA10 NE 
   
N ATC CODE CATEGORISATION 
labelling 
Nabilone  A04AD11 II 
Nabumetone M01AX01 I 
Nadolol C07AA12 I 
Nadolol and thiazides C07BA12 I 
Nadroparin B01AB06 0 
Naftidrofuryl C04AX21 I 
Naftifine  D01AE22 0 
Nalbuphine N02AF02 NE 
Naltrexone N07BB04 II 
Nandrolone A14AB01 0 
Nandrolone S01XA11 NE 
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Naphazoline R01AA08 0 
Naphazoline R01AB02 NE 
Naphazoline S01GA01 I 
Naphazoline, combinations S01GA51 Depending on the medicine in 
combination 
Naproxen M02AA12 NE 
Naproxen M01AE02 
N02BG 
I 
Naratriptan N02CC02 II 
 Narcobarbital N01AG01 NE 
Natamycin A01AB10 
A07AA03 
D01AA02 
S01AA10 
NE 
Nateglinide A10BX03 I 
Natural phospholipids R07AA02 NE 
Nebivolol C07AB12 I 
Nedocromil R01AC07 
R03BC03 
0 
Nedocromil S01GX04 I 
Nefazodone N06AX06 II 
Nefopam N02BG06 II 
Neltenexine R05CB14 NE 
Neomycin   A01AB08 
A07AA01 
D06AX04 
0 
Neomycin B05CA09 
R02AB01 
S02AA07 
S03AA01 
NE 
Neomycin 
- Drops 
- Oinment 
S01AA03  
0 
I 
Neomycin, combinations A07AA51 0 
Neostigmine 
- Oral administration 
- Parenteral administration   
N07AA01  
II 
III 
Neostigmine S01EB06 NE 
Neostigmine, combinations N07AA51 NE 
Nepafenac S01BC10 NE 
Nepinalone R05DB26 NE 
Nesiritide C01DX19 NE 
Netilmicin S01AA23 NE 
Nialamide N06AF02 NE 
Niaprazine N05CM16 NE 
Nicardipine C08CA04 I 
Nicergoline C04AE02 I 
Niceritrol C10AD01 NE 
Nicofetamide A03AC04 NE 
Nicofuranose C10AD03 NE 
Nicomorphine N02AA04 NE 
Nicorandil C01DX16 I 
Nicotinamide  A11HA01 0 
Nicotine N07BA01 0 
Nicotinic acid C04AC01 
C10AD02 
0 
Nicotinic acid, combinations C10AD52 0 
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Nicotinyl alcohol (pyridylcarbinol) C04AC02 
C10AD05 
NE 
Nicotinyl methylamide A05AB01 NE 
Nifedipine C08CA05 I 
Nifedipine, combinations C08CA55 I 
Nifenazone M02AA24 
N02BB05 
NE 
Niflumic acid M01AX02 I 
Niflumic acid (topic use) M02AA17 0 
Nifuroxazide A07AX03 NE 
Nifurzide A07AX04 NE 
Nikethamide R07AB02 NE 
Nikethamide, combinations R07AB52 NE 
Nilvadipine C08CA10 I 
Nimesulide M01AX17 I 
Nimodipine C08CA06 I 
Niperotidine  A02BA05 NE 
Nisoldipine C08CA07 I 
Nitisinone  A16AX04 I 
Nitrazepam N05CD02 III 
Nitrendipine C08CA08 I 
Nitric oxide R07AX01 0 
Nitrofural D08AF01 
D09AA03 
0 
Nitrofural B05CA03 
S01AX04 
S02AA02 
NE 
Nitroprusside C02DD01 I 
 Nitrous acid combinations N01AX63 NE 
 Nitrous oxide N01AX13 III 
Nizatidine A02BA04 I 
Nizofenone N06BX10 NE 
Nomifensine N06AX04 NE 
Nonacog alfa B02BD09 0 
Nordazepam N05BA16 NE 
Norepinephrine C01CA03 I 
Norethandrolone A14AA09 NE 
Norfenefrine C01CA05 NE 
Norfloxacin S01AX12 0 
Normethadone R05DA06 NE 
Nortriptyline N06AA10 II 
Noscapine R05DA07 0 
Noxytiolin B05CA07 NE 
Nystatin A07AA02 
D01AA01 
0 
   
O ATC CODE CATEGORISATION 
labelling 
Octenide, combinations D08AJ57 NE 
Octinoxate D02BA02 0 
Octopamine C01CA18 NE 
Ofloxacin S01AX11 0 
Ofloxacin S02AA16 NE 
Oil A06AG06 0 
Olaflur A01AA03 NE 
Olanzapine 
- Oral administration 
N05AH03  
II 
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- Parenteral administration: i.m. III 
Olmesartan medoxomil C09CA08 I 
Olmesartan medoxomil and amlodipine C09DB02 I 
Olmesartan medoxomil and diuretics C09DA08 I 
Olopatadine S01GX09 I 
Olopatadine R01AC08 NE 
Olsalazine  A07EC03 0 
Omalizumab R03DX05 0 
Omega-3-triglycerides C10AX06 NE 
Omeprazole A02BC01 I 
Omeprazole, amoxicillin and clarithromycin  A02BD05 NE 
Omeprazole, amoxicillin and metronidazole  A02BD01 NE 
Omoconazole D01AC13 NE 
Ondansetron A04AA01 0 
Opipramol N06AA05 NE 
Opium  A07DA02 II 
Opium N02AA02 NE 
Opium alkaloids with morphine R05DA05 NE 
Opium derivatives and expectorants R05FA02 II or higher depending on the 
medicine in combination 
Opium derivatives and mucolytics R05FA01 NE 
Oral rehydration salt formulations A07CA 0 
Orciprenaline R03AB03 NE 
Orciprenaline R03CB03 I 
Orciprenaline, combinations R03CB53 NE 
Ordinary salt combinations A02AD01 0 
Ordinary salt combinations and antiflatulents A02AF02 0 
Organic nitrates in combination C01DA20 NE 
Organic nitrates in combination with 
psycholeptics 
C01DA70 NE 
Organo-heparinoid C05BA01 0 
Orgotein M01AX14 NE 
Orlistat  A08AB01 0 
Ornithine oxoglurate A05BA06 NE 
 Orphenadrine  N04AB02  II 
Orphenadrine (citrate)  M03BC01 II 
Orphenadrine, combinations M03BC51 II 
Other antipruritics D04AX NE 
Other emollients and protectives D02AX 0 
Other plasma protein fractions B05AA02 NE 
Other preparations, combinations C05AX03 0 
Others (Medicated shampoos) D11AC30 NE 
Otilonium bromide A03AB06 0 
Otilonium bromide and psycholeptics A03CA04 NE 
Oxabolone cipionate A14AB03 NE 
Oxaceprol D11AX09 
M01AX24 
NE 
Oxaflozane N06AX10 NE 
Oxametacin M01AB13 NE 
Oxandrolone A14AA08 NE 
Oxaprotilin N06AA 
Not yet determined 
NE 
Oxaprozin M01AE12 NE 
Oxatomide R06AE06 II 
Oxazepam N05BA04 III 
 Oxcarbazepine N03AF02 II 
Oxedrine C01CA08 NE 
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S01GA06 
Oxedrine, combinations S01GA56 NE 
Oxeladin R05DB09 NE 
Oxetacaine C05AD06 0 
Oxetorone N02CX06 NE 
Oxiconazole D01AC11 0 
Oxidized cellulose  B02BC02 NE 
Oxiracetam N06BX07 NE 
Oxitriptan N06AX01 NE 
Oxitropium bromide R03BB02 NE 
Oxolamine R05DB07 NE 
Oxomemazine R06AD08 II 
Oxovinca C04AX 
Not yet determined 
NE 
Oxprenolol C07AA02 I 
Oxprenolol - chlortalidone C07BA 
Not yet determined 
NE 
Oxprenolol and other diuretics C07CA02 I 
Oxprenolol and thiazides C07BA02 I 
Oxybuprocaine D04AB03 NE 
Oxybuprocaine S01HA02 I 
Oxycinchophen M01CA03 NE 
Oxycodone  N02AA05 III/II* 
*) prolonged release 
formulation; when a steady 
state of dosage has been 
reached 
Oxyfedrine C01DX03 I 
Oxyfedrine, combinations C01DX53 NE 
Oxymetazoline R01AA05 0 
Oxymetazoline R01AB07 NE 
Oxymetazoline S01GA04 I 
Oxymetholone A14AA05 NE 
Oxymorphone N02AA 
Not yet determined 
NE 
Oxypertine N05AE01 NE 
Oxyphenbutazone M01AA03 
M02AA04 
S01BC02 
NE 
Oxyphencyclimine A03AA01 NE 
Oxyphencyclimine and psycholeptics A03CA03 NE 
Oxyphenisatine A06AB01 NE 
Oxyphenonium A03AB03 NE 
Oxyquinoline  A01AB07 0 
Oxyquinoline D08AH03 NE 
Oxyquinoline R02AA14 NE 
Oxytetracycline D06AA03 0 
Oxytetracycline 
- Drops 
- Oinment 
S01AA04  
0 
I 
   
P ATC CODE CATEGORISATION 
labelling 
Paliperidone N05AX13 NE 
Palonosetron  A04AA05 0 
Pamidronic acid  M05BA03 II 
Pancuronium M03AC01 III 
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Pantethine A11HA32 NE 
Pantoprazole A02BC02 I 
Pantoprazole, amoxicillin and clarithromycin  A02BD04 NE 
Papaveretum N02AA10 NE 
Papaverine A03AD01 NE 
Paracetamol N02BE01 0 
Paracetamol, combinations excl psycholeptics N02BE51 NE 
Paracetamol, combinations with Psycholeptics N02BE71 NE 
Paraldehyde N05CC05 NE 
 Paramethadione N03AC01 NE 
Paraoxon S01EB10 NE 
Parecoxib M01AH04 
N02BG 
I 
Pargyline C02KC01 NE 
Pargyline and diuretics C02LL01 NE 
Parnaparin B01AB07 NE 
Paromomycin A07AA06 0 
Paroxetine N06AB05 I 
Passiflore aubepine C01EB 
Not yet determined 
NE 
Passiflore-extract N05CM20 NE 
Pecilocin D01AA04 NE 
Pectin  A07BC01 0 
Pegaptanib  S01LA03 III 
Pegloticase M04AX02 NE 
Pemoline N06BA05 I 
Penbutolol C07AA23 I 
Penbutolol and other diuretics C07CA23 I 
Penciclovir D06BB06 0 
Penfluridol N05AG03 II 
Penicillamine M01CC01 0 
Pentaerithrityl A06AD14 NE 
Pentaerithrityl tetranitrate C01DA05 I 
Pentaerithrityl tetranitrate, combinations C01DA55 NE 
Pentazocine  N02AD01 NE 
Pentetrazol R07AB03 NE 
Pentetrazol, combinations R07AB53 NE 
Penthienate A03AB04 NE 
Pentifylline C04AD01 NE 
Pentobarbital N05CA01 NE 
Pentosan polysulfate sodium C05BA04 0 
Pentoxifylline C04AD03 0 
Pentoxyverine R05DB05 I 
Pepsin  A09AA03 0 
Pepsin and acid preparations A09AC01 NE 
Perazine N05AB10 NE 
 Pergolide N04BC02 II 
Perhexiline C08EX02 NE 
Periciazine N05AC01 III 
Perindopril C09AA04 I 
Perindopril and amlodipine C09BB04 I 
Perindopril and diuretics C09BA04 I 
Perphenazine N05AB03 II 
Peruvoside C01AX02 NE 
Pethidine N02AB02 III 
Pethidine and antispasmodics N02AG03 NE 
Pethidine, combinations excl. Psycholeptics N02AB52 NE 
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Pethidine, combinations with. Psycholeptics N02AB72 NE 
Phedrine R01AA03 0 
 Phenacemide N03AX07 NE 
Phenacetin N02BE03 NE 
Phenacetin, combinations excl. Psycholeptics N02BE53 NE 
Phenacetin, combinations with Psycholeptics N02BE73 NE 
Phenazone N02BB01 
S02DA03 
NE 
Phenazone, combinations excl. Psycholeptics N02BB51 NE 
Phenazone, combinations with. Psycholeptics N02BB71 NE 
Phenelzine N06AF03 II 
 Pheneturide N03AX13 NE 
Phenformin A10BA01 NE 
Phenformin and sulfonamides A10BD01 NE 
 Phenglutarimide N04AA09 NE 
Phenindamine R06AX04 NE 
Phenindione B01AA02 NE 
Pheniramine R06AB05 II 
Phenobarbital N03AA02 III 
Phenobarbital - calcium gluconate and bromate C01EB 
Not yet determined 
NE 
Phenol C05BB05 
D08AE03 
R02AA19 
0 
 Phenol (other local anesthetics) N01BX03 I 
Phenolphthalein A06AB04 NE 
 Phenoperidine N01AH04 NE 
Phenoxybenzamine C04AX02 I 
Phenprobamate M03BA01 II 
Phenprobamate, combinations excl. 
psycholeptics 
M03BA51 II 
Phenprobamate, combinations with 
psycholeptics 
M03BA71 II 
Phenprocoumon B01AA04 NE 
 Phensuximide N03AD02 NE 
Phentermine A08AA01 NE 
Phentolamine C04AB01 I 
Phenylbutazone M01AA01 
M02AA01 
NE 
Phenylbutazone and corticosteroids M01BA01 NE 
Phenylephrine R01AA04 0 
Phenylephrine R01BA03 I 
Phenylephrine C01CA06 NE 
Phenylephrine (<<< 10%, 0.125%) S01GA05 I 
Phenylephrine (≥ 10%) S01FB01 III 
Phenylephrine, combinations R01BA53, 
S01GA55 
Depending on the medicine in 
combination 
Phenylephrine, sympathomimetics, 
combinations excl. corticosteroids  
R01AB01 Depending on the medicine in 
combination 
Phenylephrine+tetracaine S01FBP1 III 
Phenylmercuric borate D08AK02 NE 
Phenylmercuric nitrate D09AA04 NE 
Phenylpropanolamine R01BA01 0 
Phenylpropanolamine, Combinations R01BA51 NE 
 Phenytoin N03AB02 III 
 Phenytoin, combinations N03AB052 III 
Phloroglucinol A03AX12 NE 
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Pholcodine R05DA08 II 
Phthalylsulfathiazole A07AB02 NE 
Physostigmine S01EB05 NE 
Phytomenadione B02BA01 0 
Picloxydine S01AX16 NE 
Picodralazine and diuretics C02LG03 NE 
Picodralazine and diuretics, combinations with 
psycholeptics. 
C02LG73 NE 
Picotamide B01AC03 NE 
Pilocarpine 
  
N07AX01 
S01EB01 
II 
Pilocarpine, combinations S01EB51 NE 
Pimecrolimus (topical use) D11AH02 0 
Pimethixene R06AX23 II 
Pimozide N05AG02 II 
Pinacidil C02DG01 NE 
Pinacidil and diuretics C02LX01 NE 
Pinaverium A03AX04 0 
Pinazepam N05BA14 NE 
Pindolol C07AA03 I 
Pindolol and other diuretics C07CA03 I 
Pioglitazone A10BG03 0 
Pioglitazone and alogliptin A10BD09 NE 
Pipamperone N05AD05 II 
Pipazetate R05DB11 NE 
Pipecuronium bromide M03AC06 III 
Pipenzolate A03AB14 NE 
Piperidione R05DB23 NE 
Piperidolate A03AA30 NE 
Pipotiazine palmitate: injection depot i.m. N05AC04 III 
Pipradrol N06BX15 NE 
Piprozolin A05AX01 NE 
Piracetam N06BX03 II 
Pirbuterol R03AC08 
R03CC07 
NE 
Pirenzepine  A02BX03 NE 
Piretanide C03CA03 0 
Piribedil N04AX13 
C04AX13 
II 
 Piribedil N04BC08 NE 
Pirisunadol N06BX08 NE 
Piritramide N02AC03 NE 
Pirlindole N06AF 
Not yet detemined 
NE 
Piroxicam M01AC01 I 
Piroxicam S01BC06 NE 
Piroxicam (topical use) M02AA07 0 
Pirprofen M01AE08 NE 
Pitavastatin C10AA08 NE 
Pitofenone and analgesics A03DA02 NE 
Pivagabine N06AX15 NE 
Pizotifen N02CX01 II 
Podophyllotoxin D06BB04 0 
Poldine A03AB11 NE 
Policosanol C10AX08 NE 
Policresulen D08AE02 NE 
Polidocanol C05BB02 0 
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Polihexanide D08AC05 NE 
Polycarbophil calcium A06AC08 NE 
Polymyxin  S02AA11 NE 
Polymyxin B A07AA05 
S01AA18 
S03AA03 
NE 
Polynoxylin  A01AB05 
D01AE05 
NE 
Polythiazide C03AA05 NE 
Polythiazide and potassium C03AB05 NE 
Potassium acetate B05XA17 0 
Potassium canrenoate C03DA02 0 
Potassium chloride A12BA01 
B05XA01 
0 
Potassium chloride, Combinations (Depending 
on the medicine in combination) 
A12BA51 Depending on the medicine in 
combination 
Potassium citrate A12BA02 0 
Potassium clorazepate 
- Oral administration 
- Parenteral administration 
N05BA05  
II 
III 
Potassium gluconate A12BA05 0 
Potassium hydrogencarbonate A12BA04 0 
Potassium hydrogentartrate A12BA03 0 
Potassium iodide R05CA02 
S01XA04 
NE 
Potassium lactate B05XA15 0 
Potassium permanganate D08AX06 NE 
Potassium phosphate, incl. comb. with other 
potassium salts 
B05XA06 0 
Potassium salicylate N02BA12 NE 
Povidone-iodine D08AG02 
D09AA09 
D11AC06 
R02AA15 
0 
Povidone-iodine S01AX18 NE 
Practolol C07AB01 NE 
Prajmaline C01BA08 NE 
 Pramipexole N04BC05 II 
Pramlintide A10BX05 NE 
Pramocaine C05AD07 
D04AB07 
0 
Pranlukast R03DC02 NE 
Pranoprofen S01BC09 0 
Prasterone A14AA07 NE 
Prasugrel B01AC22 0 
Pravastatin C10AA03 0 
Pravastatin and acetylsalicylic acid C10BX02 NE 
Pravastatin and fenofibrate C10BA03 0 
Prazepam N05BA11 III 
Prazosin C02CA01 I 
Prazosin and diuretics C02LE01 I 
Prednicarbate D07AC18 0 
Prednisolone A07EA01 
C05AA04 
D07AA03 
D07XA02 
S01BA04 
0 
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Prednisolone R01AD02 
S02BA03 
S03BA02 
NE 
Prednisolone 
(Corticosteroids/antiinfectives/mydriatics in 
combination) 
S01CB02 Depending on the mydriatic in 
combination 
Prednisolone and antibiotics D07CA03 NE 
Prednisolone and antiinfectives 
- Drops 
- Oinment 
S01CA02  
0 
I 
Prednisolone and antiinfectives S02CA01 NE 
Prednisolone and antiinfectives S03CA02 0 
Prednisolone and antiseptics D07BA01 NE 
Prednisolone and mydriatics S01BB02 Depending on the mydriatic in 
combination 
Prednisolone, Combinations A01AC54 0 
Prednisolone, combinations R01AD52 NE 
Prednisone A07EA03 0 
 Pregabalin N03AX16 II 
Prenalterol C01CA13 NE 
Prenoxdiazine R05DB18 NE 
Prenylamine C01DX02 NE 
Prenylamine, combinations C01DX52 NE 
Prethcamide R07AB06 NE 
Pridinol M03BX03 II 
Prifinium bromide A03AB18 NE 
Prilocaine N01BB04 0 to III 
Depending on the route of 
administration 
Prilocaine combinations N01BB54 0 
Primidone N03AA03 III 
Probenecid M04AB01 I 
Probucol C10AX02 NE 
Procainamide C01BA02 I 
Procaine C05AD05 0 
Procaine S01HA05 NE 
Procaine (Anesthetic, local) N01BA03 
 
0 to III 
Depending on the route of 
administration 
Procaine combinations N01BA52 II 
Procaterol R03AC16 
R03CC08 
NE 
Prochlorperazine N05AB04 NE 
 Procyclidine N04AA04 II 
 Profenamine N04AA05 NE 
 Progabide N03AG05 NE 
Proglumetacin M01AB14 NE 
Proglumide A02BX06 NE 
Prolintane N06BX14 NE 
Promazine N05AA03 III 
Promethazine D04AA10 0 
Promethazine R06AD02 III 
Promethazine, combinations R06AD52 III 
Propacetamol N02BE05 NE 
Propafenone C01BC03 I 
Propamidine D08AC03 NE 
Propanamidine S01AX15 NE 
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 Propanidid N01AX04 NE 
Propanol D08AX03 NE 
Propanol, combinations D08AX53 NE 
Propantheline A03AB05 0 
Propantheline and psycholeptics A03CA34 NE 
Propatylnitrate C01DA07 NE 
Propatylnitrate, combinations C01DA57 NE 
Propiomazine N05CM06 NE 
Propiphenazone, combinations with. 
Psycholeptics 
N02BB74 NE 
Propofol N01AX10 III 
Propranolol C07AA05 I 
Propranolol and other antihypertensives C07FA05 I 
Propranolol and thiazides C07BA05 I 
Propyphenazone N02BB04 NE 
Propyphenazone, combinations excl. 
Psycholeptics 
N02BB54 NE 
Proquazone  M01AX13 NE 
Proscillaridin C01AB01 NE 
Proscillaridin, combinations C01AB51 NE 
Protein C B01AD12 0 
Protein hydrolysates B05BA04 0 
Prothipendyl N05AX07 NE 
Protriptyline N06AA11 NE 
Proxazole A03AX07 NE 
Proxibarbital N05CA22 NE 
Proxymetacaine S01HA04 NE 
Proxyphylline  R03DA03 NE 
Proxyphylline and adrenergics R03DB03 NE 
Prucalopride  A03AE04 I 
Pseudoephedrine R01BA02 I 
Pseudoephedrine, combinations 
+ loratadine 
+ triprolidine 
R01BA52  
I 
III 
Pyridostigmine N07AA02 II 
Pyridoxal phosphate A11HA06 0 
Pyridoxine (vit B6)  A11HA02 0 
Pyrithione zinc D11AX12 0 
Pyrithyldione N05CE03 NE 
Pyritinol N06BX02 NE 
Pyrrobutamine R06AX08 NE 
Pyrrobutamine, combinations R06AX58 NE 
Pyrrolnitrin D01AA07 NE 
   
Q ATC CODE CATEGORISATION 
labelling 
Quazepam N05CD10 NE 
Quetiapine N05AH04 II 
Quinapril C09AA06 I 
Quinapril  and diuretics C09BA06 I 
Quinbolone A14AA06 NE 
Quinethazone C03BA02 NE 
Quinethazone and potassium C03BB02 NE 
Quinidine C01BA01 I 
Quinidine, combinations excl. psycholeptics C01BA51 NE 
Quinidine, combinations with psycholeptics C01BA71 NE 
Quinine, combinations with psycholeptics M09AA72 I 
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Quinisocaine D04AB05 NE 
   
R ATC CODE CATEGORISATION 
labelling 
Rabeprazole A02BC04 I 
Racecadotril A07XA04 0 
Ramelteon N05CH02 NE 
Ramipril C09AA05 I 
Ramipril and diuretics C09BA05 I 
Ramipril and felodipine C09BB05 I 
Ranibizumab S01LA04 III 
Ranitidine A02BA02 I 
Ranitidine bismuth citrate A02BA07 I 
Ranolazine C01EB18 I 
 Rasagiline N04BD02 I 
Rauwolfia alkaloids, whole root C02AA04 NE 
Rauwolfia alkaloids, whole root and diuretics C02LA08 NE 
Reboxetine N06AX18 I 
Regadenoson C01EB21 NE 
 Remifentanil N01AH06 III 
Remikiren C09XA01 NE 
Remoxipride N05AL04 NE 
Repaglinide A10BX02 I 
Reposal N05CA12 NE 
Reproterol R03AC15 
R03CC14 
NE 
Reproterol and other drugs for obstructive 
airway diseases  
R03AK05 NE 
Rescinnamine C02AA01 NE 
Rescinnamine and diuretics C02LA02 NE 
Rescinnamine and diuretics, combinations with 
other drugs 
C02LA52 NE 
Reserpine C02AA02 NE 
Reserpine and diuretics C02LA01 NE 
Reserpine and diuretics, combinations with 
other drugs 
C02LA51 NE 
Reserpine and diuretics, combinations with 
psycholeptics 
C02LA71 NE 
Reserpine, combinations C02AA52 NE 
Resorcinol D10AX02 
S01AX06 
NE 
Retapamulin D06AX13 0 
Reteplase B01AD07 0 
Retinol D10AD02 
R01AX02 
S01XA02 
NE 
Retinol (vit A) A11CA01 0 
Reviparin B01AB08 NE 
Riboflavin (vit B2) A11HA04 0 
Rifamycin S01AA16 0 
Rifamycin S02AA12 NE 
Rifaximin A07AA11 0 
Rifaximin  D06AX11 NE 
Rilanomer D03AX09 NE 
Rilmenidine C02AC06 II 
Riluzole N07XX02 I 
Rimazolium N02BG02 NE 
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Rimexolone 
- Drops 
- Oinment 
S01BA13  
0 
I 
Rimiterol R03AC05 NE 
Rimonabant  A08AX01 NE 
Risedronic acid M05BA07 0 
Risedronic acid and calcium, sequential M05BB02 NE 
Risedronic acid, calcium and colecalciferol, 
sequential  
M05BB04 NE 
Risperidone 
- Oral administration 
- Parenteral administration: depot i.m. 
N05AX08  
II 
III 
Ritanserin N06AX 
Not yet determined 
NE 
Ritiometan R01AX05 NE 
Rivaroxaban  B01AX06 0 
Rivastigmine N06DA03 II 
Rizatriptan N02CC04 II 
Rociverine  A03AA06 NE 
Rocuronium bromide M03AC09 III 
Rofecoxib M01AH02 NE 
Roflumilast R03DX07 0 
Romiplostim (subcutaneous via) B02BX04 I 
Ronifibrate C10AB07 NE 
 Ropinirole N04BC04 II 
 Ropivacaine N01BB09 III 
Rosa bengal sodium S01JA02 NE 
Rosiglitazone A10BG02 0 
Rosuvastatin C10AA07 0 
 Rotigotin N04BC09 II 
Roxatidine A02BA06 I 
 Rufinamide N03AF03 II 
Rupatadine R06AX28 I 
Rutoside C05CA01 0 
Rutoside, combinations C05CA51 0 
   
S ATC CODE CATEGORISATION 
labelling 
Saccharated iron oxide B03AC02 0 
Saccharated iron oxide B03AB02 NE 
Saccharomyces boulardii A07FA51 0 
Sacrosidase A16AB06 NE 
Salbutamol R03AC02 
R03CC02 
0 
Salbutamol and other drugs for obstructive 
airway diseases  
R03AK04 Depending on the medicine in 
combination 
Salicylamide N02BA05 NE 
Salicylamide , combinations with psycholeptics N02BA75 NE 
Salicylamide, combinations excl. Psycholeptics N02BA55 NE 
Salicylic acid  D01AE12 0 
Salicylic acid S01BC08 NE 
Salicylic acid preparations D02AF 0 
Salmeterol R03AC12 0 
Salmeterol and other drugs for obstructive 
airway diseases  
R03AK06 Depending on the medicine in 
combination 
Salsalate N02BA06 NE 
Sapropterin A16AX07 0 
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Saruplase B01AD08 NE 
S-atenol C07AB11 NE 
Saccharated iron oxide B03AB02 NE 
Saxagliptin A10BH03 I 
Scopolamine  
- Oral and rectal administration 
- Parenteral administration 
A04AD01  
I 
II 
Scopolamine N05CM05 
S01FA02 
NE 
Scopolamine, combinations A04AD51 NE 
 Selegiline N04BD01 I 
Selenium compounds D11AC03 0 
Selenium sulfide  D01AE13 NE 
Senega R05CA06 0 
Senna glycosides A06AB06 0 
Senna glycosides, combinations A06AB56 0 
Seratrodast R03DX06 NE 
Serobarbital N05CA06 NE 
Sertaconazole D01AC14 0 
Sertindole N05AE03 NE 
Sertraline N06AB06 I 
 Sevoflurane N01AB08 III 
Sibutramine  A08AA10 NE 
Silicone products D02AA 0 
Silicones A03AX13 0 
Silver D08AL30 NE 
Silver compounds S01AX02 NE 
Silver nitrate D08AL01 0 
Silver sulfadiazine D06BA01 0 
Silver sulfadiazine, combinations D06BA51 0 
Silymarin A05BA03 0 
Simfibrate C10AB06 NE 
Simvastatin C10AA01 0 
Simvastatin and acetylsalicylic acid C10BX01 NE 
Simvastatin and ezetimibe C10BA02 0 
Sitagliptin A10BH01 I 
Sitaxentan C02KX03 I 
Sobrerol R05CB07 NE 
Sodium acetate B05XA08 0 
Sodium apolate C05BA02 0 
Sodium aurothiomalate M01CB01 0 
Sodium aurothiosulfate M01CB02 NE 
Sodium bicarbonate B05CB04 
B05XA02 
0 
Sodium borate S01AX07 NE 
Sodium chloride A12CA01 
B05CB01 
B05XA03 
0 
Sodium chloride, hypertonic S01XA03 0 
Sodium citrate B05CB02 0 
Sodium edetate S01XA05 0 
Sodium feredetate B03AB03 0 
Sodium fluoride A01AA01 
A12CD01 
0 
Sodium fluoride, combinations A01AA51 NE 
Sodium glycerophosphate B05XA14 0 
Sodium hypochlorite D08AX07 NE 
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sodium Monofluorophosphate A01AA02 NE 
Sodium monofluorophosphate A12CD02 0 
Sodium perborate A01AB19 0 
Sodium phenylbutyrate  A16AX03 I 
Sodium phosphate A06AG01 
B05XA09 
0 
Sodium phosphate A06AD17 NE 
Sodium picosulfate A06AB08 0 
Sodium picosulfate, combinations A06AB58 0 
Sodium propionate S01AX10 NE 
Sodium salicilate N02BA04 NE 
Sodium selenate A12CE01 0 
Sodium selenite A12CE02 0 
Sodium sulfate A12CA02 
A06AD13 
0 
Sodium tartrate A06AD21 NE 
Sodium tetradecyl sulfate C05BB04 0 
Soft paraffin and fat products D02AC 0 
Sorbitol B05CX02 0 
Sorbitol A06AD18 
A06AG07 
NE 
Sotalol C07AA07 I 
Sotalol and thiazides C07BA07 I 
Sotalol, combination C07AA57 I 
Spaglumic acid S01GX03 I 
Spaglumic acid R01AC05 NE 
Sparteine C01BA04 NE 
Spirapril C09AA11 I 
Spironolactone C03DA01 I 
Stannous fluoride A01AA04 NE 
Stanozolol  A14AA02 0 
Stem cells from umbilical cord blood B05AX04 NE 
Stepronin R05CB11 NE 
Sterculia A06AC03 0 
Sterculia, combinations A06AC53 NE 
 Stiripentol N03AX17 NE 
Stramoni preparations R03BB03 NE 
Streptokinase B01AD01 0 
Streptokinase, combinations B06AA55 NE 
Streptomycin A07AA04 0 
Streptomycin, combinations A07AA54 NE 
Strontium ranelate M05BX03 0 
Styramate M03BA04 NE 
Succinylsulfathiazole A07AB04 NE 
Sucralfate A02BX02 0 
 Sufentanil N01AH03 NE 
Sulbentine D01AE09 NE 
Sulbutiamine A11DA02 0 
Sulconazole D01AC09 NE 
Sulfacetamide S01AB04 NE 
Sulfadicramide S01AB03 NE 
Sulfafena S01AB05 NE 
Sulfafurazole S01AB02 NE 
Sulfaguanidine A07AB03 NE 
Sulfamerazine D06BA06 NE 
Sulfamethizole B05CA04 
D06BA04 
NE 
 
DRUID 6th Framework Programme  Deliverable D.4.3.1  
Establishment of framework for classification/categorization 
and labelling of medicinal drugs and driving 
   Page 104 of 135 
 
S01AB01 
Sulfanilamide D06BA05 0 
Sulfasalazine A07EC01 0 
Sulfathiazole  D06BA02 0 
Sulfinpyrazone M04AB02 NE 
Sulfur D10AB02 0 
Sulfur compounds D11AC08 0 
Sulglicotide A02BX08 NE 
Sulindac M01AB02 I 
Suloctidil C04AX19 NE 
Sulodexide B01AB11 0 
Sulpiride N05AL01 II 
 Sultiame N03AX03 NE 
Sultopride N05AL02 NE 
Sumatriptan N02CC01 II 
Suprofen M01AE07 NE 
Suxamethonium M03AB01 III 
Suxibuzone M01AA90 M02AA22 NE 
Syrosingopine and diuretics C02LA09 NE 
   
T ATC CODE CATEGORISATION 
labelling 
Tacalcitol D05AX04 0 
Tacrine N06DA01 NE 
Tacrolimus 
- Intravenous administration 
- Oral administration 
- Topical use 
L04AD02 
 
 
D11AH01 
 
III 
II 
0 
Tafluprost S01EE05 I 
Talastine R06AB07 NE 
Talbutal N05CA07 NE 
Talinolol C07AB13 NE 
Tars D05AA NE 
Tasosartan C09CA05 NE 
Taurolidine B05CA05 NE 
Tazarotene D05AX05 0 
Tedisamil C01BD06 NE 
Tegaserod A03AE02 NE 
Telmisartan C09CA07 I 
Telmisartan and amlodipine C09DB04 I 
Telmisartan and diuretics C09DA07 I 
Temazepam N05CD07 III 
Temocapril C09AA14 NE 
Tenecteplase B01AD11 0 
Tenidap M01AX23 NE 
Tenitramine C01DA38 NE 
Tenoxicam M01AC02 I 
Terbinafine D01AE15 0 
Terbinafine  D01BA02 0 
Terbutaline R03AC03 
R03CC03 
0 
Terbutaline, combinations R03CC53 NE 
Terfenadine R06AX12 I 
Tertatolol C07AA16 I 
Tetrabenazine N07XX06 NE 
Tetracaine C05AD02 
D04AB06 
0 
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Tetracaine S01HA03 NE 
Tetraciane (anesthetic, local) N01BAO3 0 to III 
Depending on the route of 
administration 
Tetracycline A01AB13 
D06AA04 
0 
Tetracycline S01AA09 
S02AA08 
S03AA02 
NE 
Tetragalacturonic acid hydroxymethylester  B02BC03 NE 
Tetrazepam M03BX07 II 
Tetryzoline S01GA02 I 
Tetryzoline  R01AA06 
R01AB03 
NE 
Tetryzoline, combinations S01GA52 NE 
Thebacone R05DA10 II 
Thenalidine D04AA03 
R06AX03 
NE 
Thenalidine, combinations R06AX53 NE 
Theobromine C03BD01 
R03DA07 
NE 
Theobromine, combinations R03DA57 NE 
Theodrenaline C01CA23 NE 
Theophylline 
- Oral administration 
- Parenteral administration 
R03DA04  
0 
I 
Theophylline and adrenergics R03DB04 Depending on medicine in 
combination 
Theophylline, combinations excl. psycholeptics R03DA54 NE 
Theophylline, combinations with   psycholeptics R03DA74 NE 
Thiamine (vit B1) A11DA01 0 
Thiazinam  R06AD06 NE 
Thiethylperazine R06AD03 II 
Thiocolchicoside M03BX05 II 
Thiomersal D08AK06 0 
 Thiopental N01AF03 
N05CA19 
III 
Thiopropazate N05AB05 NE 
Thioproperazine N05AB08 NE 
Thioridazine N05AC02 NE 
Thonzylamine D04AA01 
R01AC06 
R06AC06 
NE 
Thrombin  B02BD30 0 
Thrombin (with human fibrinogen)  B02BC06 0 
Thrombocytes B05AX02 NE 
Tiabendazole D01AC06 NE 
Tiadenol C10AX03 0 
 Tiagabine N04AG06 II 
Tianeptine N06AX14 NE 
Tiapride N05AL03 II 
Tiaprofenic acid M01AE11 I 
Tibezonium iodide A01AB15 NE 
Ticlatone D01AE08 NE 
Ticlopidine B01AC05 0 
Tidiacic arginine A05BA07 NE 
Tiemonium iodide A03AB17 NE 
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Tiemonium iodide and analgesics A03DA07 NE 
Tienilic acid C03CC02 NE 
Tilactase A09AA04 NE 
Tilidine N02AX01 NE 
Tiludronic acid  M05BA05 0 
Timepidium bromide A03AB19 NE 
Timolol C07AA06 
S01ED01 
I 
Timolol - amiloride - hydrochlorothiazide C07DA06 NE 
Timolol and thiazides C07BA06 I 
Timolol, combinations Timolol+brinzolamide 
(Azarga) 
S01ED51 I 
Timolol, thiazide and other diuretics C07DA06 I 
Tinzaparin B01AB10 0 
Tioclomarol B01AA11 NE 
Tioconazole D01AC07 0 
Tioctic acid A16AX01 NE 
Tiopronin R05CB12 NE 
Tiotixene N05AF04 NE 
Tiotropium bromide R03BB04 I 
Tioxolone D10AB03 NE 
Tipepidine R05DB24 NE 
Tiracizine C01EB11 NE 
Tiratricol D11AX08 NE 
Tirilazad N07XX01 NE 
Tirofiban  B01AC17 0 
Tiropramide A03AC05 NE 
Tisopurine M04AA02 NE 
Titoqualine R06AX21 NE 
Tixocortol A07EA05 
R01AD07 
NE 
Tixocortol, combinations R01AD57 NE 
Tizanidine M03BX02 II 
Tobramycin 
- Drops 
- Oinment 
S01AA12  
0 
I 
Tocainide C01BB03 NE 
Tocofersolan (paediatric patients) A11HA08 0 
Tocopherol (vit E) A11HA03 0 
Tofisopam N05BA23 NE 
Tolazamide A10BB05 NE 
Tolazoline C04AB02 
M02AX02 
NE 
Tolbutamide A10BB03 I 
Tolcapone N04BX01 II 
Tolciclate  D01AE19 NE 
Tolfenamic acid M01AG02 I 
Tolmetin M01AB03 
M02AA21 
NE 
Tolnaftate  D01AE18 0 
Toloxatone N06AG03 NE 
Tolperisone M03BX04 NE 
Tolpropamine D04AA12 NE 
Tolrestat A10XA01 NE 
Tolvaptan C03XA01 I 
Tonics A13A 0 
 Topiramate N03AX11 II 
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Torasemide C03CA04 0 
Tosylchloramide sodium D08AX04 NE 
Tramadol N02AX02 III 
Tramadol, combinations N02AX52 NE 
Tramazoline R01AA09 0 
Trandolapril C09AA10 I 
Trandolapril and verapamil C09BB10 I 
Tranexamic acid B02AA02 0 
Tranylcypromine N06AF04 II 
 Trapatepine N04AA12 NE 
Trapidil C01DX11 NE 
Travoprost S01EE04 I 
Trazodone N06AX05 III 
Trepibutone A03AX09 NE 
Treprostinil B01AC21 NE 
Tretinoin D10AD01 0 
Tretinoin, combinations (with erythromycin, 
topical use) 
D10AD51 0 
Tretoquinol R03AC09 
R03CC09 
NE 
Triamcinolone A01AC01 
A07EA 
D07AB09 
D07XB02 
R01AD11 
0 
Triamcinolone R03BA06 
S01BA05 
C05AA12 
NE 
Triamcinolone and antibiotics D07CB01 0 
Triamcinolone and antiinfectives S02CA04 0 
Triamcinolone and antiseptics D07BB03 NE 
Triamterene C03DB02 0 
Triazolam N05CD05 III 
Tribenoside C05AX05 NE 
Tribenoside C05CX01 0 
Tribromometacresol D01AE03 NE 
Trichlormethiazide C03AA06 NE 
Trichlormethiazide and potassium C03AB06 NE 
Trichlormethiazide and potassium-sparing 
agents (spironolactone) 
C03EA02 NE 
Trichloroethylene N01AB05 NE 
Triclofos N05CM07 NE 
Triclosan D08AE04 
D09AA06 
0 
Tridihexethyl A03AB08 NE 
Trifluoperazine N05AA05 NE 
Trifluoperazine N05AB06 III 
Trifluperidol N05AD02 NE 
Trifluridine S01AD02 NE 
Triflusal B01AC18 0 
 Trihexyphenidyl N04AA01 II 
Trimazosin C02CA03 NE 
Trimebutine A03AA05 0 
Trimetazidine C01EB15 I 
 Trimethadione N03AC02 NE 
Trimethyldiphenylpropylamine A03AX30 NE 
Trimipramine N06AA06 II 
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Trioxysalen D05AD01 
D05BA01 
NE 
Tripelennamine D04AA04 0 
Tripelennamine R06AC04 NE 
Triprolidine  R06AX07 III 
Triticum (wheat fibre) A06AC07 NE 
Troglitazone A10BG01 NE 
Trolnitrate C01DA09 NE 
Trolnitrate, combinations C01DA59 NE 
Tromantadine D06BB02 0 
Trometamol B05BB03 0 
Trometamol (only in combination) B05XX02 NE 
Tropenzilone and analgesics A03DA01 NE 
Tropicamide S01FA06 III 
Tropicamide, combinations S01FA56 III 
Tropisetron  A04AA03 0 
Trospium and analgesics A03DA06 NE 
Troxerutin C05CA04 0 
Troxerutin, combinations C05CA54 0 
Troxipide A02BX11 NE 
Trypsin D03BA01 0 
Trypsin B06AA07 NE 
Trypsin, combinations M09AB52 NE 
Tryptophan N06AX02 NE 
Tuaminoheptane R01AA11 
R01AB08 
NE 
Tubocurarine  M03AA02 III 
Tulobuterol R03AC11 NE 
Tulobuterol R03CC11 NE 
Tyloxapol  R05CA01 NE 
Tymazoline R01AA13 NE 
Tyrothricin D06AX08 
R02AB02 
0 
Tyrothricin S01AA05 NE 
   
U ATC CODE CATEGORISATION 
labelling 
Ubidecarenone C01EB09 I 
Ulobetasol D07AC21 NE 
Undecylenic acid D01AE04 NE 
Undecylenic acid, combinations D01AE54 NE 
Unoprostone S01EE02 NE 
Urapidil C02CA06 I 
Urate oxidase  M04AX01 NE 
Urokinase B01AD04 0 
Ursodeoxycholic acid A05AA02 0 
   
V ATC CODE CATEGORISATION 
labelling 
Valdecoxib M01AH03 NE 
Valerian N05CM09 I 
Valnoctamide N05CM13 NE 
 Valproic acid 
-  Oral administration 
-  Parenteral administration 
N03AG01  
II 
III 
 Valpromide N03AG02 NE 
Valsartan C09CA03 I 
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Valsartan and aliskiren C09DX02 NE 
Valsartan and amlodipine C09DB01 I 
Valsartan and diuretics C09DA03 I 
Valsartan, amlodipine and hydrochlorothiazide C09DX01 I 
Vancomycin A07AA09 NE 
Varenicline N07BA03 I 
Various (Antiinfectives and antiseptics for local oral 
treatment) 
A01AB11 0 
Various (Antiseptics) R02AA20 NE 
Various (Other agents for local oral treatment) A01AD11 NE 
Various (Other nasal preparations) R01AX10 NE 
Various (Other topical products for joint and muscular 
pain) 
M02AX10 NE 
Various combinations (Iron in other combinations) B03AE10 0 
Various combinations (Other anti-acne preparations 
for topical use) 
D10AX30 NE 
Vecuronium M03AC03 III 
Velaglucerase alfa A16AB10 I 
Venlafaxine N06AX16 II 
Veralipride N05AL06 NE 
Verapamil C08DA01 I 
Verapamil, combinations C08DA51 I 
Veratrum C02KA01 NE 
Veratrum and diuretics C02LK01 NE 
Verteporfin  S01LA01 III 
Vidarabine S01AD06 NE 
 Vigabatrin N03AG04 II 
Vildagliptin A10BH02 I 
Viloxazine N06AX09 NE 
Viminol N02BG05 NE 
Vinbarbital N05CA09 NE 
Vinburnine C04AX17 I 
Vincamine C04AX07 I 
Vinpocetine N06BX18 NE 
 Vinyl ether N01AA02 NE 
Vinylbarbital N05CA08 NE 
Virginiamycin D06AX10 NE 
Visnadine C04AX24 NE 
Vitamins B05XC 0 
Vitamin B-complex, plain A11EA 0 
Vitamin B1 in combination with vitamin B6 
and/or vitamin B12 
A11DB 0 
Vitamin B-complex with vitamin C A11EB 0 
Vitamin B-complex with minerals A11EC 0 
Vitamin B-complex with anabolic steroids A11ED 0 
Vitamin B-complex, other combinations A11EX 0 
Vitamins, other combinations A11JC 0 
Vitamins with minerals A11JA 0 
Voglibose A10BF03 NE 
Von Willebrand factor and coagulation factor 
VIII in combination  
B02BD06 0 
   
W ATC CODE CATEGORISATION 
labelling 
Warfarin B01AA03 0 
   
X ATC CODE CATEGORISATION 
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labelling 
Xaliproden N07XX03 NE 
Xamoterol C01CX07 NE 
Xantinol nicotinate C04AD02 NE 
 Xenon N01AX15 NE 
Xenysalate D11AC09 NE 
Ximelagatran B01AE05 NE 
Xipamide C03BA10 0 
Xylometazoline R01AA07 0 
Xylometazoline  R01AB06 
S01GA03 
NE 
Xylometazoline, combinations S01GA53 NE 
   
Z ATC CODE CATEGORISATION 
labelling 
Zafitlukast R03DC01 0 
Zaleplon 
- after 12h 
N05CF03 III 
I 
Ziconotide N02BG08 III 
Zimeldine N06AB02 NE 
Zinc acetate A16AX05 0 
Zinc bandage with supplements D09AB02 0 
Zinc bandage without supplements D09AB01 0 
Zinc chloride B05XA12 0 
Zinc compounds S01AX03 NE 
Zinc gluconate A12CB02 NE 
Zinc preparations C05AX04 0 
Zinc products D02AB 0 
Zinc protein complex A12CB03 NE 
Zinc sulphate  A12CB01 0 
Zipeprol R05DB15 NE 
Ziprasidone 
- Oral administration 
- Parenteral administration: i.m. 
N05AE04  
II 
III 
Zofenopril C09AA15 I 
Zofenopril and diuretics C09BA15 I 
Zoledronic acid M05BA08 I 
Zolimidine A02BX10 NE 
Zolmitriptan N02CC03 II 
Zolpidem 
- after 8h 
N05CF02 III 
II 
Zomepirac M01AB04 NE 
 Zonisamide N03AX15 II 
Zopiclone N05CF01 III 
Zotepine N05AX11 NE 
Zucapsaicin M02AB02 NE 
Zuclopenthixol 
- Oral administration 
- Parenteral administration: depot i.m. 
N05AF05  
II 
III 
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6. The DRUID Patient-oriented information 
 
Within DRUID WP4, medicines were categorized following DRUID criteria on medicines and 
driving. Furthermore, DRUID WP4 partners have produced patient-oriented information for each 
one of the medicines categorized.  
 
The aim of producing this patient-oriented information is to help physicians and pharmacists 
(and other health professionals) in providing appropriate information to their patients. It is true 
that Patient Information Leaflets contain some sort of information regarding driving. However, 
DRUID WP4 partners considered that it is also quite important that health professionals provide 
further information for medicines and driving to their patients. 
 
Tables 15 to 29 show some examples of patient-oriented information concerning the DRUID 
categorisation of the evaluated medicines. We have tried, in each table, to put an example of 
each of the DRUID categories (0, I, II, III, multiple categorisation and depending on medicine in 
combination), pointing out the different presentations or the different routes of administration. 
 
The complete list with all the medicines from each ATC group and the patient-oriented 
information is shown in the annexes of this deliverable of each ATC group categorized 
(Annexes 2 to 17). 
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Table 15: Example of information to the patient and Categorisation and labelling of some 
available A-ALIMENTARY TRACT AND METABOLISM MEDICINES on driving. 
 
A  
ALIMENTARY 
TRACT AND 
METABOLIS
M 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENT 
A02BA01 Cimetidine  I 
A02BA02 Ranitidine I 
A02BA03 Famotidine I 
A02BA04 Nizatidine I 
A02BA06 Roxatidine I 
- Advise your patient not to drive if he/she 
experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness) 
particularly during the first day of treatment, 
and not to drive as long as side-effects persist. 
A03BA01 Atropine  III 
- Inform the patient that this medication may 
cause dilated pupils with loss of 
accommodation and photophobia and 
increased intraocular pressure and headache, 
mental confusion or excitement (especially in 
the elderly), drowsiness, which may impair 
their ability to drive.  
- Advise the patient not to drive until the next 
visit after start of treatment and also to be 
careful in other situations (e.g. using 
machinery and working at heights) 
- Advise the patient not to drink alcohol or use 
other psychoactive substances when taking 
this medicine. 
A10AB01 
Insulin 
(human) 
 
I 
A10AB02 Insulin (beef) 
 
I 
A10AC03 Insulin (pork) 
 
I 
A10AC04 Insulin lispro 
 
I 
A10AC30 Combinations 
(Insulins) 
I 
- Advise your patient to take precautions to 
avoid hypoglycaemia, this may constitute a 
risk in situations where these abilities are of 
special importance (e.g. driving a car or 
operating machinery), and not to drive as long 
as side-effects persist. 
- If your patient have frequent episodes or if 
he/she find it hard to recognise 
hypoglycaemia. The advisability of driving 
should be considered in these circumstances.  
- Advise your patient not to drink alcohol nor 
use any psychoactive substances when taking 
this medication 
A10BD02 Metformin and sulfonamides I 
- Advise your patient to take precautions to 
avoid hypoglycaemia, this may constitute a 
risk in situations where these abilities are of 
special importance (e.g. driving a car or 
operating machinery), and not to drive as long 
as side-effects persist. 
- If your patient has frequent episodes or if 
he/she find it hard to recognise 
hypoglycaemia. The advisability of driving 
should be considered in these circumstances. 
- Advise your patient not to drink alcohol nor 
use any psychoactive substances when taking 
this medication 
A10BD03 Metformin and rosiglitazone 0 
- No special advice 
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Table 16: Example of information to the patient and Categorisation and labelling of some 
available B - BLOOD AND BLOOD FORMING ORGANS MEDICINES on driving. 
 
B  
BLOOD AND 
BLOOD 
FORMING 
ORGANS 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENTS 
B01AC11 
Iloprost 
(for inhalation 
use)  
II 
- Inform your patient that the medication can 
cause side effects that impair driving abilities 
(down blood pressure and may cause 
dizziness or light-headedness). Do not drive 
or operate any tools or machines if you feel 
these effects of low blood pressure. 
- Advise the patient not to drive for the first few 
days of treatment until any effects on the 
individual have been determined and also to 
be careful in other situations (e.g. using 
machinery and working at heights) 
B02BX01   Etamsylate  0 - No special advice 
B02BX04   
Romiplostim 
(subcutaneous 
via)  
I 
- Advise your patient not to drive if he/she 
experiences side-effects that can impair 
his/her driving abilities (e.g. dizziness, 
paraesthesia, etc.) and not to drive as long 
as side-effects persist. 
B03XA01 
Erythropoietin 
(epoetin alfa, 
beta, theta) 
0 
- No special advice 
B03XA02 Darbepoetin alfa 0 
- No special advice 
B03XA03 
Methoxy 
polyethylene 
glycol-epoetin 
beta 
0 
- No special advice 
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Table 17: Information to the patient based on the categorisation and labelling of the C - 
CARDIOVASCULAR SYSTEM MEDICINES on driving. 
 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENT 
0 - No special advice. 
I 
- Advise your patient not to drive if he/she experiences side-effects that 
can impair his/her driving abilities (e.g. dizziness, fatigue, hypotension, 
decreased attention, etc.) and not to drive as long as side-effects persist.
 
- Advise your patient not to drink alcohol nor use any psychoactive 
substances when taking this medication. 
II 
- Inform your patient that the medication can cause side effects that impair 
driving abilities (e.g. dizziness, drowsiness, hypotension, fatigue, etc.). 
 
- Advise your patient not to drive for the first few days of treatment and to 
be careful in other situations, as well (e.g. operating machinery and 
working at heights). 
 
- Advise the patient not to drink alcohol nor use any psychoactive 
substance when taking this medicine. 
 
 
DRUID 6th Framework Programme  Deliverable D.4.3.1  
Establishment of framework for classification/categorization 
and labelling of medicinal drugs and driving 
   Page 115 of 135 
 
Table 18: Example of information to the patient and Categorisation and labelling of some 
available D - DERMATOLOGICALS MEDICINES on driving. 
 
D 
DERMATOLO
GICALS 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENTS 
D05BA02 Methoxsalen  0 No special advice 
D05BB02 Acitretin  I - Advise your patient not to drive if he/she 
experiences side-effects that can impair 
his/her driving abilities (blurred or 
decreased night vision) and not to drive 
as long as side-effects persist. 
- Advise your patient not to drink alcohol 
nor use any psychoactive substances 
when taking this medication. 
D06AA02 Chlortetracycline 0 - No special advice 
D06AA03 Oxytetracycline 0 - No special advice 
D07AA02 Hydrocortisone 0 - No special advice 
D07AA03 Prednisolone 0 - No special advice 
D10AD01 Tretinoin 0 - No special advice 
D10AD03 Adapalene 0 - No special advice 
D10BA01 Isotretinoin  
- Oral 
administration 
- Topical use 
 
II 
0 
- Inform your patient that the medication 
can cause side effects that impair driving 
abilities (e.g., decreased night vision in 
some cases was sudden, visual and 
neurological disturbances etc.) 
- Advise your patient not to drive for the 
first few days of treatment and to be 
careful in other situations, as well (e.g. 
operating machinery and working at 
heights). 
- Advise the patient not to drink alcohol nor 
use any psychoactive substance when 
taking this medicine.  
D11AX19 Alitretinoin  
- Oral 
administration 
- Topical use 
 
I 
0 
- Advise your patient not to drive if he/she 
experiences side-effects that can impair 
his/her driving abilities (blurred or 
decreased night vision) and not to drive 
as long as side-effects persist. 
- Advise your patient not to drink alcohol 
nor use any psychoactive substances 
when taking this medication. 
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Table 19: Example of information to the patient and Categorisation and labelling of some 
available M - MUSCULOSKELETAL SYSTEM MEDICINES on driving. 
 
M  
MUSCULOSK
ELETAL 
SYSTEM 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENTS 
M01AB01 Indometacin I 
M01AB02 Sulindac I 
M01AB05 Diclofenac I 
M01AB08 Etodolac I 
M01AB11 Acemetacin I 
M01AB15 Ketorolac I 
M01AB16 Aceclofenac I 
M01AB51 Indometacin, 
combinations 
I 
M01AB55 Diclofenac, 
combinations 
I 
- Inform the patient that the medication can 
cause side effects that impair driving and 
that reaction time can also be reduced 
without experiencing side effects. 
- Advise the patient also to be careful in 
other situations than driving (e.g. using 
machinery and working at heights) 
- Advise the patient to avoid any alcohol or 
other psychoactive substances during the 
treatment. 
M03AA01 Alcuronium III 
M03AA02 Tubocurarine  III 
M03AA04   Dimethyltubocur
arine 
III 
M03AC01 Pancuronium III 
M03AC02 Gallamine  III 
M03AC03   Vecuronium III 
- Advise the patient not to drive or operate 
machinery until the effects of the 
anaesthetic, and the immediate effects of 
surgery have passed. 
- Advise the patient (and explain to 
caregivers) not to drink any alcohol 24 
hours after anaesthesia 
M03BA01 Phenprobamate II 
M03BA02 Carisoprodol II 
M03BA03 Methocarbamol II 
M03BA04 Styramate  
M03BA05 Febarbamate II 
M03BA51 Phenprobamate, 
combinations 
excl. 
psycholeptics 
II 
M03BB02 Chlormezanone II 
M03BB03 Chlorzoxazone II 
M03BB52 Chlormezanone, 
combinations 
excl. 
psycholeptics 
II 
- Inform the patient about the effects of the 
medicine on reaction time and that the 
medication can cause side effects that 
impair driving (dizziness, drowsiness, 
sleepiness, blurred/double vision and 
reduced alertness) 
- Advise the patient not to drive for the first 
few days of treatment or until the next visit 
after the start of treatment and also to be 
careful in other situations (e.g. using 
machinery and working at heights) 
- Advise the patient not to drink alcohol or 
use other psychoactive substances when 
taking this medicine. 
- One time (occasional) use: inform your 
patient that his/her response is reduced. 
Advise your patient not to drive then. 
M04AC01 Colchicine 0 - No special advice 
M05BA02 Clodronic acid  0 - No special advice 
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Table 20: Example of information to the patient and Categorisation and labelling of some 
available N01- ANESTHETICS MEDICINES on driving. 
 
N01 
ANESTHETICS 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENT 
N01A  Anesthetics, 
general 
  
N01AB06 Isoflurane III 
N01AB07 Desflurane III 
N01AB08 Sevoflurane III 
N01AF03 Thiopental III 
  Fentanyl III 
N01AH02 Alfentanil III 
N01AH06 Remifentanil III 
N01AX01 Droperidol III 
- Advise the patient (and explain to 
caregivers), in the event an early discharge 
is envisaged following general anaesthesia, 
not to drive or operate machinery during 
the first 24 hours after anaesthesia.  
- Advise the patient (and explain to 
caregivers) not to drink any alcohol 24 
hours after anaesthesia 
N01B Anesthetics, 
local 
  
N01BA02 Procaine 
N01BA03 Tetracaine 
N01BA05 Benzocaine 
N01BA52 Procaine 
combinations 
N01BB01 Bupivacaine 
N01BB02 Lidocaine 
N01BB03 Mepivacaine  
N01BB04 Prilocaine 
N01BB09 Ropivacaine 
N01BB10 Levobupivacai
ne 
N01BB20 Combinations 
N01BB51 Bupivacaine 
combinations 
(with 
adrenalina) 
N01BB52 Lidocaine 
combinations 
N01BB53 Mepivacaine 
combinations  
(with 
epinephrine) 
N01BB54 Prilocaine 
combinations 
(with lidocaine) 
N01BB58 Articaine 
combinations 
N01BX03 Phenol: 
N01BX04 Capsaicin  
 
 
 
 
0 
 
I 
 
 
 
 
 
 
 
II 
 
 
 
 
 
III 
 
 
 
 
 
 
 
 
 
Categorisation, labelling and information 
to the patient  depending of the route of 
administration 
 
Topic administration (skin, mucous) 
 
Infiltration (dental anaesthesia) 
Intrarticular, intrabursal, tendon sheath 
administration, etc.. 
- Advise the patient not to drive or operate 
machinery until the effect of the 
anaesthesia and the immediate effects of 
surgery are passed. 
 
Ocular administration: 
- Advise at the patient that their sight may 
become blurred, and not to drive or operate 
machinery during the first 24 hours after 
using local anesthetics. 
 
Regional anaesthesia (nerve-block, 
intravenous regional anaesthesia). 
Spinal /Epidural 
- Advise the patient (and explain to 
caregivers), in the event an early discharge 
is envisaged following  regional / epidural / 
spinal anaesthesia, not to drive or operate 
machinery during the first 24 hours after 
anaesthesia.  
- Advise the patient (and explain to 
caregivers) not to drink any alcohol 24 
hours after anaesthesia 
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Table 21: Example of information to the patient and Categorisation and labelling of some 
available N02 - ANALGESICS MEDICINES on driving. 
 
N02 
ANALGES
ICS 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENT 
N02AA01 
Morphine 
- Oral 
administration 
- Parenteral admin. 
 
III 
III 
N02AA03 Hydromorphone III 
N02AA05 Oxycodone III 
N02AA08 Dihydrocodeine III 
N02AB03 
Fentanyl 
- Oral 
administration 
- Parenteral admin. 
- Transdermal 
admin. 
 
III 
III 
III 
N02AE01 
Buprenorphine 
‐ Oral 
administration 
- Parenteral admin. 
- Transdermal 
admin. 
 
III 
III 
III 
- Inform the patient that the medication can 
cause side effects that impair driving and 
that reaction time can also be reduced 
without experiencing side effects. 
- Advise the patient (and explain to 
caregivers) not to drive until the next visit 
after start of treatment or after changes in 
dosage. 
- Advise the patient also to be careful in 
other situations than driving (e.g. using 
machinery and working at heights) 
- Advise the patient to strictly follow the 
prescribed doses and the intake scheme.  
- Advise the patient to avoid any alcohol or 
other psychoactive substances during the 
treatment. 
- Opiate cessation can also cause behavioral 
changes and requires follow-up and 
counseling. 
N02BA01 
A01AD05 
B01AC06 
Acetylsalicylic acid 0 
- No special advice. 
N02BE01 Paracetamol 0 - No special advice. 
N02BG06 Nefopam II - Advise the patient (and explain to 
caregivers) not to drive during the first days 
of treatment. 
- Inform the patient that the medication can 
cause side effects that impair driving and 
that reaction time can also be reduced 
without experiencing side effects. 
- Advise the patient also to be careful in 
other situations than driving (e.g. using 
machinery and working at heights) 
- Advise the patient to strictly follow the 
prescribed doses and intake scheme..  
- Advise the patient to avoid any alcohol or 
other psychoactive substances during the 
treatment. 
N02CA52 Ergotamine, 
combinations excl. 
psycholeptics 
I - Inform the patient that the medication can 
cause side effects that impair driving and 
that reaction time can also be reduced 
without experiencing side effects. 
- Advise the patient also to be careful in 
other situations than driving (e.g. using 
machinery and working at heights) 
- Advise the patient to avoid any alcohol or 
other psychoactive substances during the 
treatment. 
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Table 22: Example of information to the patient and Categorisation and labelling of some 
available N03 - ANTIEPILEPTIC MEDICINES on driving. 
 
N03 
ANTIEPILE
PTIC 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENT 
 N03AA02 Phenobarbital 
- Oral 
administration 
- Parenteral 
administration 
 
III 
III 
Advise the patient not to drive. 
- Advise the patient to take the medicine as 
prescribed by the physician. 
- Advise the patient not to stop taking the 
medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
- Advise the patient not to drink alcohol while 
taking this medication. 
 N03AA03 Primidone III 
Advise the patient not to drive. 
- Advise the patient to take the medicine as 
prescribed by the physician. 
- Advise the patient not to stop taking the 
medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
- Advise the patient not to drink alcohol while 
taking this medication. 
Essential tremor 
- Advise the patient not to drive  
N03AB02 
Phenytoin 
- Oral 
administration 
- Parenteral 
administration 
 
III 
III 
Advise the patient not to drive. 
- Advise the patient to take the medicine as 
prescribed by the physician. 
- Advise the patient not to stop taking the 
medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
- Advise the patient not to drink alcohol while 
taking this medication. 
Trigeminal neuralgia 
- Advise the patient not to drive. 
N03AE01 
Clonazepam 
- Oral 
administration 
- Parenteral 
administration 
 
 
II 
III 
Advise the patient not to drive during the 
first days of treatment as well as after dose 
increases. 
- Advise the patient to take the medicine as 
prescribed by the physician. 
- Advise the patient not to stop taking the 
medicine suddenly, and to inform the 
physician – doctor if he/she should do so.  
- Advise the patient not to drink alcohol while 
taking this medication 
N03AX16 Pregabalin 
 
 
 
 
 
 
 
 
 
 
 
II 
Advise the patient not to drive during the 
first days of treatment as well as after dose 
increases. 
- Advise the patient to take the medicine as 
prescribed by the physician. 
- Advise the patient not to stop taking the 
medicine suddenly, and to inform the 
physician – doctor if he/she should do so. 
- Advise the patient not to drink alcohol while 
taking this medication. 
Neuropathic pain; Generalised Anxiety 
Disorder 
- Advise the patient not to drive during the first 
days of treatment as well as after dose 
increases. 
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Table 23: Example of information to the patient and Categorisation and labelling of some 
available N04 - ANTIPARKINSON MEDICINES on driving. 
 
N04  
ANTIPARKI
NSON 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENT 
N04AA02 
Biperiden 
- Oral 
administration  
- Parenteral 
administration 
II 
 
III 
- Advise the patient (and explain to caregivers) 
not to drive during the first days of treatment 
N04BA02 
Levodopa and 
decarboxylase 
inhibitor 
Levodopa+carbid
opa 
Levodopa+bense
razide 
II 
- Advise the patient (and explain to caregivers) 
not to drive during the first days of treatment. 
- Inform patients that unwanted effects are 
seen rapidly during the dosage adjustment 
period. 
- Advise the patient (and explain to caregivers) 
not to drive at all if suffering from “sleep 
attacks”. 
- Advise the patient (and explain to caregivers) 
not to drive at all if suffering from severe 
fluctuations in mobility “(“on-off” phenomena). 
N04BB01 Amantadine I 
- Advise the patient (and explain to caregivers) 
not to drive during the first days of treatment. 
- Some central nervous system unwanted 
effects (like confusion) are more common 
when amantadine is administered 
concurrently with anticholinergic agents. 
 
 
 
N04BD01 
 
 
 
Selegiline I 
N04BD02 Rasagiline I 
Monotherapy:  
 
- Advise the patient (and explain to caregivers) 
not to drive during the first days of treatment. 
 
In adjunct therapy with levodopa: 
 
- Advise the patient (and explain to caregivers) 
not to drive during the first days of treatment. 
- Inform patients that unwanted effects are 
seen rapidly during the dosage adjustment 
period. 
- Advise the patient (and explain to caregivers) 
not to drive at all if suffering from “sleep 
attacks”. 
- Advise the patient (and explain to caregivers) 
not to drive at all if suffering from severe 
fluctuations in mobility “(“on-off” phenomena). 
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Table 24: Example of information to the patient and Categorisation and labelling of some 
available N05 - PSYCHOLEPTICS MEDICINES on driving. 
 
N05 
PSYCHOL
EPTICS 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENT 
N05AA01 Chlorpromazine 
- Oral 
administration 
- Parenteral 
administration 
 
III 
III 
- Inform the patient about the effects of the 
medicine on reaction time and that the 
medication can cause side effects that impair 
driving (dizziness, drowsiness, sleepiness, 
blurred/double vision and reduced alertness) 
- Advise the patient not to drive until the next visit 
after start of treatment and also to be careful in 
other situations (e.g. using machinery and 
working at heights) 
- Advise the patient not to drink alcohol when 
taking this medicine. 
- In short-term use (eg intractable hiccup, nausea 
and vomiting) inform your patient that his/her 
response is still reduced for approximately 24 
hours. Advise the patient not to drive then. 
N05AB02 Fluphenazine II - Inform the patient about the effects of the 
medicine on reaction time and that the 
medication can cause side effects that impair 
driving (dizziness, drowsiness, sleepiness, 
blurred/double vision and reduced alertness) 
- Advise the patient not to drive for the first few 
days of treatment or until the next visit after the 
start of treatment and also to be careful in other 
situations (e.g. using machinery and working at 
heights) 
- Advise the patient not to drink alcohol when 
taking this medicine. 
N05AD01 Haloperidol 
- Oral 
administration 
- Parenteral 
administration 
 
II 
 
III 
- Inform the patient about the effects of the 
medicine on reaction time and that the 
medication can cause side effects that impair 
driving (dizziness, drowsiness, sleepiness, 
blurred/double vision and reduced alertness) 
- Advise the patient not to drive for the first few 
days of treatment or until the next visit after the 
start of treatment and also to be careful in other 
situations (e.g. using machinery and working at 
heights) 
- Advise the patient not to drink alcohol when 
taking this medicine. 
- In short-term use (eg intractable hiccup, nausea 
and vomiting), inform your patient that his/her 
response is still reduced for approximately 24 
hours. Advise the patient not to drive then. 
N05AH04 Quetiapine 
- start of 
treatment 
- continuation 
treatment 
 
III 
 
II 
Start of treatment: 
- Inform the patient about the effects of the 
medicine on reaction time and that the 
medication can cause side effects that impair 
driving (dizziness, drowsiness, sleepiness, 
blurred/double vision and reduced alertness) 
- Advise the patient not to drive until the next visit 
after start of treatment and also to be careful in 
other situations (e.g. using machinery and 
working at heights) 
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- Advise the patient not to drink alcohol when 
taking this medicine. 
 
Continuation treatment: 
- Inform the patient about the effects of the 
medicine on reaction time and that the 
medication can cause side effects that impair 
driving (dizziness, drowsiness, sleepiness, 
blurred/double vision and reduced alertness) 
- Advise the patient not to drive for the first few 
days of treatment or until the next visit after the 
start of treatment and also to be careful in other 
situations (e.g. using machinery and working at 
heights) 
- Advise the patient not to drink alcohol when 
taking this medicine. 
N05BA01 Diazepam 
- Oral 
administration 
- Parenteral 
administration 
- Other routes 
 
III 
 
III 
 
III 
- Inform the patient about the effects of the 
medicine on reaction time, that the medication 
can cause side effects that impair driving 
(dizziness, drowsiness, sleepiness, 
blurred/double vision and reduced alertness) 
and that reaction time can also be reduced 
without experiencing side effects. 
- Advise the patient not to drive until the next visit 
after start of treatment and also to be careful in 
other situations (e.g. using machinery and 
working at heights) 
- Advise the patient not to drink alcohol or use 
other psychoactive substances when taking this 
medicine. 
- One time (occasional) use: inform your patient 
that his/her response is still reduced for 
approximately 3 days to one week. Advise your 
patient not to drive then. 
N05BA09 Clobazam II - Inform the patient about the effects of the 
medicine on reaction time and that the 
medication can cause side effects that impair 
driving (dizziness, drowsiness, sleepiness, 
blurred/double vision and reduced alertness) 
- Advise the patient not to drive for the first few 
days of treatment or until the next visit after the 
start of treatment and also to be careful in other 
situations (e.g. using machinery and working at 
heights) 
- Advise the patient not to drink alcohol or use 
other psychoactive substances when taking this 
medicine. 
- One time (occasional) use: inform your patient 
that his/her response is still reduced for 
approximately 3 days to one week. Advise your 
patient not to drive then. 
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Table 25: Example of information to the patient and Categorisation and labelling of some 
available N06A - ANTIDEPRESSANT MEDICINES on driving. 
 
N06A 
ANTIDEPRE- 
SSANT 
MEDICINES 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENT 
N06AA21 
Maprotiline 
- Oral 
administration 
- Parenteral 
administration 
II 
 
III 
- Inform your patient about the effects of the 
medication on reaction time as well as that 
the medication can cause side-effects that 
impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
- Advise your patient not to drive for the first 
few weeks of treatment or until the next visit 
and to be careful in other situations, as well 
(e.g. operating machinery and working at 
heights). 
- Advise your patient not to drink alcohol nor 
use any other psychoactive substance when 
taking this medication. 
- In case of short-term use of the medication, 
advise your patient not to drive because 
his/her driving skills are still impaired for 
approximately 24 hours. 
N06AB03 Fluoxetine I 
- Inform your patient about the effects of the 
medication on reaction time as well as that 
the medication can cause side-effects that 
impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
- Advise your patient not to drive if he/she 
experiences side-effects that can impair 
his/her driving abilities. 
- Advise your patient not to drive as long as 
side-effects persist. 
- Advise your patient not to drink alcohol nor 
use any other psychoactive substance when 
taking this medication. 
- N06AX03 - Mianserin - III 
- Inform your patient about the effects of the 
medication on reaction time as well as that 
the medication can cause side-effects that 
impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, etc.). 
- Advise your patient not to drive until the next 
visit and to be careful in other situations, as 
well (e.g. operating machinery and working at 
heights). 
- Advise your patient not to drink alcohol nor 
use any other psychoactive substance when 
taking this medication. 
- In case of short-term use of the medication, 
advise your patient not to drive because 
his/her driving skills are still impaired for 
approximately 24 hours. 
-  
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Table 26: Example of information to the patient and Categorisation and labelling of some 
available N06B - PSYCHOSTIMULANT and N06D – ANTI-DEMENTIA MEDICINES on driving. 
 
N06B  
PSYCHOSTIMU- 
LANT 
MEDICINES 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENT 
 
 
 
N06BA02 
 
 
 
Dexamafetamine II 
N06BA04 Methylphenidate II 
- Inform your patient about the effects of the 
medication on reaction time as well as that 
the medication can cause side-effects that 
impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, 
etc.). 
- Advise your patient not to drive for the first 
few weeks of treatment or until the next 
visit and to be careful in other situations, as 
well (e.g. operating machinery and working 
at heights). 
- Advise your patient not to drink alcohol nor 
use any other psychoactive substance 
when taking this medication. 
- In case of short-term use of the medication, 
advise your patient not to drive because 
his/her driving skills are still impaired for 
approximately 24 hours. 
N06BA05 Pemoline I 
- Inform your patient about the effects of the 
medication on reaction time as well as that 
the medication can cause side-effects that 
impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, 
etc.). 
- Advise your patient not to drive if he/she 
experiences side-effects that can impair 
his/her driving abilities. 
- Advise your patient not to drive as long as 
side-effects persist. 
- Advise your patient not to drink alcohol nor 
use any other psychoactive substance 
when taking this medication. 
N06D  
ANTIDEMENTIA 
MEDICINES 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENT 
N06DA02 Donepezil II 
- Inform your patient (and explain his/her 
caregiver) about the effects of the 
medication on reaction time as well as that 
the medication can cause side-effects that 
impair driving abilities (e.g. dizziness, 
drowsiness, sleepiness, blurred vision, 
etc.). 
- Advise your patient (and explain his/her 
caregiver) not to drive for the first few 
weeks of treatment or until the next visit 
and to be careful in other situations, as well 
(e.g. operating machinery and working at 
heights). 
- Advise your patient (and explain his/her 
caregiver) not to drink alcohol nor use any 
other psychoactive substance when taking 
this medication. 
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- In case of short-term use of the medication, 
advise your patient (and explain his/her 
caregiver) not to drive because his/her 
driving skills are still impaired for 
approximately 24 hours. 
- Driving with this treatment should require 
an approval by driving licence 
administration. 
N06DX02 Ginkgo biloba 0 - No special advice. 
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Table 27: Example of information to the patient and Categorisation and labelling of some 
available N07 - OTHER NERVOUS SYSTEM MEDICINES on driving. 
 
N07  
OTHER 
NERVOUS 
SYSTEM  
DRUGS  
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENT 
N07AA01 Neostigmine 
- Oral 
administration 
- Parenteral 
administration   
 
II 
III 
- Advise the patient (and explain to 
caregivers) not to drive during the first 
days of treatment.   
- The treatment can impair patient’s vision 
especially by night. 
N07AX01 Pilocarpine  
- Oral 
administration 
- Ophthalmic eye 
drops/ Gel 
II 
II 
- Advise the patient (and explain to 
caregivers) not to drive during the first 
days of treatment.   
- The treatment can impair patient’s vision 
especially by night and may require an 
ophthalmological advice. 
N07BA01 
Nicotine 
- Oral and nasal 
administration 
0 
- The treatment has to be used according to 
the recommended dose to avoid side effect 
on driving.  
- Smoking cessation can also cause 
behavioural changes. 
N07BA03 Varenicline I 
- Advise the patient (and explain to 
caregivers) not to drive during the first 
days of treatment and after changes in 
doses. 
- The treatment has to be used according to 
the recommended dose. 
- Advise the patient about possibles effects 
on behavior.  
- Smoking cessation can also cause 
behavioural changes. 
N07BB01 Disulfiram II 
- Advise the patient (and explain to 
caregivers) not to drive during the first 
days of treatment and after changes in 
doses. 
- Advise the patient to strictly follow the 
prescribed doses and treatment 
procedures and to avoid any alcohol or 
other psychoactive substances during the 
treatment.  
- Alcohol cessation can also cause 
behavioural changes and requires follow-
up and counselling. 
- Driving with this treatment should require 
an approval by driving licence 
administration. 
N07BC02 
Methadone 
- Oral 
administration:  
- Parenteral 
administration:  
 
II 
III 
- Advise the patient (and explain to 
caregivers) not to drive during the first 
days of treatment and after changes in 
doses. 
- Advise the patient to strictly follow the 
prescribed doses, the treatment and 
delivery procedures and to avoid any 
alcohol or other psychoactive substances 
during the treatment. 
- Opiate cessation can also cause 
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behavioural changes and requires follow-
up and counselling. 
- Driving with this treatment should require 
an approval by driving licence 
administration. 
N07BC51 
Buprenorphine, 
combinations 
(buprenorphine+nal
oxone) 
III 
- Advise the patient (and explain to 
caregivers) not to drive during the first 
days of treatment and after changes in 
doses. 
- Advise the patient to strictly follow the 
prescribed doses, the treatment and 
delivery procedures and to avoid any 
alcohol or other psychoactive substances 
during the treatment. 
- Opiate cessation can also cause 
behavioural changes and requires follow-
up and counselling. 
- Driving with this treatment should require 
an approval by driving licence 
administration. 
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Table 28: Example of information to the patient and Categorisation and labelling of some 
available R - RESPIRATORY SYSTEM MEDICINES on driving. 
 
R 
RESPIRATO
RY SYSTEM 
MEDICINES 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENT 
R01AA03 Phedrine 0 - No special advice. 
R01AD05 Budesonide 0 - No special advice. 
R01BA02 Pseudoephedrine I - Inform the patient about the effects that the 
medicine can have on reaction time and 
that the medication can cause side effects 
that impair driving (anxiety, restlessness, 
termor, insomnia) 
- Advise the patient not to drive when this 
side effects occur and also to be careful in 
other situations (e.g. using machinery and 
working at heights) 
- Advise the patient not to drink alcohol or 
use other psychoactive substances when 
taking this medicine. 
R01BA52 Pseudoephedrine, 
combinations 
+ loratadine 
+ triprolidine 
 
 
I 
III 
+ loratadine 
- Inform the patient about the effects that the 
medicine can have on reaction time and 
that the medication can cause side effects 
that impair driving (anxiety, restlessness, 
tremor, insomnia, dizziness, fatigue) 
- Advise the patient not to drive when this 
side effects occur and also to be careful in 
other situations (e.g. using machinery and 
working at heights) 
- Advise the patient not to drink alcohol or 
use other psychoactive substances when 
taking this medicine. 
+ triprolidine 
- Inform the patient about the effects of the 
medicine on reaction time and that the 
medication can cause side effects that 
impair driving (anxiety, restlessness, 
tremor, insomnia, drowsiness) 
- Advise the patient not to drive until the next 
visit after start of treatment and also to be 
careful in other situations (e.g. using 
machinery and working at heights) 
- Advise the patient not to drink alcohol or 
use other psychoactive substances when 
taking this medicine. 
R03DA04 Theophylline 
**Oral 
administration 
**Parenteral 
administration 
 
0 
I 
Oral: 
- No special advice  
Parenteral: 
- Inform the patient about the effects that the 
medicine can have on reaction time and 
that the medication can cause side effects 
that impair driving (insomnia, confusion, 
anxiety, vertigo, dizziness, tremor, visual 
disturbances) 
- Advise the patient not to drive when this 
side effects occur and also to be careful in 
other situations (e.g. using machinery and 
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working at heights) 
- Advise the patient not to drink alcohol or 
use other psychoactive substances when 
taking this medicine. 
R06AA02 Diphenhydramine III - Inform the patient about the effects of the 
medicine on reaction time and that the 
medication can cause side effects that 
impair driving (dizziness, drowsiness, 
blurred vision and reduced alertness) 
- Advise the patient not to drive until the next 
visit after start of treatment and also to be 
careful in other situations (e.g. using 
machinery and working at heights) 
- Advise the patient not to drink alcohol or 
use other psychoactive substances when 
taking this medicine. 
R06AX19 Azelastine I 
R06AX22 Ebastine I 
- Inform the patient about the effects that the 
medicine can have on reaction time and 
that the medication can cause side effects 
that impair driving (drowsiness, 
somnolence) 
- Advise the patient not to drive when this 
side effects occur and also to be careful in 
other situations (e.g. using machinery and 
working at heights) 
- Advise the patient not to drink alcohol or 
use other psychoactive substances when 
taking this medicine. 
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Table 29: Example of information to the patient and Categorisation and labelling of some 
available S - SENSORY ORGANS MEDICINES on driving. 
  
S 
SENSORY 
ORGANS 
ACTIVE 
SUBSTANCE 
CATEGORY 
LABELLING INFORMATION FOR THE PATIENTS 
S01AA01 Chloramphenicol 
S01AA16 Rifamycin 
S01AA17 Erytromycin 
S01AX13 Ciprofloxacin 
S01AX17 Lomefloxacin 
General rule 
Drops: 0 
 
Oinment: I 
- Inform the patient that as with any ocular 
medication, if transient, blurred vision 
occurs at application.  
- Advise the patient that he/she should wait 
until his/her vision clears before driving or 
using machinery. 
S01BB01 Hydrocortisone and 
mydriatics 
S01BB02 Prednisolone and 
mydriatics 
Depending 
on the 
mydriatic in 
combination 
Depending on the mydriatic in combination 
S01EA03  
Apraclonidine 
 
II 
S01EA04  
Clonidine 
 
 
II 
S01EA05  
Brimonidine 
 
II 
- Inform the patient that this ocular 
medication may cause fatigue and/or 
drowsiness, blurred and/or abnormal vision 
which may impair the ability to drive or 
operate machinery, especially at night or in 
reduced lighting.                                             
- Advise the patient that he/she should wait 
until these symptoms have cleared before 
driving or using machinery. 
S01EC02 Diclofenamide I 
S01EC04 Brinzolamide I 
S01ED01 Timolol I 
S01ED02 Betaxolol  I 
S01ED03 Levobunolol I 
S01ED05 Carteolol I 
- Inform the patient that as with any ocular 
medication, if transient, blurred vision 
occurs at application.  
- Advise the patient that he/she should wait 
until his/her vision clears before driving or 
using machinery. 
S01FA01 Atropine  III 
S01FA05 Homatropine III 
S01FA06 Tropicamide III 
S01FA56 Tropicamide, 
combinations 
III 
S01FAP1 Atropine+escopola
mine+phenylephrin
e 
III 
- Inform the patient that this ocular 
medication may cause transient blurring of 
vision or that he/she may suffer from 
photophobia and that this may impair their 
ability to drive under certain circumstances. 
Complete recovery from the effects of 
mydriatic anticholinergics may take up to 
24 hours. 
- Advise the patients not to drive or operate 
hazardous machinery until 24 hours after 
receiving ocular medication (recovery 
occurs within 24 hours) or until vision is 
clear. 
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7. Categorisation and labelling of medicines 
approved by the EMA january 2008-
september 2010 
 
 
In Task 4.3, we have also provided a classification/categorisation for the “new” medicines 
approved by the EMA from January 2008 to September 2010. Table 30 shows the new 
medicines approved by the EMA during this period. 
 
The categorisation of these new medicines has been carried out using the methodology 
described in chapter 2. 
 
The medicines in ATC groups G, J, L, V, as well as medicines ATC (code not yet assigned), 
have been categorized as an exercise according to DRUID criteria, even though no patient-
oriented information has been produced for these medicines and they have not been included in 
the alphabetical list 
 
Table 30: Categorisation and labelling of “new” medicines approved by EMA from January 2008 
to September 2010 
 
ATC ACTIVE SUBSTANCE INVENTED NAME CATEGORY LABELLING 
 
A ALIMENTARY TRACT AND METABOLISM 
A03AE04 Prucalopride RESOLOR I I 
A06AH01 Methylnaltrexone bromide RELISTOR 0 0 
A10BD07 Sitagliptin and 850 mg of 
metformin hydrochloride. 
JANUMET/VELMETIA
/EFFICIB 
I II 
A10BH03 Saxagliptin ONGLYZA I I 
A10BX02  
 
Repaglinide ENYGLID I I 
A10BX07  Liraglutide VICTOZA I I 
A11HA08 Tocofersolan VEDROP (from birth 
to 16 or 18 years of 
age) 
0 
 
0 
 
A16AB10 Velaglucerase alfa  VPRIV  I I 
A16AX07 Sapropterin 
dihydrochloride 
KUVAN 0 0 
 
B BLOOD AND BLOOD FORMING ORGANS 
B01AC22 Prasugrel EFIENT 0 0 
B01AC30 Clopidogrel + acido 
acetilsalicilico 
DUOCOVER/DUOPL
AVIN 
0 0 
B01AE07 Dabigatran etexilate (as 
mesilate) 
PRADAXA 0 0 
B01AX06 Rivaroxaban XARELTO 0 0 
B02BC 
 
Human fibrinogen / human 
thrombin 
EVICEL 0 0 
B02BX04 Romiplostim NPLATE I I 
B02BX05 Eltrombopag olamine REVOLADE 0 0 
B03XA01 Epoetin theta BIOPIN 0 0 
 
C CARDIOVASCULAR SYSTEM 
C01EB18 Ranolazine LATIXA (RANEXA) I I 
C01EB19 Icatibant - acetate FIRAZYR I I 
C01EB21 Regadenoson RAPISCAN NE (not NE (not 
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SmPC 
published) 
SmPC 
published) 
C02KX02 Ambrisentan VOLIBRIS I I 
C03XA01 Tolvaptan SAMSCA I I 
C09DX01 Valsartan/Amlodipine 
besylate/ 
hydrochlorothiazide 
DAFIRO HTC I I 
C09XA52 Aliskiren hemifumarate / 
hydrochlorothiazide 
RASILEZ HCT 0 0 
C10AD52 Nicotinic acid / Laropiprant
 
TREDAPTIVE/TREVA
CLYN/PELZONT 
I I 
 
G GENITO URINAY SYSTEM AND SEX HORMONES 
G03GA06  Follitropin beta,  FERTAVID 0  0 
G03GA09 Corifollitropin alfa ELONVA I I 
G03XC02  Bazedoxifene  COMBRIZA I I 
G04BE08 Tadalafil ADCIRCA I I 
G04CA04 Silodosin SILODYX I I 
 
J ANTIINFECTIVES FOR SYSTEMIC USE 
J01DF01 Aztreonam CAYSTON 0 0 
J01DH04 Doripenem monohydrate DORIBAX 0 0 
J02AX05 Micafungin (as sodium).  MYCAMINE 0 0 
J05AG04 Etravirine INTELENCE I I 
J06BA02 Human normal 
immunoglobulin (IVIg)   
PRIVIGEN I I 
J06BB04 
 
Human hepatitis B 
immunoglobulin 
ZUTRECTA 0 0 
J07AH Meningococcal Group A, 
C, W-135 and Y 
Coniugate Vaccine 
MENVEO I I 
J07AL52 Streptococcus 
pneumoniae 
polysaccharide serotypes 
1, 4, 5, 6B, 7F, 9V, 14, 
18C, 19F and 23F each 
conjugated to a carrier 
protein (Pneumococcal 
vaccine) 
SYNFLORIX 
(indicated for children 
from 6 weeks up to 2 
years of age) 
 
NE (Only 
paediatric 
patients) 
NE (Only 
paediatric 
patients) 
J07BA02  
 
Japanese Encephalitis 
vaccine, inactivated, 
adsorbed 
IXIARO I I 
J07BB02 Pandemic influenza 
vaccine (H5N1) (split 
virion, inactivated, 
adjuvanted) 
A/VietNam/1194/2004 
NIBRG-14 
PANDEMRIX 
 
I I 
 
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 
L01AC01 Thiotepa TEPADINA III III 
L01BC07 Azatizine VIDAZA III III 
L01CA05 Vinflunine ditartrate JAVLOR II II 
L01XC09 Catumaxomab REMOVAB II II 
L01XC10 Ofatumumab ARZERRA I I 
L01XE07 Lapatinib TYVERB I I 
L01XE10 Everolimus AFINITOR I I 
L01XE11 Pazopanib VOTRIENT I I 
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L01XX31 Gefinitib IRESSA I I 
L02BX02 Degarelix FIRMAGON I I 
L03AB08 Interferon beta-1b EXTAVIA II II 
L03AX14 Histamine dihydrochloride CEPLENE II II 
L03AX15 Mifamurtide MEPACT II II 
L03AX16 Plerixafor MOZOBIL I I 
L04AA13 Leflunomide 
 
LEFLUNOMIDE 
WINTHROP 
I  
L04AA06 Mycophenolate mofetil  MYCLAUSEN    
L04AA27 Fingolimod GILENYA   
L04AB05 Certolizumab pegol CIMZIA I I 
L04AB06 Golimumab SIMPONI I I 
L04AC04 Canakinumab ILARIS I I 
L04AC05 Ustekinumab STELARA I I 
L04AC07  Tocilizumab ROACTEMRA I I 
L04AC08 Rilonacept RILONACEPT 
REGENERON 
II  II 
L04AX02 Thalidomide THALIDOMIDE 
CELGENE 
III III 
 
M MUSCULO-SKELETAL SYSTEM 
M04AA03 Febuxostat ADENURIC I I 
M05BC02 Eptotermin alfa OPGENRA 0 0 
M05BX04 Denosumab PROLIA I I 
 
N NERVOUS SYSTEM 
N01BX04 Capsaicin QUTENZA 0 0 
N03AF04 Eslicarbazepin EXALIEF II II 
N03AX18 Lacosamide VIMPAT II II 
N05CF04  Eszopiclone LUNIVIA NE (not 
SmPC 
published) 
NE (not 
SmPC 
published) 
N06AX22 Agomelatine VALDOXAN/ 
THYMANAX 
II II 
N07XX05 Amifampridine FIRDAPSE II II 
 
R RESPIRATORY SYSTEM 
R03AC18 Indacaterol maleate OSLIF BREEZHALER 0 0 
R03DX07 Roflumilast DAXAS 0 0 
 
S OPHTHALMOLOGICALS 
S01ED51 Brinzolamide / timolol AZARGA I I 
 
V VARIOUS 
V03AB35 Sugammadex BRIDION  II II 
V03AE02  Sevelamer (carbonate) RENVELA 0 0 
V09HA03 Besilesomab SCINTIUM 0 0 
 
 
ATC CODE NO YET ASSIGNED 
ATC code 
not yet 
assigned 
Ulipristal acetate ELLAONE I I 
ATC code 
not yet 
assigned 
Dronedarone MULTAQ I I 
ATC code Lasofoxifene FABLYN 0 0 
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not yet 
assigned 
ATC code 
not yet 
assigned 
Characterised viable 
autologous cartilage-
forming cells expanded in 
vivo expressing specific 
marker proteins 
CHONDROCELECT II II 
 
NE: Not evaluted  
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